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Effect of Comorbidities on HIV-1 Pathogenesis in Monocytic Cells
Abstract
The advent of antiretroviral therapy (ART) has substantially increased the life span of people living with
HIV-1 (PLWH). However, the presence of comorbid conditions such as high prevalence of drug abuse and
coinfections have deteriorated the health outcomes in PLWH and progression of HIV-1 infection to AIDS.
In this study, we will be focusing on the independent effect of two major comorbidities: cigarette smoking
and human papilloma virus (HPV) coinfection on HIV-1 replication and pathogenesis in monocytic cells.
The prevalence of smoking is approximately 3-times higher in PLWH compared to the general population.
Scientific evidences suggest that smoking aggravates HIV-1 pathogenesis and leads to decreased
responses to ART. However, the exact mechanism by which smoking enhances HIV-1 replication is still
not clear. The Kumar group has demonstrated the role of nicotine, at least in part, on HIV-1 replication in
monocytic cells via cytochrome P450 (CYP)-mediated oxidative stress pathway. They have also shown
the role of cigarette smoke condensate (CSC), which contains numerous organic compounds such as
polyaryl hydrocarbons (PAHs), on cytotoxicity and HIV-1 replication in monocytic cells. Therefore, the goal
in this study was to identify active ingredient of CSC, especially PAHs, which is responsible for cytotoxicity
and HIV-1 replication in monocytic cells, and their underlying mechanism. PAHs such as benzo(a)pyrene
(BaP), naphthalene (NPh), phenanthrene (Phe), benzo(a)antharacene (BeA), and benzo(b)fluoranthene
(BeF) are known carcinogens present in cigarette smoke. As a first part of our study, we examined the
relative effect of these constituents on the cytotoxicity of monocytic cells and the possible mechanism of
PAH-mediated cytotoxicity. We examined the acute (6-24 hours) and chronic (7 days) effects of these
PAHs on the expression of cytochromes P450 (CYPs), oxidative stress, and cytotoxicity. The treated cells
were examined for mRNA and protein levels of CYPs (1A1 and 3A4) and antioxidants enzymes (AOEs)
superoxide dismutase-1 (SOD1) and catalase. Further, we assessed the levels of reactive oxygen species
(ROS), caspase-3 cleavage activity, and cell viability. We performed these experiments in U937 cell lines
and/or primary monocytic cells. Of the five PAHs tested, after chronic treatment only BaP (100 nM)
showed a significant increase in the expression of CYP1A1, AOEs (SOD1 and catalase), ROS generation,
caspase-3 cleavage activity, and cytotoxicity. However, acute treatment with BaP showed only an increase
in the mRNA expression of CYP1A1. These results suggested that of the five PAHs tested, BaP is the
major contributor to the toxic effect of PAHs in monocytic cells, which is likely to occur through CYP and
oxidative stress pathways.
Secondly, we investigated a molecular mechanism that would explain BaPinduced HIV-1 replication. We
hypothesized that CYP-mediated BaP metabolism generates ROS, and the resultant oxidative stress
aggravates HIV-1 replication. As expected, we observed ~4-fold increase in HIV-1 replication in
differentiated U1 (HIV-1- infected U937) monocytic cell lines and human primary macrophages after
chronic BaP exposure. We also observed ~30-fold increase in the expression of CYP1A1 at mRNA level,
~2-fold increase in its enzymatic activity, as well as, an elevated ROS level and cytotoxicity in U1 cells. The
knock-down of the CYP1A1 gene using siRNA and treatment with selective CYP inhibitors and
antioxidants significantly reduced HIV-1 replication. Further, we observed a nuclear translocation of NF-κB
subunits (p50 and p65) after chronic BaP exposure, which was reduced by treatment with siRNA/
inhibitors of CYP and antioxidants. Suppression of NF-κB pathway using specific NF-κB inhibitors also
significantly reduced HIV-1 replication. Together, our results suggest that BaP enhances the HIV-1
replication in macrophages by CYP-mediated oxidative stress pathway via NF-κB signaling cascade.
Thirdly, we explored the underlying mechanism by which HPV increases HIV-1 pathogenesis. HPV
infection is one of the major factors that contribute to a reduced suppression of the virus in HIV-1
patients. There is a high prevalence of comorbidity of HIV-1 and HPV (which leads to cervical cancer)
among HIV-1-infected population. We proposed that exosomes secreted from HPV-infected cervical

cancer cells exacerbate HIV-1 replication in HIV-1-infected macrophages. To test the hypothesis, we
treated U1 cells (HIV-1-infected monocytic cell line) with the cell culture supernatant (CCS) obtained from
caski cells (HPV-infected cervical cancer cells). We observed an ~2-fold increase in HIV-1 replication in
the treated U1 cell. We also observed a significant increase in the expression of CYPs (CYP 1A1 and 2A6)
at the mRNA level. However, we did not observe any significant change in the expression of CYPs as well
as antioxidants enzymes (catalase, PRDX6) at the protein level. Furthermore, we isolated exosomes from
the caski cell culture supernatant and observed the presence of CYPs (1A1, 2A6), SOD1 and HPV protein
HPV16 E6 in caski exosomes. The exosomes derived from caski cells (CCS-Exo) significantly reduced
cytotoxicity, while it increased HIV-1 replication in U1 cells. Treatment of antioxidant such as resveratrol,
CYP1A1 inhibitor (ellipticine) and CYP2A6 inhibitor (Tryptamine) including chemodietary agents such as
curcumin (20 μM) and curcubitacin-D (0.1 μM), significantly reduced the CCS and CCS-Exo mediated
HIV-1 replication in U1 cells. These results suggest the role of specific CYP-induced oxidative stress
pathway in HIV-1 replication. Altogether, we demonstrated that cervical cancer cells exacerbate HIV-1
replication in monocytic cells via transferring oxidative stress factors such as CYPs and HPV
oncoproteins through exosomes. We also showed that the viral replication undergoes via a CYP-mediated
oxidative stress pathway and it can be reduced by treatment of chemodietary agents like curcumin and
Cucurbitacin-D. The present study therefore, illustrates that comorbidities such as smoking and HPV
coinfection contribute to HIV-1 replication and pathogenesis in monocytic cells via a CYP-mediated
oxidative stress pathway. The study also provides scientific rationale for the development of novel
therapeutic treatment for PLWHs with these comorbidities by targeting CYP and specific oxidative stress
pathway.
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ABSTRACT
The advent of antiretroviral therapy (ART) has substantially increased the life
span of people living with HIV-1 (PLWH). However, the presence of comorbid
conditions such as high prevalence of drug abuse and coinfections have deteriorated the
health outcomes in PLWH and progression of HIV-1 infection to AIDS. In this study, we
will be focusing on the independent effect of two major comorbidities: cigarette smoking
and human papilloma virus (HPV) coinfection on HIV-1 replication and pathogenesis in
monocytic cells.
The prevalence of smoking is approximately 3-times higher in PLWH compared
to the general population. Scientific evidences suggest that smoking aggravates HIV-1
pathogenesis and leads to decreased responses to ART. However, the exact mechanism
by which smoking enhances HIV-1 replication is still not clear. The Kumar group has
demonstrated the role of nicotine, at least in part, on HIV-1 replication in monocytic cells
via cytochrome P450 (CYP)-mediated oxidative stress pathway. They have also shown
the role of cigarette smoke condensate (CSC), which contains numerous organic
compounds such as polyaryl hydrocarbons (PAHs), on cytotoxicity and HIV-1 replication
in monocytic cells. Therefore, the goal in this study was to identify active ingredient of
CSC, especially PAHs, which is responsible for cytotoxicity and HIV-1 replication in
monocytic cells, and their underlying mechanism. PAHs such as benzo(a)pyrene (BaP),
naphthalene (NPh), phenanthrene (Phe), benzo(a)antharacene (BeA), and
benzo(b)fluoranthene (BeF) are known carcinogens present in cigarette smoke. As a first
part of our study, we examined the relative effect of these constituents on the cytotoxicity
of monocytic cells and the possible mechanism of PAH-mediated cytotoxicity. We
examined the acute (6-24 hours) and chronic (7 days) effects of these PAHs on the
expression of cytochromes P450 (CYPs), oxidative stress, and cytotoxicity. The treated
cells were examined for mRNA and protein levels of CYPs (1A1 and 3A4) and
antioxidants enzymes (AOEs) superoxide dismutase-1 (SOD1) and catalase. Further, we
assessed the levels of reactive oxygen species (ROS), caspase-3 cleavage activity, and
cell viability. We performed these experiments in U937 cell lines and/or primary
monocytic cells. Of the five PAHs tested, after chronic treatment only BaP (100 nM)
showed a significant increase in the expression of CYP1A1, AOEs (SOD1 and catalase),
ROS generation, caspase-3 cleavage activity, and cytotoxicity. However, acute treatment
with BaP showed only an increase in the mRNA expression of CYP1A1. These results
suggested that of the five PAHs tested, BaP is the major contributor to the toxic effect of
PAHs in monocytic cells, which is likely to occur through CYP and oxidative stress
pathways.
Secondly, we investigated a molecular mechanism that would explain BaPinduced HIV-1 replication. We hypothesized that CYP-mediated BaP metabolism
generates ROS, and the resultant oxidative stress aggravates HIV-1 replication. As
expected, we observed ~4-fold increase in HIV-1 replication in differentiated U1 (HIV-1infected U937) monocytic cell lines and human primary macrophages after chronic BaP
exposure. We also observed ~30-fold increase in the expression of CYP1A1 at mRNA
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level, ~2-fold increase in its enzymatic activity, as well as, an elevated ROS level and
cytotoxicity in U1 cells. The knock-down of the CYP1A1 gene using siRNA and
treatment with selective CYP inhibitors and antioxidants significantly reduced HIV-1
replication. Further, we observed a nuclear translocation of NF-κB subunits (p50 and
p65) after chronic BaP exposure, which was reduced by treatment with siRNA/inhibitors
of CYP and antioxidants. Suppression of NF-κB pathway using specific NF-κB inhibitors
also significantly reduced HIV-1 replication. Together, our results suggest that BaP
enhances the HIV-1 replication in macrophages by CYP-mediated oxidative stress
pathway via NF-κB signaling cascade.
Thirdly, we explored the underlying mechanism by which HPV increases HIV-1
pathogenesis. HPV infection is one of the major factors that contribute to a reduced
suppression of the virus in HIV-1 patients. There is a high prevalence of comorbidity of
HIV-1 and HPV (which leads to cervical cancer) among HIV-1-infected population. We
proposed that exosomes secreted from HPV-infected cervical cancer cells exacerbate
HIV-1 replication in HIV-1-infected macrophages. To test the hypothesis, we treated U1
cells (HIV-1-infected monocytic cell line) with the cell culture supernatant (CCS)
obtained from caski cells (HPV-infected cervical cancer cells). We observed an ~2-fold
increase in HIV-1 replication in the treated U1 cell. We also observed a significant
increase in the expression of CYPs (CYP 1A1 and 2A6) at the mRNA level. However,
we did not observe any significant change in the expression of CYPs as well as
antioxidants enzymes (catalase, PRDX6) at the protein level. Furthermore, we isolated
exosomes from the caski cell culture supernatant and observed the presence of CYPs
(1A1, 2A6), SOD1 and HPV protein HPV16 E6 in caski exosomes. The exosomes
derived from caski cells (CCS-Exo) significantly reduced cytotoxicity, while it increased
HIV-1 replication in U1 cells. Treatment of antioxidant such as resveratrol, CYP1A1
inhibitor (ellipticine) and CYP2A6 inhibitor (Tryptamine) including chemodietary agents
such as curcumin (20 μM) and curcubitacin-D (0.1 μM), significantly reduced the CCS
and CCS-Exo mediated HIV-1 replication in U1 cells. These results suggest the role of
specific CYP-induced oxidative stress pathway in HIV-1 replication. Altogether, we
demonstrated that cervical cancer cells exacerbate HIV-1 replication in monocytic cells
via transferring oxidative stress factors such as CYPs and HPV oncoproteins through
exosomes. We also showed that the viral replication undergoes via a CYP-mediated
oxidative stress pathway and it can be reduced by treatment of chemodietary agents like
curcumin and Cucurbitacin-D.
The present study therefore, illustrates that comorbidities such as smoking and
HPV coinfection contribute to HIV-1 replication and pathogenesis in monocytic cells via
a CYP-mediated oxidative stress pathway. The study also provides scientific rationale for
the development of novel therapeutic treatment for PLWHs with these comorbidities by
targeting CYP and specific oxidative stress pathway.

vi

TABLE OF CONTENTS
CHAPTER 1. INTRODUCTION .....................................................................................1
HIV-1 Prevalence and Epidemiology ..............................................................................1
HIV-1 Biology .................................................................................................................1
HIV-1 Structure ...........................................................................................................1
HIV Life Cycle ............................................................................................................2
Viral entry. .............................................................................................................. 2
Reverse transcription. ............................................................................................. 2
Viral integration and transcription. ......................................................................... 3
Viral translation. ..................................................................................................... 3
Viral assembly and budding.................................................................................... 3
Viral latency. ........................................................................................................... 4
HIV Treatment Strategies ................................................................................................4
Drug Abuse ......................................................................................................................6
Smoking .......................................................................................................................7
Alcohol .........................................................................................................................7
Marijuana .....................................................................................................................8
Cocaine ........................................................................................................................9
Coinfections in HIV-1 .....................................................................................................9
Tuberculosis (TB) ......................................................................................................10
Hepatitis B and C .......................................................................................................10
Human Papilloma Virus (HPV) .................................................................................11
CHAPTER 2. INTERACTION OF HIV-1 WITH TOBACCO SMOKING AND
HPV INFECTION ...........................................................................................................13
Tobacco Smoking ..........................................................................................................13
Tobacco Prevalence in HIV-1 Patients ......................................................................13
Effect of Tobacco on HIV-1 Pathogenesis ................................................................13
Effect of Tobacco on HIV-1 Treatment Outcomes ....................................................15
HPV Coinfection............................................................................................................16
HPV Prevalence in HIV-1-infected Patients ..............................................................16
Effect of HPV on HIV-1 Pathogenesis ......................................................................18
Effect of Antiretroviral Therapy on HPV ..................................................................20
CHAPTER 3. SPECIFIC AIMS OF THE STUDY ......................................................22
Scientific Premise ..........................................................................................................22
Hypothesis .....................................................................................................................23
Clinical Significance and Impact ...................................................................................23
Objectives ......................................................................................................................25
Aim 1: Study of Contribution of CYP Enzymes in PAH-enhanced Cytotoxicity
in Monocytic Cells. ....................................................................................................25
Aim 2: Study of Contribution of CYP Enzymes in BaP-enhanced HIV-1
Replication in Monocytic Cells Latently Infected with HIV-1..................................25

vii

Aim 3: Study of Contribution of Exosomes Derived from HPV-infected Cervical
Cancer Cells in Enhancing HIV-1 Replication in U1 cells. .......................................26
CHAPTER 4. EFFECT OF POLYARYL HYDROCARBONS ON
CYTOTOXICITY IN MONOCYTIC CELLS .............................................................27
Introduction ....................................................................................................................27
Materials and Methods...................................................................................................28
Cell Culture and Treatment ........................................................................................28
U937 monocyte cells............................................................................................. 28
Primary macrophages............................................................................................ 28
Isolation of DNA, RNA, and Protein .........................................................................29
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR) ..............29
Western Blotting ........................................................................................................29
Measurement of Reactive Oxygen Species (ROS) and Cell Viability ......................30
XTT Assay .................................................................................................................30
Caspase-3 Activity Assay ..........................................................................................30
Statistical Analysis .....................................................................................................31
Results ............................................................................................................................31
Effect of Acute Treatment of BaP, NPh, and Phe on CYP and AOE Expression,
ROS and Cell Viability in U937 Cells .......................................................................31
Effect of Chronic Treatment of BaP, NPh, and Phe on ROS and Cell Viability .......31
Effect of Chronic Treatment of BaP, NPh, and Phe on Caspase-3 Activity ..............37
Effect of Chronic Treatment of BaP, NPh, and Phe on the Expression of CYPs at
mRNA and Protein Levels .........................................................................................37
Effect of Chronic Treatment of BaP, NPh, and Phe on the Expression of AOEs at
the mRNA and Protein Levels ...................................................................................37
Effect of Chronic Treatment of BeA and BeF on ROS, Cell Viability, and
Caspase-3 Activity .....................................................................................................42
Effect of Chronic Treatment of BaP on CYP Expression, ROS and Cell Viability
in Primary Macrophages ............................................................................................42
Discussion ......................................................................................................................42
Conclusions ....................................................................................................................48
CHAPTER 5. BENZO(A)PYRENE ENHANCES HIV-1 REPLICATION IN
MONOCYTIC CELLS ...................................................................................................49
Introduction ....................................................................................................................49
Materials and Methods...................................................................................................50
Cell Culture and Treatment ........................................................................................50
U1 cells ................................................................................................................. 50
Human primary macrophages infected with HIV-1.............................................. 50
Viral Load ..................................................................................................................51
Isolation of RNA and Protein ....................................................................................51
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR) ..............51
Western Blotting ........................................................................................................51
Measurement of ROS Level.......................................................................................52
7-Ethoxy-Resorufin-O-Deethylase (EROD) Assay ...................................................52
viii

Apoptotic DNA Damage ............................................................................................52
Statistical Analysis .....................................................................................................52
Results ............................................................................................................................53
BaP Induces HIV-1 Replication in U1 Cells and HIV-1-infected Human Primary
Macrophages ..............................................................................................................53
BaP Induces the Expression of CYP1A1 ...................................................................53
BaP Does Not Alter the Expression of AOEs ............................................................53
Role of CYP1A1 on BaP-induced ROS Generation ..................................................57
Role of CYP1A1 and Oxidative Stress Pathways on BaP-induced HIV-1
Replication .................................................................................................................57
Nuclear Translocation of NF-κB Subunits upon BaP Exposure ................................57
Role of NF-κB Pathway in BaP-induced HIV-1 Replication ....................................57
Discussion ......................................................................................................................62
Conclusion .....................................................................................................................66
CHAPTER 6. EXOSOMES FROM HUMAN PAPILLOMA VIRUS-INFECTED
CERVICAL CANCER CELLS ENHANCE HIV-1 REPLICATION IN
MACROPHAGES............................................................................................................67
Introduction ....................................................................................................................67
Materials and Methods...................................................................................................68
Cell Culture and Treatment ........................................................................................68
Caski cells ............................................................................................................. 68
U1 cells. ................................................................................................................ 68
Exosome Isolation and Characterization....................................................................69
Viral Load ..................................................................................................................69
Measurement of ROS .................................................................................................69
Total Antioxidant Capacity ........................................................................................70
Cytotoxicity................................................................................................................70
Apoptotic DNA Damage ............................................................................................70
RNA and Protein Isolation .........................................................................................70
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR) ..............70
Western Blotting ........................................................................................................71
Exosome Uptake ........................................................................................................71
Statistical Analysis .....................................................................................................71
Results ............................................................................................................................71
Cell Culture Supernatant from Caski Cells Enhances Oxidative Stress and Viral
Load in U1 Cells ........................................................................................................71
Cell Culture Supernatant from Caski Cells Induces CYP Expression in U1 Cells ...74
Cell Culture Supernatant from Caski Cells Have No Significant Effect on AOEs
Expression in U1 Cells...............................................................................................76
U1 Cells Uptake CCS-derived Exosomes Containing Oxidative Stress Factors .......76
CCS-derived Exosomes Enhance Oxidative Stress and Viral Load in U1 Cells .......76
Treatment of Antioxidants, CYP-inhibitors, and Chemodietary Agents Reduce
Viral Load in Caski Exosomes-treated U1 Cells .......................................................82
Discussion ......................................................................................................................82
Conclusion .....................................................................................................................88

ix

CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS ................................89
LIST OF REFERENCES ................................................................................................93
VITA................................................................................................................................117

x

LIST OF TABLES
Table 2-1.

Prevalence of smoking among HIV-1-infected population. .........................14

Table 2-2.

Standard incidence ratio (SIR) for HPV-induced cervical cancer among
women living with HIV-1 worldwide. .........................................................17

Table 2-3.

HPV genotypes observed in HIV-1-postive women with cervical cancer. ..19

xi

LIST OF FIGURES
Figure 1-1. HIV-1 life cycle and antiretroviral drugs that act on its various stages. .........5
Figure 3-1. Hypothesis: Polyaryl hydrocarbons in cigarette smoke and HPV-infected
cervical cancer cells exacerbate HIV-1 replication via CYP-mediated
oxidative stress pathway. ..............................................................................24
Figure 4-1. Effect of acute treatment of BaP, NPh, and Phe on ROS level (A) and
cell viability (B) in U937 cells. ....................................................................32
Figure 4-2. Effect of acute treatment of BaP (A), NPh (B), and Phe (C) on mRNA
and protein expression of CYP1A1 in U937 cells. ......................................33
Figure 4-3. Effect of acute treatment of BaP (A), NPh (B), and Phe (C) on mRNA
and protein expression of CYP3A4 in U937 cells. ......................................34
Figure 4-4. Effect of acute treatment of BaP (A), NPh (B), and Phe (C) on mRNA
and protein expression of SOD1 in U937 cells. ...........................................35
Figure 4-5. Effect of acute treatment of BaP (A), NPh (B), and Phe (C ) on mRNA
and protein expression of catalase in U937 cells. ........................................36
Figure 4-6. Effect of chronic (7 days) treatment of BaP, NPh, and Phe on reactive
oxygen species (ROS) level (A-B) and caspase-3 activity (C) in U937
cells...............................................................................................................38
Figure 4-7. Cell viability upon chronic treatment by BaP, NPh, and Phe measured by
flow cytometry (A-B) and XTT assay (C). ..................................................39
Figure 4-8. Effect of chronic (7 days) treatment of BaP, NPh, and Phe on mRNA
and protein expression of CYP1A1 (A) and CYP3A4 (B) in U937 cells. ...40
Figure 4-9. Effect of chronic (7 days) treatment of BaP, NPh, and Phe on mRNA
and protein expression of AOEs SOD1 (A) and catalase (B) in U937
cells...............................................................................................................41
Figure 4-10. Cell viability (A), ROS level (B) and caspase-3 activity (C) upon
chronic treatment by BeA and BeF in U937 cells. .......................................43
Figure 4-11. Cell viability (A), ROS level (B) and mRNA expression level of
CYP1A1 (C) and CYP3A4 (D) upon chronic treatment by BaP in
primary macrophages. ..................................................................................44
Figure 5-1. Chronic treatment of BaP induces HIV-1 replication and apoptotic DNA
damage in HIV-1-infected macrophages. .....................................................54

xii

Figure 5-2. Chronic treatment of BaP induces expression of CYPs in U1 cells. ............55
Figure 5-3. Chronic treatments of BaP have no significant effect on the expression
of AOEs in U1 cells. ....................................................................................56
Figure 5-4. Treatment of antioxidants and CYP1A1 inhibitors reduce ROS in U1
cells due to BaP exposure.............................................................................58
Figure 5-5. Treatment of antioxidants and CYP1A1 inhibitors reduce HIV-1
replication in U1 cells due to BaP exposure. ...............................................59
Figure 5-6. Translocation of NF-κB subunits from cytoplasm to nucleus upon BaP
exposure. ......................................................................................................60
Figure 5-7. Treatment of NFκ-B inhibitors reduce HIV-1 replication in U1 cells due
to BaP exposure. ...........................................................................................61
Figure 5-8. Schematic diagram showing the mechanism of BaP-induced -1-1
replication in macrophages...........................................................................63
Figure 6-1. Caski cell culture supernatant (CCS) increases HIV-1 replication and
oxidative stress in U1 macrophages. ............................................................72
Figure 6-2. Caski cell culture supernatant (CCS) enhances CYP expression in U1
macrophages. ................................................................................................75
Figure 6-3. Caski cell culture supernatant (CCS) alters antioxidant enzyme (AOE)
expression in U1 macrophages. ....................................................................77
Figure 6-4. U1 macrophages uptake CCS-derived exosomes (CCS-Exo) that contain
oxidative stress factors. ................................................................................79
Figure 6-5. CCS-derived exosomes (CCS-Exo) increases HIV-1 replication and
oxidative stress in U1 macrophages. ............................................................80
Figure 6-6. Treatment of antioxidant, CYP inhibitors, and chemodietary agents
reduce CCS or CCS-derived exosomes (CCS-Exo)-induced HIV-1
replication in U1 macrophages. ....................................................................83
Figure 6-7. Proposed model for HPV-HIV-1 interaction via exosomes. ........................85

xiii

LIST OF ABBREVIATIONS
AHR
AIDS
ART
APOBEC
Arnt
AOE
ASK1
BaP
BeA
BeF
BHT
BHA
CCS
CCS-Exo
CCR5
CD4/8
CDC
C/EBPβ
CSC
CXCR4
CYP
DC-SIGN
Epi
ESCRT
gp120
HIV-1
HPV
HSIL
IL1-β
IKK-16
IARC
LTR
MAPK
MHC I
MIP-1a
Nef
NFAT
NF-κB
NMDA
NPh
Nrf-2
NRTI

Aryl Hydrocarbon Receptor
Acquired Immunodeficiency Syndrome
Antiretroviral Therapy
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-like
AHR Nuclear Translocator
Antioxidant Enzymes
Apoptosis Signal-regulating Kinase 1
Benzo(a)pyrene
Benzo(a)antharacene
Benzo(b)fluoranthene
Butylatedhydroxy Toluene
Butylatedhydroxy Anisole
Cell Culture Supernatant from Caski Cells
Exosomes Derived from Caski Cell Culture Supernatant
C-C Chemokine Receptor Type 5
Cluster of Differentiation 4/8
Center for Disease Control and Prevention
CCAAT Enhancer Binding Protein β
Cigarette Smoke Condensate
C-X-C Chemokine Receptor Type 4
Cytochrome P450
Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing NonIntegrin
Ellipticine
Endosomal Sorting Complex Required for Transport
Glycoprotein 120
Human Immunodeficiency Virus-1
Human Papilloma Virus
High-grade Squamous Epithelial Lesions
Interleukin 1-beta
IkB Kinase 16
International Agency for Research on Cancer
Long Terminal Repeat
Mitogen-Activated Protein Kinases
Major Histocompatibility Complex
Macrophage Inflammatory Protein
Negative Regulatory Factor
Nuclear Factor of Activated T cells
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
N-Methyl-D-Aspartate
Naphthalene
Nuclear Factor Erythroid 2- related Factor
Nucleoside Reverse Transcriptase Inhibitor

xiv

NNRTI
PAH
PBMC
PLWH
PLWHA
Phe
PI
PIC
Pin
P-TEFb
RANTES
Res
RT
ROS
SOD1/2
SiRNA
TAC
TAR
Tat
TB
TNF-β
UNAIDS
Vif
Vpr
Vpu
Vit C
Vit E
XRE

Non- Nucleoside Reverse Transcriptase Inhibitor
Polyaryl Hydrocarbon
Peripheral Blood Mononuclear Cells
People Living with HIV-1
People Living with HIV-1/AIDS
Phenanthrene
Protease Inhibitors
Preintegration Complex
Pinnostilbene
Positive Transcription Elongation Factor b
Regulated on Activation, Normal T cell Expressed and Secreted
Resveretrol
Reverse Transcriptase
Reactive Oxygen Species
Superoxide Dismutase 1/2
Small Interfering RNA
Total Antioxidant Capacity
Transactivation Response
Transactivator of Transcription
Tuberculosis
Tumor Necrosis Factor-beta
Joint United Nations Programme on HIV/AIDS
Viral Infectivity Factor
Viral Protein R
Viral Protein U
Vitamin C
Vitamin E
Xenobiotic Responsive Element

xv

CHAPTER 1.

INTRODUCTION*

HIV-1 Prevalence and Epidemiology
According to the surveillance report by Center for Disease Control and Prevention
(CDC), 36.7 million people are currently living with HIV-1 worldwide and about the
same number of people (35 million) have died since the start of the epidemic. The Joint
United Nations Program on HIV-1/AIDS (UNAIDS) published a report in 2017, which
revealed that the global prevalence of HIV-1 is 0.8% in adults. The report also revealed
that, approximately 69.4% of the people living with HIV/AIDS (PLWHA) reside in the
Sub-Saharan Africa, 13.8% in Asia and Pacific, 5.7% in West and Central Europe and
North America, 5.7% in Latin America and Caribbean, 4.3% in East Europe and Central
Asia, and 0.6% in Middle East and North Africa [1]. In the United States alone, there
were around 1.1 million PLWHA with 38,500 new infections and 6465 deaths due to
HIV infection in the year 2015 (CDC report). However, the deaths resulting from HIV-1
infection dropped by 45% between 2005 and 2015 (UNAIDS 2015 report). The decrease
in HIV-1-related deaths may be attributed to the advancements in antiretroviral therapy
(ART). It was reported that 62% of the PLWH received ART, 48% retained continuous
treatment and 49% achieved viral suppression in 2014 [2]. Although, there was a
substantial decrease in deaths due to HIV-1, the rate of incidence of HIV-1 decreased
only by 8% from year 2010 to 2015. The incidence rate was observed highest among
males (IR= 24.1), persons aged 25-34 (IR=31.3) and black/African Americans (IR=49%).
The introduction of ART has indeed elongated the life span of PLWHA, however, they
are now vulnerable to various HIV-1-associated comorbidities like cancer, tuberculosis
and HIV-associated neurodegenerative diseases (HAND). The burden of cancer
(especially non-Hodgkin’s lymphoma, Kaposi’s sarcoma, anal cancer and lung cancer)
has substantially increased in PLWHA by about 50% in 2010 [3]. Cancer-related deaths
in PLWHA have also increased by 8% within a decade from 2000 to 2010 [4]. Similarly,
in a study conducted by Sactor et al. (2016), they observed that the frequency of HAND
increased in PLWHA by 6% from 2009 to 2012 [5].
HIV-1 Biology
HIV-1 Structure
HIV-1 is a primate lentivirus that belongs to a family of retrovirus. Retroviruses
are capable to reverse-transcribe their RNA into DNA and incorporate the viral DNA into
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the host genome, which is an important mechanism of sustenance for the viruses
belonging to this category Lentivirus is a type of retroviruses with longer incubation
period. HIV-1 is spherical in shape with a diameter of approximately 100 nm. The virus
comprises of two single-stranded RNA enclosed within a cone shaped capsid made of
p24 proteins. The RNA comprises of three essential genes (gap, pol and env), two
regulatory genes (tat and rev) and four accessory genes (vif, vpr, vpu, and nef) that
encodes for altogether 15 proteins. Within the capsid, there are other proteins and
enzymes such as reverse transcriptase, integrase, protease, vif vpr, nef, and p7, which are
crucial for viral development. Surrounding the capsid is a matrix made of p17 protein,
whose integrity is maintained by bilayered phospholipid membrane. The phospholipid
membrane, which forms the viral envelope is embedded with 72 Env knobs, each
comprised of trimer of gp41 topped with trimer of gp120. The gp41 trimer form a stem of
Env protein, which is embedded into the lipid membrane, while gp120 forms a cap that
protrudes out of the membrane [6].
HIV Life Cycle
Viral entry. HIV-1 entry to the host cells is initiated by binding of viral envelope
protein, gp120 with CD4 receptors on the surface of the host cell membrane. Binding of
gp120 with CD4 receptor changes the conformation of gp120, which facilitates its
binding to host cell co-receptors such as CCR5 and CXCR4. This interaction exposes the
gp41 subunit of the viral Env protein, which causes fusion of viral envelop and host cell
membrane. The viral matrix and capsid are then phosphorylated by cellular kinases (e.g.
MAPK kinases), which uncoats the capsid and releases its contents including the two
single-stranded RNA, into the host cytoplasm [7]. HIV-1 enters the host cell through
CCR5 coreceptors during the early stages of viral infection, while during the later stages
of developing immunodeficiency, the virus tends to enter via CXCR4 coreceptors [8].
HIV-1 also enters macrophages through endocytic pathway in a CD4 and CCR5independent manner, especially via clathrin-mediated micropinocytosis. However, the
viruses that enter the host cells via endocytosis have lesser infectivity, which is most
likely due to the inactivation of viral particles within the endosomes and lysosomes [9].
Another mechanism of HIV-1 entry is via DC-SIGN (a C-type lectin expressed in the
surface of dendritic cells), independent of CD4 receptor. Dendritic cells are present in
peripheral mucosal tissues and have a major function as antigen- presenting cells in
lymphoid organs. HIV-1 gp120 proteins binds to DC-SIGN lectins on the immatured
dendritic cells. Upon maturation, the dendritic cells transport the DC-SIGN-bound
viruses to the T-cells in the lymphatic organs [8].
Reverse transcription. Shortly after the virus fuses to the host plasma
membrane, there occurs the formation of reverse transcription complex into the host
cytoplasm, which comprises two single-stranded viral RNA, cellular lysine transfer RNA
(tRNA Lys), reverse transcriptase (RT), integrase, capsid and cellular proteins and viral
matrix. RT enzymes comprise of two components: DNA polymerase and RNase H. DNA
polymerase uses cellular nucleotides to synthesize DNA strands. Cellular tRNA Lys
binds to the primer binding site near the 5’ terminal end of the viral RNA genome and
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serves as a primer for the synthesis of (-)-strand DNA by adding complementary
nucleotides along the 5’ end of the viral RNA genome. RNase H degrades sections of
RNA from the RNA/DNA duplex, except for the purine-rich segments. These purinerich segments serve as primers for the synthesis of (+)-strand DNA using tRNA Lys
bound (-)-strand DNA as a template [10]. After the formation of linear double stranded
DNA, it forms a preintegration complex (PIC) with viral proteins (integrase, matrix, Vpr
and capsid), which is translocated into the host nucleus via microtubule network [11].
Viral integration and transcription. Within the host nucleus, the preintegration
complex is integrated into the host DNA by viral protein, integrase, preferentially near
the DNAse-hypersensitive sites [12]. As the host cell is unable to distinguish between the
proviral DNA and the DNA of its own, the host nuclear enzymes transcribe proviral
DNA into viral messenger and genomic RNA. The LTR region of the proviral DNA
contains binding sites for host cell nuclear transcription factors such as nuclear factor kappa B (NF-κB) and nuclear factor of activated T cells (NFAT) and RNA polymerase II.
NF-κB and NFAT are present in the cytoplasm in their inactive state, which translocate
into the nucleus after activation by ROS, various cytokines or antigens. Binding of these
transcription factors and RNA polymerase II at the proviral LTR region leads to the
initiation of viral DNA transcription, forming short HIV-1 transcripts with RNA stem
loop called transactivation response (TAR) element. The elongation of these short
transcripts is facilitated by the binding of a viral transactivator protein, Tat and positive
transcription elongation factor b (P-TEFb) at the TAR element. The complex of Tat and
P-TEFb activates RNA polymerase II to elongate the viral transcripts. The viral mRNA
and genomic RNA thus formed are exported from the host nucleus to the host cytoplasm.
Viral translation. Within the cytoplasm, the cellular enzymes translate the viral
mRNA into viral proteins. Unspliced transcripts are used to synthesize Gag and Gag-ProPol proteins and spliced transcripts are used to synthesize Env, Nef, Tat, and Vpr. Larger
polypeptides are cleaved by viral protein, protease into small functional proteins. Viral
proteins such as Tat and Rev have functions in the transcription of proviral DNA within
the nucleus, while viral Nef and Vpr alter the cellular environment for efficient viral
replication. Nef downregulates the expression of CD4 and MHC I determinants on the
surface of the infected cells, thereby protecting them from being engulfed by CD8
cytotoxic T cells. Nef also inhibits p53-mediated apoptosis of the infected cells [13] and
promotes viral morphogenesis, budding, and infectivity [14]. During the budding stage,
vif protects the virion from the antiviral activity of a cellular protein, APOBEC through
polyubiquitination and proteosomal degradation [15].
Viral assembly and budding. All viral structural proteins can be derived from
three polyproteins: Gag, Gag-Pro-Pol, and Env. Viral assembly occurs by clustering of
~1500-2000 Gag proteins, ~200 Gag-Pol-Pro, and 2 copies of viral RNA genome at the
inner surface of the plasma membrane. Env proteins synthesized at the rough
endoplasmic reticulum also translocate towards the viral budding site of the plasma
membrane and package on the surface of the Gag after budding of the virion. The
immature virion buds from the plasma membrane by hijacking the host cell endosomal
sorting complex required for transport (ESCRT) [16]. After budding, the viral protease
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cleaves Gag and Gag-Pol-Pro proteins into functional proteins of a mature, infectious
virion [17, 18]. The schematic diagram for the HIV-1 life cycle and antiretroviral drugs
that act on its various stages has been shown in Figure 1-1.
Viral latency. HIV-1 particles can reside within the cells in a dormant state
without replicating, which is termed as viral latency. Viral latency may occur either via
failure of PIC integration into the host gene or inhibition of the proviral DNA
transcription. PIC integration may be interrupted if the nuclear transport of the complex is
inhibited or if a weak PIC complex is synthesized due to poor reserve transcription [19].
Unintegrated PICs are often observed in viral reservoirs such as macrophages and they
are capable of transcribing viral genes such as Nef and Tat [20]. If PIC is able to reach
the nucleus, but binds to transcriptionally inactive heterochromatins, proviral DNA
transcription does not occur [19]. Some cells lack transcription factors (NFκB, NFAT)
and viral proteins (Tat), which impedes the proviral DNA transcription within them.
While some cells, for example, monocytes contain high levels of anti-HIV-1 miRNA
(miRNA-382, miRNA-150, miRNA-28, miRNA-223) that also inhibit the proviral DNA
transcription [21].
HIV Treatment Strategies
HIV-1 mainly targets the immune cells with CD4 receptors such as T
lymphocytes, monocytes, macrophages and dendritic cells [22]. After infection, the virus
replicates within the cells leading to progressive loss of CD4+ T cells and
immunosuppression. Over the time, the immune deficiency develops characteristic
opportunistic infections and/or cancerous conditions called Acquired Immunodeficiency
Syndrome (AIDS). With the introduction of antiretroviral therapy (ART), HIV-1 is no
longer a life-threating disease but a chronic manageable disease. According to the recent
guidelines by the U.S. department of health and human services, ART treatment for HIV1 is recommended for all individuals with HIV-1, regardless of CD4+ cell counts [23].
ART does not cure or eradicate HIV-1, but suppresses the viral replication and minimizes
the risk of viral transmission. There are 5 different classes of antiretroviral (ART) drugs
approved by Food and Drug Administration (FDA) that are currently available
commercially: 1. Nucleoside reverse transcriptase inhibitors (NRTIs) 2. Non-nucleoside
reverse transcriptase inhibitors (NNRTIs) 3. Protease inhibitors (PIs) 4. Entry inhibitors,
and 5. Integrase inhibitors [24].
NRTIs are the first FDA approved ARTs for HIV-1 treatment. As they have
structural similarity to the cellular nucleosides, they compete with these natural
nucleosides to make up viral DNA. Since, they do not have a 3’-hydroxyl group at the
sugar moiety, the drugs targeting this hinder the formation of 3, 5’-phosphodiester bond
between a NRTI and incoming 5’-nucleosides, thus interrupting the formation of viral
DNA chain. On the other hand, NNRTIs binds to the noncatalytic allosteric site of the
reverse transcriptase enzyme, which brings about a conformational change in its substrate
binding site, leading to its reduced polymerase activity. NRTIs are administered as
prodrugs, which require activation by cellular kinases to mediate its action, while
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Figure 1-1.

HIV-1 life cycle and antiretroviral drugs that act on its various stages.
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NNRTIs are administered in their active forms. NRTIs and NNRTIs include 50% of the
commercially available ART drugs [25]. Integrase inhibitors acts by inhibiting the HIV-1
DNA strand transfer and integration into the cellular DNA. Protease inhibitors interfere
with viral particle synthesis by blocking proteolysis of essential viral polyproteins, gag
and gag-pol. Entry inhibitors are relatively new class of ART drugs that are subclassified
into Fusion inhibitors, CCR5 antagonists, and post attachment inhibitors. By binding to
the viral envelop proteins, fusion inhibitors block the formation of six helical bundle
structure, which provides the force necessary for fusion pore formation in the cell
membrane. CCR5 antagonists block viral entry by binding to the allosteric sites of CCR5
coreceptors thereby, changing its structural conformation such that the HIV-1 envelop
protein, gp41 cannot recognize the binding site [26]. Post attachment inhibitors act after
gp120 binds to CD4 receptors. Binding of these inhibitors changes the conformation of
gp120-bound CD4 receptors such that it impedes the interaction of the later with the
CCR5 and CXCR4 coreceptors, which is an important step for viral entry into the host
cells [27]. Pharmacokinetic enhancer drugs such as cobicistat and ritonavir are also used
in combination with other ART drugs. Although ritonavir has some antiviral activity,
cobicistat does not have antiviral activity but it boosts the activity of other antiviral drugs
(such as PIs and elvitegravir) by inhibiting CYP3A4 enzymes, which metabolize majority
of the antiretroviral drugs [28].
Drug Abuse
Drug abuse is a major problem among PLWHA with approximately three-fold
higher prevalence compared to the general population [29]. A study done by the NIH
during 2005-2009 revealed that about one-third of the HIV-1 population were current
drug users or alcoholics and 24% of them received medical treatment for drug abuse [30].
A cross sectional analysis study from the data obtained from 16 studies conducted at 14
sites across United States revealed that 47.7% of PLWHA are involved in alcohol use and
38.1% involved in illicit drug use. The report also suggested that 22.1% of the
participants used more than one drugs of abuse [31]. Another report published by
Gamarel et al. (2016) suggests that out of 2216 PLWHA they surveyed, 32.9% frequently
use tobacco, 27.5% use marijuana, 21.3% use alcohol, and 22.5% use other illicit drugs
[32]. These drugs directly affect the pathogenesis of HIV-1/AIDS by enhancing
immunosuppression or by activating cellular signaling pathways that enhance the viral
replication [33]. As an indirect effect, substance abuse alters the mood, behavior, and
capacity of judgement and decision making in PLWHA. This behavioral change indulges
them in activities such as sharing needles, unprotected sex, and sex with multiple
partners, which highly increase the risk of exposure to blood and other fluids of infected
individuals and therefore HIV-1 transmission. The report by the NIH also showed that
16% of HIV-1 transmission occurred through intravenous drug use and the remaining
84% via sexual contact, especially men having sex with men (MSM). Drug abuse also
causes non-adherence to ART and drug-drug interactions resulting in reduced efficacy
and increased toxicity of ART [34, 35]. Moreover, PLWHA are usually involved in the
use of more than one drugs of abuse [35] , which directly act on central nervous system,
causing neuroinflammation and neurotoxicity. The neurotoxic effects from multiple drug
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use further accentuates the neuronal damage caused by HIV-1 and increase risk of HIV1-associated neurodegenerative diseases.
Smoking
The frequency of tobacco smoking is more than twice as high among PLWHA as
it is in the general population [36]. Due to this increased prevalence, the deleterious
effects of smoking on treatment outcomes for PLWHA have been investigated in several
studies [37, 38]. While smoking in the general population is known to enhance the risk of
cancers and various respiratory and cardiovascular diseases, PLWHA face an even
greater likelihood of developing life-threatening conditions related to tobacco use [39,
40]. Additionally, an analysis of patient populations provided with sufficient access to
ART and quality healthcare has demonstrated that HIV-1-infected smokers display the
highest rate of all-cause mortality compared to other HIV-1-infected individuals and
population controls [41]. The explanation about how tobacco plays role in HIV-1
replication and pathogenesis will be discussed in detail in later sections.
Alcohol
The prevalence of alcohol abuse among PLWHA is 2-4 times higher than the
general population [42]. Approximately 40-50% PLWHA are reported to have used
alcohol, among which ~28.8% and ~10% are involved in harmful and hazardous drinking
habits respectively [43-46]. High prevalence of heavy alcohol drinking is observed more
among PLWHA who use one or more kinds of illicit drugs but the opposite has been
observed in case of patients on ART with low CD4 counts [44, 47]. PLWH involved in
hazardous drinking are 35% less likely to show adherence to ART, and the viral
suppression among these patients is also 25% lesser than their non-drinking counter parts
[44]. Alcohol also enhances the metabolism of ART drugs (such as PIs and NNRTIs) by
upregulating the expression of drug metabolizing enzyme CYP3A4. The enhanced
metabolism prevents ART to attain optimal concentrations at the target tissues and
therefore reduces their efficacy [29]. Alcohol induces oxidative stress by upregulating the
expression of CYP2E1, NAPDH oxidase, chemokines, and cytokines [29, 48-50] in
hepatic cells, monocytes/macrophages, astrocytes, and neurons. The alcohol-induced
oxidative stress causes liver damage and aggravates other comorbid conditions (like
Hepatitis B and C infections, hypertension, and diabetes) in PLWH. Within the brain, the
oxidative stress compromises the integrity of the blood-brain-barrier, making the brain
tissues more vulnerable to neurotoxic effects of HIV-1 and other toxic substances. The
alcohol-induced oxidative stress adds to the effect of HIV-1-induced oxidative stress,
which further aggravate viral replication and apoptosis in brain cells. By enhancing the
expression of various pro-inflammatory cytokines and chemokines within the brain
tissues, alcohol promotes neuroinflammation and further elevate ROS generation.
Alcohol exposure is also reported to cause glutamate toxicity in neurons through
overstimulation of NMDA receptors [51]. Moreover, alcohol exposure is shown to
potentiate the neurotoxic effects of HIV-1 proteins such as Tat, Nef, Vpr and gp120 [52,
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53]. Several clinical studies have shown that alcohol use has both additive and interactive
effects on mediating neuropathological conditions in HIV-1 patients, including HAND
[54, 55].
Marijuana
Marijuana is the most commonly used illicit drug among PLWHA. Recent studies
conducted on a cohort of HIV-1-infected patients receiving ART report that
approximately 20-30% of the infected population are addicted to marijuana [32, 56-59].
A study conducted by Fogarty et al. (2007) reported that ~60% of 408 HIV-1 infected
patients in their study used marijuana; 55.7% of which reported to use it for recreational
purpose, while 44.3% used marijuana for both recreational and medicinal purpose [60].
The effect of marijuana on adherence to ART and viral suppression in PLWH under care,
is a disputed subject due to the mixed findings obtained in different cohorts of PLWH
depending upon its use as illicit, medicinal, or recreational purpose. Some studies have
revealed that non-adherence to ART is frequently observed in PLWH who are addicted to
marijuana [61, 62]. In contrast, some studies suggest that use of marijuana can have a
positive effect on ART adherence through management of HIV symptoms and side
effects of ART like anxiety, depression, fatigue, nausea, diarrhea, and peripheral
neuropathy [58, 59, 63]. Interestingly, a recent study has revealed no significant
association between the high-intensity marijuana use and ART adherence, suggesting that
its use can rather be clinically beneficial for HIV symptom management [64]. Similarly,
there is also a discrepancy on whether marijuana use affect the viral suppression in
PLWH, with different studies showing contrast results [57, 61, 65]. However, a
significant decrease in neurocognitive performance, learning, memory, and poor mental
quality of life have been observed in PLWH who use marijuana in a moderate to heavy
range, compared to those who used lightly or none [65-68]. Moreover, higher impact on
learning and memory impairment have been observed among PLWH with early onset of
marijuana (regular use prior to age 18) compared to the non-marijuana users or those with
late onset of marijuana (regular use at 18 or later) [69]. Use of marijuana also leads to
behavioral changes like involving in unprotected sex, which increases the probability of
HIV-1 transmission [70].
FDA has approved Δ9-tetrahydrocannabinol (Δ9-THC), a major psychoactive
component in marijuana, for the treatment of anorexia in PLWH. Clinical studies have
also shown that its administration have minimal or very less effect on the viral load,
CD4+ and CD8+ cell counts and protease inhibitor levels over a short-term treatment [71].
Chronic exposure of Δ9-THC in SIV-infected rhesus macaques showed that Δ9-THC
does not enhance viral load or morbidity but attenuates the SIV progression through
reduction of viral levels and inflammation [72]. However, the effect of Δ9-THC in SIVinfected rhesus macaques is sex-dependent. In case of female rhesus macaques, Δ9-THC
did not show any reduction in viral load or CD4+/CD8+ ratio; instead, it increased the
expression of CXCR4 in CD4+/CD8+ lymphocytes prior to SIV inoculation [73]. With
these mixed results, it is not clear if the use of marijuana can actually attenuate HIV-1
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progression in human, which highlights the need of further clinical investigation in this
regard.
Cocaine
After Marijuana, cocaine is the second most used illicit drugs among PLWH with
8-15% PLWH involved in cocaine abuse [31, 74, 75]. Unlike marijuana, cocaine use has
a negative impact on ART adherence. The adherence to ART is observed to be ~3-fold
lower in cocaine users compared to non-users [76]. In addition, decreased ART response,
increased viral load and CD4+ T cell depletion, and increased progression of AIDS have
also been observed in PLWH who used cocaine [77, 78]. Furthermore, patients under
ART are more prone to show increased cocaine toxicity through cocaine-ART
interactions. Since, ART drugs such as PIs and NNRTIs are inducers/inhibitors of
CYP3A4, they alter the CY3A4-mediated metabolism of cocaine. Enhanced formation of
norcocaine, a hepatotoxic metabolite of cocaine leads to severe liver injury [34].
Cocaine abuse directly impacts HIV-1 replication in various immune cells by
enhancing the viral entry into the host cells through upregulation of CCR5 and CXCR4
coreceptors and downregulation of chemokines (RANTES, MIP-1a and MIP-1b) that
suppress HIV-1 entry into the host cell membrane [79, 80]. Cocaine also induces viral
replication by enhancing the integration of PIC into host cell DNA [81]. Studies have
also shown that cocaine negatively modulates anti-HIV miRNAs (such as miRNA-125b),
which suppress HIV-1 replication in monocyte-derived dendritic cells by inhibiting the
translation of HIV-1 transcripts [82]. In addition to its role in viral replication, cocaine
exposure has also shown to cause apoptosis of CD4+ cells by inducing oxidative stress
and mitochondrial depolarization [83].
Moreover, cocaine also plays a major role in the progression of HAND in PLWH.
Higher extent of neurocognitive impairment and neurodegeneration, and faster
progression to NeuroAIDS have been observed in PLWH who use cocaine compared to
the non-drug users [84]. By compromising the integrity of BBB, cocaine increases the
viral invasion into the brain tissues. More importantly, cocaine exposure not only
enhances viral replication in macrophages and microglia but also in astrocytes, which are
normally resistance to viral replication [85]. Cocaine also forms platelet-monocyte
complex in the blood, which can easily cross the BBB and cause neuroinflammation. In
addition, cocaine activates viral proteins such as Tat and gp120, which causes
neurotoxicity by inducing oxidative stress, loss of mitochondrial potential, and neuronal
apoptosis [86, 87]
Coinfections in HIV-1
As HIV-1 weakens the immune system in HIV-1-infected individuals, they are
susceptible to infections by various pathogens, including bacteria, fungus, protozoa, and
virus. The coinfection with these pathogens is also common in HIV-1 patients who are on
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ART because ART does not completely restore the immune response to normal levels.
The most common types of coinfections as reported by National Institute of health (NIH)
are tuberculosis, hepatitis B and C, and human papilloma virus (HPV) coinfections [88].
Tuberculosis (TB)
According to epidemiological data reported by WHO, the prevalence of TB is
about 16-27 times higher among PLWH compared to general population [89]. The report
also indicated TB to be the most common coinfection in PLWH and one of the major
causes of HIV-1-related deaths [90]. The risk of TB is observed to be high among PLWH
with higher viral load, lower CD4+ cell counts, and prior history of TB, however, the risk
is observed to be lower in patients who are under ART [91]. CD4+ T cells protect against
M. tuberculosis by releasing proinflammatory cytokines; macrophages engulf M.
tuberculosis by phagocytosis and autophagy; CD8+ T cells inactivate TB antigen by
lysing the antigen-presenting cells [92]. The number of these cells, (especially CD4+ T
cells which are major cells for protecting against M. tuberculosis) are reduced in PLWH,
which increase the risk and pathogenesis of TB in this population compared to the
general population. Further, HIV-1 proteins such as Nef inhibits apoptotic response of
macrophages against M. tuberculosis [93, 94].
HIV-1 viral load in lung tissues has been observed to be increased by 4-fold
compared to the plasma viral load in PLWH coinfected with TB [95]. Similarly,
macrophage cell lines (U937 and THP-1) coinfected with HIV-1 and M. tuberculosis also
exhibited ~3-fold increase in viral load compared to their counterparts without TB
infection [96]. Innate and adaptive immune response to M. tuberculosis release different
proinflammatory cytokines (IL1-β, IL-6 and TNF-β). These cytokines stimulate the
nuclear transcription factors that cause the activation of HIV-1 LTR, thereby enhancing
the transcription of HIV-1 genome [97-99]. Activated lymphocytes are shown to increase
HIV-1 replication in HIV-1/TB coinfected alveolar macrophages through downregulation
of CCAAT enhancer binding protein β (C/EBPβ) and upregulation of NF-κB in infected
macrophages. These are nuclear transcription factors that inhibit and promote activation
of HIV-1 long terminal repeat (LTR), respectively [97]. Innate immune response to TB
has also been shown to increase the gene and protein expression of another nuclear
transcription factor, nuclear factor of activated T cells 5 (NFAT 5), which also act on
HIV-1 LTR leading to enhanced HIV-1 gene transcription [98]. Furthermore, release of
cytokines in response to TB causes accumulation of T cells, which are major targets for
HIV-1 infection [100, 101]
Hepatitis B and C
Coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are
common in PLWH. The prevalence of hepatitis B and C are 10-times and 6-times,
respectively, higher in PLWH compared to the general population [102]. However, CDC
reported that the incidence of HCV is approximately 3-times higher than hepatitis B
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among PLWH in USA [103]. The higher prevalence of HCV and HBV coinfection in
PLWH is perhaps due to the common mode of transmission for these viruses through
sharing of infected needles and sexual contact. However, HCV is more prevalent among
PLWH who use intravenous drugs (72-95%) compared to those who are MSM (1-12%)
or heterosexuals (9-27%) [102]. With the depletion of CD4+ T cells in HIV-1 infection,
there is further loss of HCV specific CD4+ and CD8+ T cell responses in HIV-1/hepatitis
coinfection, which provides a favorable environment for HCV replication and
pathogenesis [104, 105]. Further, HIV-1 envelop proteins such as gp120 directly enhance
HCV replication by binding to CCR5 and CXCR4 coreceptors in hepatocytes and
subsequently by upregulating cytokines like TGF-β1, which have a stimulatory effect on
HCV infection [106].
The effect of HIV-1/hepatitis virus coinfection in the progression of HIV-1
disease is not clear due to the conflicting evidences presented by different studies.
Several studies conducted before ART era reported that HIV-1/hepatitis coinfection does
not impact the progression of HIV-1 disease [107-110]. A study done in 9802 European
HIV-1 cohorts revealed that HIV-1/HBV coinfection did significantly increase the liverrelated mortalities, but it did not have any effect on the progression of HIV-1/AIDS
[111]. Another study done in a cohort of 328 HIV-1 patients under antiretroviral therapy
also indicated no association of HCV on the mortality observed in PLWH [108]. In
contrast, many studies conducted in ART era reported increased morbidity and mortality
in HIV-1/hepatitis coinfected patients compared to patients infected with HIV-1 alone
[112, 113]. For example, a study conducted in 3111 Swiss HIV-1 cohorts under potent
ART showed that HCV coinfection increased the clinical progression to AIDS and death
rate in HIV-1/HCV coinfected patients, possibly via impaired CD4-cell recovery [112].
HIV-1 envelop proteins and the use of ART are also associated with severe
hepatotoxicity, which could have increased the risk of hepatitis infections and subsequent
morbidity and mortality in the HIV-1/hepatitis coinfected patients [106, 114]. Further,
several studies have suggested the role of HBV protein X (pX) as transcriptional
transactivator that lead to HIV-1 replication in CD4+ T cells. HBV pX does not directly
bind to HIV-1 LTR, but it activates HIV-1 transcription by stimulating the signaling
pathways that activate transcription factors involved in HIV-1 transcription (NF-κB,
NFAAT) or by interacting with the basal transcriptional machinery [115].
Human Papilloma Virus (HPV)
Infection with low-risk HPV strains (type 6 and 11) only causes benign warts and
condylomas, whereas infection with high risk HPV strains (type 16 and 18) leads to
malignant diseases. The incidence of HPV among PLWHA is 1.5-times higher compared
to general population. Both HPV 16 and 18 genotypes, which cause cervical cancer, are
highly prevalent among PLWHA, with the predominance of the later genotype [116]. The
incidence rate high risk HPV infection of cervix is approximately 3-times higher in HIV1-positive woman compared to HIV-1-negative women. Similarly, the progression of
HPV to high-grade squamous epithelial lesions (HSIL) was also ~2.55 times higher
among HIV-1-positive women compared to HIV-1-negative women [117]. Several
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studies showed that progression of invasive cervical cancer in these patients increased
with the decrease in CD4+ cell counts, suggesting a strong association of
immunosuppression in the progression of the cancer [118-120]. Furthermore, many
studies suggested that HIV-1 infection promotes HPV acquisition either by disrupting the
mucosal epithelium or weakening the mucosal immune system, which facilitates HPV
entry [121]. In addition to increased HPV acquisition, increased reactivation of latent
HPV has also been observed in HIV-1-positive women [122]. HIV-1 proteins like Tat has
also been reported to enhance transcription of HPV genome, leading to increased HPV
replication [123].
On the other hand, several studies have indicated higher risk of HIV-1 acquisition
in HPV-infected patients compared to uninfected individuals [124-126]. A study
conducted by Averbach et al. (2010) indicated that HPV-infected women were 2.4-times
more susceptible to HIV-1 infection compared to uninfected women [126]. Furthermore,
another study suggested the involvement of specific strains of HPV, especially oncogenic
HPV Type 16 and 18 in increasing HIV-1 acquisition among PLWHA [127]. However,
the actual mechanism by which HPV induces the progression of HIV-1 disease is still
unclear. HPV 16 oncoprotein E7 downregulates E-cadherin, an adhesion molecule in the
genital epithelial layer [128]. HPV could possibly increase HIV-1 acquisition by
interfering with the expression of E-cadherin. Immunological response to HPV
accumulates CD4+ T cells at the site of infection, which are primary targets for HIV-1
infection [129]. More than 10-fold increase in the level of the cytokines (IL-6, IL-8,
TNF-α, MIP-1α) has also been observed during HPV infection [130]. Several of these
cytokines including IL-6, IL-8, and TNF-α are shown to increase the expression of HIV-1
in host immune cells [131-133]. Massive oxidative stress occurs during HPV infection.
HPV 16 oncoproteins (E6 and E7) and HPV 18 E2 proteins are known to cause chronic
oxidative stress by a NADPH oxidase pathway or by increasing the mitochondrial ROS,
respectively [134]. This increase in ROS could possibly activate ROS-sensitive nuclear
transcription factors such as NF-κB, leading to the enhanced expression of HIV-1.

12

CHAPTER 2.

INTERACTION OF HIV-1 WITH TOBACCO SMOKING AND
HPV INFECTION*
Tobacco Smoking

Tobacco Prevalence in HIV-1 Patients
In a cross-sectional survey conducted on 419,945 patients with HIV-1 in the US
in 2015, 42.4% were current smokers, 20.3% were former smokers, and 37.3% were nonsmokers [36]. According to the study, the prevalence of smoking among patients with
HIV-1 (42.4%) was more than two times higher than the uninfected US adult population
(20.6%). A similar trend of smoking prevalence was observed in a study that surveyed
HIV-1-infected patients in New York in 2016, which found the association of smoking
with poor health outcomes among PLWHA [135]. A study conducted in Ontario, Canada,
in 2008 reported that 39.3% of the patients with HIV-1 were smokers, which declined by
1.6% by 2014. However, the rate of smoking remained higher among HIV-1 population
than the general population [136]. About 33% of patients with HIV-1 in a study
conducted on South Africans were also found to be smokers [136]. Furthermore, the
prevalence of smoking is much higher among male HIV-1 patients who have sex with
men (MSM) than it is among uninfected men [137-140]. A meta-analysis conducted by
Jin et al. on Chinese PLWHA reported the prevalence of smoking to be 41.1% among the
study population [141]. Table 2-1. summarizes the prevalence of smoking among
patients with HIV-1 in different countries (most of the patients are from the US) from
2014 to 2017 [142-144], showing that smoking is highly prevalent in HIV-1-infected
populations.
Effect of Tobacco on HIV-1 Pathogenesis
Combustion of cigarette smoke constituents generates large quantity of reactive
oxygen species (ROS) such as superoxide, hydrogen peroxide, hydroxyl radical, and
peroxynitrite, which are circulated through the blood to various tissues [145]. Excessive
-------------------* Portions of chapter 2 modified with permission. Ranjit, S., Kumar, S. Recent advances
in cancer outcomes in HIV-positive smokers. F1000 Faculty Rev, 2018. 718
(doi:10.12688/f1000research.12068.1)
* Portions of chapter 2 modified with permission. Ranjit, S., Patters, B.J., Gerth, K.A.,
Haque, S., Choudhary, S., Kumar, S. Potential neuroprotective role of astroglial
exosomes against smoking-induced oxidative stress and HIV-1 replication in the central
nervous system. Expert Opinion on Therapeutic Targets, 2018. 22 (8)
(doi.org/10.1080/14728222.2018.1501473)
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Table 2-1.

Prevalence of smoking among HIV-1-infected population.

Authors
Mdodo et al. [36]
Hile et al. [135]
Bekele et al. [136]
Akhtar-Khaleel et
al. [138]
Pacek et al. [142]
Pollack et al. [144]
Murrison et al.
[146]
Brath et al. [143]

Date of
publication
2015
2016
2017
2016

Location
United States
United States
Canada
United States

HIV-1
patients (n)
419,945
14,713
4473
6577

HIV-1
smokers (%)
42.4
40
39.3
36.9

2014
2017
2016

United States
Vietnam
South Africa

358
636
146

75
36.3
33

2016

Austria and
Germany

447

49.4
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ROS causes oxidative stress that leads to oxidation of vital cellular components such as
DNA, RNA, proteins, and lipids causing cytotoxicity and cell death. Furthermore, ROS
also triggers the expression of pro-inflammatory cytokines and chemokines by activating
the redox-sensitive nuclear transcription factor, NF-κB [147]. The surge of proinflammatory cytokines and chemokines causes the recruitment of leukocytes, primarily
monocytes and neutrophils, to the inflamed vascular endothelial cells [148]. Free radicals,
elastase, and collagenase released from leukocytes, especially neutrophils, cause
endothelial injury contributing to the development of atherosclerotic plaques. Oxidative
stress induced by smoking and the subsequent complex pro-inflammatory cascade and
atherosclerosis is linked to the pathogenesis of various chronic cardiovascular and
respiratory disorders in smokers. As HIV-1 also causes oxidative stress [149-151], the
oxidative damage is more pronounced in HIV-1 smokers, which increases the severity of
the smoking-induced chronic diseases in PLWH. Higher incidence and severe forms of
respiratory infections have been observed in HIV-1 smokers compared to HIV-1 nonsmokers and uninfected smokers [152]. The meta-analysis study done by Marshall et al.
(2009) suggested that there was high incidence of respiratory infections and non-AIDSrelated mortality in HIV-1 smokers compared to HIV-1 non-smokers [140]. HIV-1
smokers mainly suffered death due to smoking-induced chronic diseases like stroke,
asthma, COPD, coronary artery disease, peripheral vascular diseases, or cancers of
organs like oropharynx, larynx, esophagus, lungs, cervix, stomach, bladder or kidney
[37].
Studies have shown that smoking enhances HIV-1 replication in immune cells
[153, 154]. Recent studies from Kumar’s lab demonstrated higher nicotine metabolism,
HIV-1 viral load, ROS level and oxidative damage in HIV-1-positive smokers relative to
HIV-1-positive non-smokers and uninfected smokers [153, 155]. Similar increase in
HIV-1 viral load and oxidative stress have been reported in vitro in cigarette smoke
condensate (CSC)-treated HIV-1-infected monocytic cells (U1 cells) or HIV-1-infected
human primary cells [154]. We also observed significant increase in CYP enzyme
expression: CYP2A6 and CYP3A4 in HIV-1 patients and HIV-1 smokers respectively;
CYP1A1 and CYP1B1 in HIV-1-infected monocytic cells. When we inhibited the
activity of these CYPs using specific CYP inhibitors or by specific siRNA knockdown,
we observed a reduction in oxidative stress and viral load in CSC-treated cells, indicating
the role of CYP enzymes in smoking-mediated oxidative stress and HIV-1 replication.
Similarly, other studies have also revealed that CYP enzymes metabolize polyaromatic
hydrocarbons in cigarette smoke into toxic metabolites that enhances HIV-1 gene
expression by forming DNA adducts [156]. Another study showed that, tobacco enhances
HIV-1 infectivity by up-regulating the expression of genes involved in viral replication
(e.g. CD59 and TAX1BP1) as well as by down-regulating the genes that modulate
cellular defense (e.g. TXNIP and PHGPX) and antigen presentation (e.g. MHC) [157].
Effect of Tobacco on HIV-1 Treatment Outcomes
Several studies have indicated that cigarette smoke decreases the response to ART
[158, 159]. However, it is not clear how tobacco use in PLWH impact ART efficacy. A

15

study done by Feldman et al. (2006) demonstrated that there is higher rate of mortality
(53%) and morbidity (AIDS-defining cancer = 36%) among PLWH on ART who smoked
compared to those who did not smoke [158]. The study findings emphasize nonadherence to ART as a possible cause for decreased response to ART among HIV-1
smokers. Another report by Miguez-Burbano et al. (2003) also showed that the immune
and virologic response to ART decreased by 40% in HIV-1 smokers compared to HIV-1
non-smokers [160]. This study suggested that tobacco use may reduce ART efficacy by
interfering with the metabolism of ART drugs. Tobacco induces the expression of various
CYP enzymes such as CYP 1A1, 1B1, 2A6, and 3A4 in different cell types including
monocytes and macrophages [153, 154]. CYP3A4, which is a major drug metabolizing
enzyme, metabolizes different ART drugs especially, NNRTIs and PIs [161]. Induction
of CYP3A4 by tobacco may result in the enhanced metabolism of ARTs and
consequently its reduced efficacy [159]. On the other hand, inhibition of CYPs by
tobacco can also lead to decreased metabolism of the drugs, resulting in drug toxicity.
Nicotine, an addictive substance in tobacco, also alter the expression of drug efflux
transporters such as P-gp, MRP, and BCRP in the intestinal cells [162]. Alteration in the
expression of these efflux transporters can have a direct impact on the absorption of
orally administered ART drugs. As ART drugs are taken in combination, the drug-drug
interactions with concomitant tobacco use can be even more complex.
HPV Coinfection
HPV Prevalence in HIV-1-infected Patients
The prevalence of any kinds of HPV infection is approximately 20-25% higher in
PLWH compared to general population [163, 164]. A survey conducted among African
women with or without HIV-1 reported that the prevalence of any kind of HPV infection
was about 72.2% in HIV-1-positive women, which was about 25% higher than the
prevalence in uninfected women (47%) [164]. Similarly, another study conducted on
Italian women by Tartaglia et al. (2017) revealed that 48% of HIV-1-positive women had
HPV compared to 28% of HIV-1-negative women [163].
High risk HPV that causes malignant diseases are more common compared to low
risk HPV among HIV-1-infected individuals [165, 166]. High risk HPV type 16 and 18
are responsible for most of the cervical carcinoma in general population [166]. Table 2-2.
shows the standard incidence ratio (SIR) for HPV-induced cervical cancer among HIV-1positive women all over the world, mainly in USA. The data in the table suggests that the
average SIR for cervical cancer in HIV-1-positive women compared to uninfected
women is 4.7, which has remained fairly constant for almost the last two decades. Several
studies have mentioned that the higher incidence and severity of cervical cancer in HIV1-positive women is associated with the decrease in the rate of CD4+ cell counts [119].
Joshi et al. (2014) reported that, the most common HPV genotypes causing
cervical intraepithelial neoplasia (CIN) stages 2 and 3 among Indian HIV-1-positve
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Table 2-2.
Standard incidence ratio (SIR) for HPV-induced cervical cancer
among women living with HIV-1 worldwide.
Authors

Year

Massad et al. [172]
Chen et al. [173]
Abraham et al. [119]
Massad et al. [174]
Chaturvedi et al. [175]
Engels et al. [176]
Clifford et al. [177]
Frisch et al. [178]

2017
2015
2013
2010
2009
2006
2005
2000

Location

SIR
(per 100,000)
United States
3.31
Taiwan
4.01
North America
3
United States
1.32
United States
8.9
United States
4.2
Global
8
United States
5.3
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women were type 16 (58.5%), type 31 (22.6%), and type 18 and 68a (11.3%) [167].
Similarly, a study conducted in HIV-1-infected women with CIN (stages 2 and 3) living
in Botswana, indicated the presence of either HPV 16 or 18 or both in 51% of the
participants [168]. However, Clifford et al. (2016) indicated higher prevalence of HPV
types 16 (42.5%), 18 (22.2%), 45 (14.4%), and 35 (7.1%) in HIV-1-positive women with
invasive cervical cancer [166]. Table 2-3. demonstrates data from 9 different studies
showing HPV genotypes observed in HIV-1-positive women with different stages of
cervical cancer, living at different geographic locations. According to the data tabulated
in Table 2-3, infection with multiple types of HPV are involved in the progression of
cervical cancer. Infection with HPV type 16 and 18 has been observed commonly in
HIV-1-positive women with ICC. In case of the HIV-1 patients with CIN, infection with
HPV type 16 and other high-risk HPV such as 31, 35, 45, 52, and 58 are also commonly
observed.
Effect of HPV on HIV-1 Pathogenesis
Several studies have indicated higher risk of HIV-1 acquisition in HPV-infected
patients compared to uninfected individuals [124-126]. HPV-infected women are 2.4times more susceptible to HIV-1 infection compared to uninfected women [126]. The
actual mechanism involving HPV-mediated HIV-1 acquisition is still not clear. HPV 16
oncoprotein E7 downregulates E-cadherin, an adhesion molecule in the genital epithelial
layer [128]. HPV could possibly increase HIV-1 acquisition by increasing the
permeability of the genital linings through interference with E-cadherin. Persistent HPV
infections lead to preinvasive lesions and invasive cervical cancer. Large number of
CD4+ and CD8+ T cells have been observed in the stromal infiltrates from invasive
cervical carcinoma as well as from preinvasive lesions [169]. Accumulation of CD4+ and
CD8+ T cells, which are major targets of HIV-1 infection, could increase the risk of HIV1 acquisition. Some studies have also shown the association of non-persistent HPV
infections with the increased risk of HIV-1 acquisition [127]. The immune response for
HPV clearance could also aggravate HIV-1 acquisition.
High levels of HIV-1 RNA has also been detected in the plasma of HIV-1infected women with high risk HPV cervical infection [170]. In an in vitro study done by
Gage et al. (2000), there was a significant increase in viral load in U1 monocytic cells
after treatment with supernatant collected from the cultured cervical biopsies and cervical
cancer cell lines [171]. The study also suggested that cytokines released in response to
HPV infection, especially IL-6, may be responsible for increased HIV-1 replication.
More than 10-fold increase in the level of the cytokines (IL-6, IL-8, TNF-α, MIP-1α) has
also been observed during HPV infection [130]. Several of these cytokines including IL6, IL-8, and TNF-α are shown to increase the expression of HIV-1 in host immune cells
[131-133].
Massive oxidative stress occurs during HPV infection. HPV 16 oncoproteins (E6 and E7)
are known to cause chronic oxidative stress by a NADPH oxidase pathway [134]. The
oxidative stress caused by these HPV oncoproteins is shown to cause genomic instability
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Table 2-3.
cancer.

HPV genotypes observed in HIV-1-postive women with cervical

Authors

Year

Location

HPV types

Badial et al. [165]

2018

Brazil

Ortiz et al. [179]

2017

Puerto
Rico

Menon et al. [180]

2016

Kenya

56 (17%) and 16
(15.3%)
52 (17.6%), 58
(11.0%), 59 (11.0%),
16 (9.9%) and 18
(9.9%)
16 (37%) and 18 (24%)

Clifford et al. [181]

2016

Africa

Joshi et al. [167]

2014

Marchetti et al. [182]

2013

Ramogola-masire et
al. [168]
Sahasrabudhhe et al.
[183]

2011

16 (42.5%), 18
(22.2%), 45 (14.4%)
and 35 (7.1%)
India
16 (58.5%), 31 (22.6%)
and 18 & 68a (11.3%)
United
16 (45%), 35 (40%) ,
States
45 (40%)
Milan
16 (19%), 31 & 52
(11%) and 18 (4%)
Bostwana 16 and/or 18 (51%)

2007

Zambia

McKenzie et al. [166] 2014

52 (37.2%), 58
(24.1%), 53 (20.7%),
16 (17.2%) and 18
(13.1%)
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Stage of HPV
infection

ICC
ICC
CIN stage 2
and 3
Cervical
dysplasia
CIN stage 2
and 3
high-grade
squamous
intraepithelial
lesions

and DNA damage in infected cells. The oxidative DNA damage caused by HPV may
enhance integration of HIV-1 DNA into the host DNA. Similarly, HPV 16 and 18 protein
E2, which controls the HPV transcription, also contribute to ROS generation in
mitochondria [184]. HPV 16 and 18 proteins E6, E1, and E2 are known to decrease the
level and activity of several antioxidant enzymes and molecules like superoxide
dismutase 2 (SOD2), catalase, and glutathione (GSH) [185, 186]. Significant increase in
thioredoxin reductase and GST has also been reported in HPV 16 -infected dysplastic and
neoplastic tissue samples [187]. Both, increase or decrease in the level of antioxidants is
an indicative of the ongoing oxidative stress in the cells.
Cytokines like IL-6, IL-8, and TNF-α have the ability to stimulate nuclear
transcription factors that regulate the transcription of HIV-1 DNA. TNF-α increases HIV1 expression by facilitating the nuclear translocation of NF-κB, a nuclear transcription
factor that binds to HIV-1 LTR and activate HIV-1 transcription [188]. IL-6
independently increases expression of HIV-1 proteins, facilitates viral transcription by
enhancing RT activity, and in synergy with TNF-α it also helps to enhance the viral
transcription [189]. Similarly, ROS such as superoxide and hydrogen peroxide are also
known to activate NF-κB and cause reactivation of latent HIV-1 [190, 191]. Schreck et
al. (1991) demonstrated that treatment of micromolar concentrations of hydrogen
peroxide in Jurkat T cells enhances the nuclear translocation of NF-κB as well as binding
of NF-κB to the HIV-1 LTR, leading to activation of the latent HIV-1 [192]. Another
study done by Piette et al. (1994) also suggested the role of ROS as secondary
messengers in activation of latent HIV-1 in monocytes and lymphocytes through
activation of signaling pathways regulating HIV-1 transcription [190].
Effect of Antiretroviral Therapy on HPV
Studies suggest that PLWHA on ART show more rapid HPV clearance and higher
rate of regression of cervical dysplasia and invasive cervical cancer compared to their
counterparts who are not on ART [193]. ART is beneficial in clearing most of the
oncogenic HPV, however some studies have mentioned that ART is not effective enough
to clear HPV 16 and 18, which are the major strains causing cervical cancer [194]. A
study by Clifford et al. (2016) showed that HIV-1-positive women receiving ART for > 2
years showed high regression of cervical intraepithelial neoplasia compared to those who
never received ART [195]. Another study by Konopnicki et al. (2013) also reported that
ART significantly controlled high risk HPV, and it lowered the risk of even HPV 16 and
18 [196]. These studies suggested a strong role of ART on HPV clearance and alleviation
of cervical lesions through restoration of immune response. A meta-analysis done by
Kelly et al. (2017) with 31 studies, also concluded that patients on ART, showing
sustained HIV-1 suppression and stable high CD4+ cell count, have reduced incidence
and progression of cervical lesions and cancer [197]. However, another meta-analysis
study by Cobucci et al. (2015) suggested the opposite, i.e. higher risk of cervical cancer
with ART treatment [198]. Most of these studies were performed in early ART era, when
ART was initiated at lower nadir CD4+ cell count. In these studies, ART could not have
caused the complete immune restoration in the patients, which could be a possible reason
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for the persistent HPV infection and cervical cancer progression [197]. Unlike smoking,
HPV coinfection in HIV-1-infected patients do not have an adverse effect on ART
prevalence and efficacy.
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CHAPTER 3.

SPECIFIC AIMS OF THE STUDY
Scientific Premise

Antiretroviral therapy has prolonged the life span of PLWHA. However, the
quality of life of this population has not improved much, because of the presence of
comorbidities. Since HIV-1 causes immunosuppression, PLWHA are highly prone to
opportunistic infections by various pathogens [199]. Furthermore, high prevalence of
smoking, alcohol, and substance drug abuse has also been reported in this population
[32]. PLWHA with these comorbidities are observed to have higher progression of HIV-1
disease despite ART use, mainly because of their impact on ART adherence, HIV-1
acquisition, and multiplication. In this study, we will be focusing mainly on smoking and
HPV coinfection as comorbid factors, because of their high prevalence and high impact
on HIV-1 replication in PLWHA.
The prevalence of tobacco smoking is 2-times higher in PLWHA compared to the
general population [36], and is known to exacerbate HIV-1 pathogenesis [153, 154]. In
vivo and in vitro studies have demonstrated that tobacco smoking is associated with
decreased immune responses [200], increased inflammation [201] and oxidative stress
[202, 203], and increased occurrence of opportunistic infections [160, 204]. In particular,
tobacco smoking is known to accelerate HIV-1 replication in monocytes and
macrophages, which are viral sanctuary sites where low concentrations of ART drugs fail
to eliminate the virus [154, 205] . HIV-1-infected macrophages can also infiltrate the
brain and spread the virus to perivascular macrophages, leading to the development of
neuro-AIDS. Previous studies have demonstrated that cigarette smoke condensate
induces HIV-1 replication in monocytic cells via a CYP-mediated oxidative stress
pathway [154]. Similarly, other studies have also revealed that CYP enzymes metabolize
polyaromatic hydrocarbons in cigarette smoke into toxic metabolites that enhance HIV-1
gene expression by forming DNA adducts [156].
On the other hand, higher risk and prevalence of HPV infections that lead to
cervical cancer, has also been reported in HIV-1-positive women [163, 164]. Presence of
HPV coinfection in HIV-1-positive women has also been shown to exacerbate HIV-1
pathogenesis [124-126]. HPV-infected women are 2.4-times more susceptible to HIV-1
infection compared to uninfected women [126]. However, it is not clear how smoking or
HPV coinfection in PLWHA enhance HIV-1 replication and pathogenesis. In the present
study we will investigate the molecular mechanism by which smoking or HPV-infection
induce HIV-1 replication in monocytic cells, particularly focusing on CYP and oxidative
stress pathway.
In this study, we have used three different types of cell lines: U937, U1 and Caski
Cells. U937 cells are monocytic cells derived from the histolytic lymphoma of a 37-yearold male patient and U1 cells are U937 cells chronically infected with HIV-1. As U1 cells
comprise of HIV-1 incorporated into their genome but the cells are not capable of
producing a new virus, they represent an ideal model for cells latently infected with HIV-
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1. Further, monocytes/monocyte-derived macrophages are one of the major targets and
reservoirs for HIV-1 infection [206]. Once infected, these cells can travel through
bloodstream and spread the virus in other organ systems such as brain [207]. Therefore, it
is imperative to study HIV-1 replication in monocytes and monocyte-derived
macrophages. We used U1 monocyte-derived macrophages, instead of U1 monocytes for
the experimental purpose because monocytes lack cellular machinery required for HIV-1
transcription [208, 209]. Monocytes express high levels of transcriptionally inactive NFκB p50 homodimers, which are replaced by transcriptionally active NF-κB p50/p65 or
p50/RelB as they differentiate into macrophages after stimulation by PMA [208].
Monocytes also lack cellular cofactors for HIV-1 Tat-mediated transactivation of viral
LTR promotor, which is critical for HIV-1 transcription. However, the cofactors essential
for HIV-1 Tat transactivation are abundantly expressed in monocyte-derived
macrophages [209]. To confirm the results from the U937 and U1 cells, we used
infected/uninfected human primary monocytes and macrophages. We also used Caski
cells which are cervical cancer cells with integrated HPV 16 and 18 genomes. Although,
there are other HPV-infected cell lines (e.g. Siha, hela, C33A), we particularly employed
Caski cells because these cells have higher p53 expression, lower antioxidant genes
expression, and higher extent of oxidative stress compared to other cell lines [210].
Hypothesis
We propose that smoking and HPV infection independently increase HIV-1
replication in monocytic cells latently infected with HIV-1, via Cytochrome p450 (CYP)mediated oxidative stress pathways. Cigarette smoke constituents especially polyaryl
hydrocarbons (PAH) enhance the expression of CYPs (CYP 1A1, 1A2, 1B1), which in
turn metabolize PAHs into various water-soluble metabolites. During the metabolism of
PAHs, CYPs generate large amount of reactive oxygen species (ROS). The ROS thus
generated acts as secondary messengers for activating signaling pathways that regulate
HIV-1 replication. On the other hand, HPV-infected cervical cancer cells also contribute
to increased oxidative stress in monocytic cells latently infected with HIV-1, by
encapsulating oxidative stress factors, especially CYPs into exosomes and transporting
them into the HIV-1-infected monocytic cells. These exosomes release the CYPs into the
infected monocytic cells, which aids the endogenous CYPs to generate more ROS. The
excess of ROS leads to oxidative stress and HIV-1 replication via a similar mechanism as
explained in case of smoking. Hypothesis of the project has been illustrated in
Figure 3-1.
Clinical Significance and Impact
The proposed project will help to find the mechanism by which comorbidities
such as, smoking and HPV coinfection enhance HIV-1 replication in monocytic cells
latently infected with HIV-1. Through the elucidation of the mechanism, the project will
increase scientific understanding and help improve clinical practice in HIV-1 patients
with tobacco addiction or HPV coinfection, by providing knowledge of the contribution
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Figure 3-1. Hypothesis: Polyaryl hydrocarbons in cigarette smoke and HPVinfected cervical cancer cells exacerbate HIV-1 replication via CYP-mediated
oxidative stress pathway.
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of monocytic and/or exosomal CYP enzymes in tobacco/HPV-mediated HIV-1
pathogenesis. The project would impact the treatment of HIV-1 in patients with these
comorbidities, by providing a target for novel therapeutic interventions, adjustment of
drug regimens, and potential application of exosomes as therapeutic carriers. This project
would also provide new knowledge for exosomal biology thus impacting the
understanding of other diseases and drugs of abuse.
Objectives
Our objectives are 1). To identify specific PAHs in cigarette smoke that cause
oxidative stress and cytotoxicity in monocytic cells and show the potential role of CYPs
in PAH-mediated cytotoxicity; 2). To demonstrate that PAHs cause HIV-1 replication in
monocytic cells latently infected with HIV-1 via CYP-mediated oxidative stress pathway;
3). To show that exosomes from HPV-infected cervical cancer cells transfer oxidative
stress factors, especially CYPs to the monocytic cells latently infected with HIV-1 and
thereby induce HIV-1 replication via CYP-mediated oxidative stress pathway. Based on
our objectives, we designed 3 aims for the study, which are described below:
Aim 1: Study of Contribution of CYP Enzymes in PAH-enhanced Cytotoxicity in
Monocytic Cells.
We examined the acute (3-9 hours) and chronic (7 days) effects of five different
carcinogenic PAHs such as Benzo(a)pyrene (BaP), Phenanthrene (Phe), Naphthalene
(NPh), Benzo(a)fluoranthene (BeF), and Benzo(a)anthracene (BeA) on cytotoxicity in
U937 monocytic cells. We also monitored ROS level, expression of CYPs (CYP1A1,
CYP3A4) and antioxidant enzymes (AOEs: SOD1 and catalase) at mRNA and protein
level and caspase-3 activity after PAH exposure and showed an association of the
expression of CYPs and oxidative stress with PAH-induced cytotoxicity. Out of the five
compounds tested, chronic exposure of BaP induced the highest level of cytotoxicity in
U937 cells, which were associate with increased expression of CYP and oxidative stress,
suggesting the potential role of CYPs in BaP-induced toxicity. We also confirmed these
results in human primary macrophages.
Aim 2: Study of Contribution of CYP Enzymes in BaP-enhanced HIV-1 Replication
in Monocytic Cells Latently Infected with HIV-1.
We examined if chronic exposure of BaP would increase HIV-1 viral load in U1
cells. As expected, we observed a significant increase in p24 levels in the supernatant of
BaP-treated U1 cells, as measured by p24 ELISA. These results were also confirmed in
HIV-1-infected human primary macrophages. In order to see the involvement of CYPmediated oxidative stress in BaP-induced HIV-1 replication, we monitored ROS level
and expression of CYPs (CYP1A1, CYP3A4) and AOEs (SOD1, Catalase) at mRNA and
protein level. Furthermore, we established the role of CYPs and oxidative stress pathway
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in BaP-induced HIV-1 replication in U1 cells, by knocking-down the CYP1A1 gene
using siRNA and treatment with selective CYP inhibitors and antioxidants. We also
demonstrated that BaP-induced oxidative stress leads to the nuclear translocation of NFκB subunits (NF-κB p50 and p65), which was reduced by treatment with siRNA and
antioxidants/CYP inhibitors. Treatment of specific NF-κB inhibitors (IKK-16 and SC540) significantly decreased HIV-1 replication in BaP-exposed U1 cells, indicating the
specific role of NF-κB pathway. Altogether, our results suggested that BaP enhances
HIV-1 replication in U1 cells by activation of NF-κB through ROS generated by CYPmediated pathway.
Aim 3: Study of Contribution of Exosomes Derived from HPV-infected Cervical
Cancer Cells in Enhancing HIV-1 Replication in U1 cells.
Initially, we examined whether supernatant from Caski cells can induce HIV-1
replication in U1 cells. We also monitored ROS level, total antioxidant capacity,
cytotoxicity, DNA damage and expression of CYPs (CYP1A1, CYP2A6), and AOEs
(SOD1, SOD2, catalase, PRDX6) after treatment of U1 cells with Caski cell culture
supernatant (CCS). Our results suggested the association of CYPs and oxidative stress
with CCS-induced HIV-1 replication. Next, we were interested to study if exosomes
derived from CCS were responsible for the CCS-induced HIV-1 replication. We isolated
exosomes from CCS using exosome isolation kit and characterized them by the methods
described earlier [211]. We observed the presence of specific exosomal markers (CD63,
CD81), CYPs (CYP1A1, CY2A6), AOEs (SOD1), and HPV-16 oncoprotein E6 in the
CCS-derived exosomes (CCS-Exo). We also demonstrated that CCS-Exo diffused into
U1 cells and induced oxidative stress and HIV-1 replication. By using specific CYP
inhibitors (ellipticine and tryptamine) and antioxidant (resveratrol), we confirmed that
both CCS and CCS-Exo induced HIV-1 replication in U1 cells via a CYP-mediated
oxidative stress pathway. Furthermore, we also showed that treatment of chemo-dietary
agents such as curcumin and cucurbitacin-D reduced HIV-1 replication in CCS and CCSExo-treated U1 cells. Overall, our results suggested the role of HPV infection on HIV-1
replication via exosome containing oxidative stress factors.
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CHAPTER 4. EFFECT OF POLYARYL HYDROCARBONS ON
CYTOTOXICITY IN MONOCYTIC CELLS*
Introduction
According to the International Agency for Research on Cancer (IARC), there are
around 5,300 chemicals identified in mainstream cigarette smoke, among which seventy
are classified as carcinogens [212, 213]. The IARC monograph program has listed several
categories of chemical compounds that are potential carcinogens in cigarettes, including
polyaryl hydrocarbons (PAHs), N-nitrosamines, aldehydes, phenols, volatile
hydrocarbons, and other organic and inorganic compounds. Since the identification of
cigarette constituents in 1950s, several studies have been conducted with regard to its
carcinogenicity in different human organs. Tobacco-specific nitrosamines and PAHs are
the most studied cigarette carcinogens. Tobacco-specific nitrosamines, 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN)
are reported to cause lung cancer and oral cavity cancer [214]. PAHs are associated with
several cancers such as skin, lung, oral, and breast cancer [215-218]. Among the
hundreds of PAHs present in the cigarette smoke, benzo(a)pyrene (BaP) is the most
extensively studied PAH due to its known carcinogenic effects. Naphthalene (NPh) and
phenanthrene (Phe) have relatively low carcinogenicity, but they contribute highly to the
total PAH yield [219].
Cytochrome P450 (CYP) enzymes metabolize PAHs successively into epoxides
and diol-epoxides [220]. These metabolites cause cellular damage either by forming
DNA and protein adducts or by generating reactive oxygen species (ROS) [221, 222].
BaP is metabolized by CYP1A1 into a carcinogen, BaP-7,8-dihydrodiol-9,10-epoxide
(BPDE), via a series of metabolic reactions. BPDE is reported to form DNA adducts
which cause mutations in DNA, ultimately leading to carcinogenesis in lung and skin
epithelial cells [223]. BaP is also reported to cause apoptosis in ovarian follicular cells
via a CYP-mediated pathway [224]. Several reports in literature suggest the role of aryl
hydrocarbon receptor-mediated CYP-induction and the subsequent oxidative stress in
various forms of cancer and cardiac toxicity [225, 226]. Some studies reveal that BaP
causes carcinogenic effects by inducing CYP1A1 expression through binding of p-53 to
promoter region of CYP1A1 [227]. Rapid formation of [D10] r-1,t-2,3,c-4-tetrahydroxy1,2,3,4-tetrahydrophenanthrene ([D10] PheT), a carcinogenic diol metabolite of Phe,
occurs in smokers [228]. Oxidative stress, DNA damage, and cell toxicity were observed
following treatment with NPh in cultured J774A.1 macrophages [229].
-------------------* Reprinted with permission. Ranjit, S., Midde, NM., Sinha, N., Patters, BJ., Rahman,
MA., Cory, TJ., Rao, PSS., Kumar, S. Effect of polyaryl hydrocarbons on cytotoxicity in
monocytic cells: potential role of cytochromes P450 and oxidative stress pathways. PLoS
ONE, 2016. 11(9): e0163827.doi:10.1371/journal. pone.0163827
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Previous studies from our lab have shown that nicotine, a major constituent of
tobacco, causes oxidative stress in U937-derived macrophages through a CYP2A6mediated nicotine metabolic pathway [230]. Our in vitro data was validated by an in vivo
study in which HIV-1-positive smokers displayed a higher rate of nicotine metabolism by
CYP2A6 than HIV-1-negative smokers [155]. HIV-1-positive smokers displayed a higher
rate of nicotine metabolism by CYP2A6 than HIV-1-negative smokers [155]. The results
from these studies were consistent with the findings from another study, in which there
was an increase in viral load, cytokines, and oxidative stress, likely through CYP
pathway, in the plasma and monocytes of HIV-1-infected smokers compared to HIV-1infected nonsmokers [153]. As the ultimate goal of the aforementioned studies was to
explore the role of CYP enzymes in smoking-induced oxidative stress and HIV-1
pathogenesis, the experiments were conducted in monocytes/macrophages. Monocytes/
macrophages are one of the cellular targets for HIV-1 and they also serve as important
viral reservoirs [231]. Smoking may enhance the infiltration of the infected
monocytes/macrophages into the brain and further infect the microglia and astrocytes,
ultimately leading to NeuroAIDS. However, it is still not clear whether other cigarette
components besides nicotine are also responsible for CYP-mediated oxidative stress and
HIV-1 replication in monocytes/macrophages. Therefore, the current study was designed
to first examine the relative contribution of five PAHs; BaP, NPh, Phe, BeA, and BeF, on
the regulation of CYP enzymes, oxidative stress, and cytotoxicity in U937 monocytic
cells followed by primary macrophages.
Materials and Methods
Cell Culture and Treatment
U937 monocyte cells. The U937 monocytic cell line used for the study was
obtained from ATCC (Manassas, VA). The cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 media (Sigma Aldrich, St. Louis, MO), which included 1%
gentamycin (Mediatech Inc. Manassas, VA), L-glutamine (Fischer Scientific, PA), and
sodium bicarbonate (Fischer Scientific, PA). To assess the acute effect of PAHs (1 μM
NPh, 1 μM Phe, and 100 nM BaP) at 3, 6, and 9 hours, 0.8 million cells/well were seeded
in a 12-well plate. The cells were incubated overnight at 37°C in an incubator with 5%
CO2 prior to treatment with PAHs. Following treatment, cells were collected at the
designated time points. To assess the chronic effect of PAHs (100 nM NPh, 100 nM Phe,
100 nM BeA, 100 nM BeF, (5, 25, and 100) nM BaP), 0.1 million cells were seeded per
well in a 6-well plate. The cells were treated with PAHs after 30 minutes of incubation.
The cells were treated every 12 hours for 7 days, with addition of 250 μl of fresh media
during each treatment to maintain the concentrations of PAHs. DMSO treated cells
served as control for both the acute and chronic treatment paradigms.
Primary macrophages. Blood from interstate blood bank Inc. (Memphis, TN)
was diluted with phosphate-buffered saline (PBS, Life Technologies, NY), layered on
Ficoll (Mediatech Inc. Manassas, VA) and centrifuged at 400g for 30 minutes. The white

28

ring of peripheral blood mononuclear cells (PBMCs) formed in between the plasma and
Ficoll layers were carefully isolated. The PBMCs were washed with PBS several times to
ensure the removal of Ficoll. The cells were incubated with ammonium-chloridepotassium (ACK) lysing buffer (Life Technologies, NY) at 4ºC for 15 minutes to lyse and
remove any red blood cells, if present. The clear pellets of PBMCs were then cultured in
RPMI media with human serum and macrophage colony-stimulating factor for
macrophage differentiation. The differentiated macrophages were treated with BaP (100
nM) for 6 days, every 24 hours with an addition of 500 μl fresh media after each
treatment.
Isolation of DNA, RNA, and Protein
DNA, RNA, and protein were isolated from the lysed cells using Allprep
DNA/RNA/Protein QIAGEN Kit (Valencia, CA) using the supplier’s protocol. RNA and
DNA were quantified using Nanodrop 2000c UV-Vis Spectrophotometer (Thermo
Fischer Scientific, Rockford, IL) by measuring their absorbance at 260 nm. The protein
was quantified using the BCA protein assay kit (Thermo Fischer Scientific, Rockford,
IL).
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR)
Quantitative RTPCR was performed to measure the relative mRNA fold
expression of the CYPs 1A1, 3A4 and the antioxidant enzymes (AOEs) superoxide
dismutase 1 (SOD1) and catalase in U937 cells upon exposure to PAHs. Purified RNA
(120 ng) was reverse transcribed to cDNA using a SimpliAmp Thermal Cycler (Applied
Biosystems, Foster City, CA). The cDNA was amplified in a Step-One Plus Real-Time
PCR System (Applied Biosystems, Foster City, CA) using TaqMan Gene Expression kit
(Applied Biosystems, Foster City, CA). The following probes from Applied Bioscience
were used for the Q-RTPCR reaction: CYP1A1 (Hs01054794_m1), CYP3A4
(Hs00430021_ml), SOD1 (Hs00533490_ml) and catalase (Hs00156308_ml). The 2-∆∆Ct
method was used to calculate the relative mRNA fold expression of the genes, using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an endogenous control.
Western Blotting
To determine the expression of proteins of interest, 30 μg of proteins in 5% SDS
were separated on a polyacrylamide gel (4% stacking, 10% resolving gel) at 150 V for 70
minutes. The proteins from the gel were transferred to a polyvinylidene fluoride
membrane at 0.35 Amp for 90 minutes. The transferred blots were blocked with 5-10 ml
of Li-Cor blocking buffer (LI-COR Biosciences, Lincon, NE) for 1 hour and incubated
overnight with primary antibodies (GAPDH Rabbit Mab, 1:2000 dilution, Cell Signaling
Technology, Danvers, MA; CYP1A1 rabbit Mab, 1:200 dilution, Abcam, Cambridge,
MA; CYP3A4 Mouse Mab. 1:200 dilution, Santa Cruz Biotechnology. Inc. Dallas, TX;
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SOD1 Mouse Mab, 1:1500 dilution, Santa Cruz Biotechnology. Inc. Dallas, TX; Catalase
Mouse Mab, 1:1200 dilution, Santa Cruz Biotechnology. Inc. Dallas, TX) at 4°C. After
subsequent washing, the blots were incubated with corresponding secondary antibodies
(1:10000 dilution, Goat anti-Mouse Mab, LI-COR Biosciences, Lincon, NE; 1:10000
dilution, Goat anti-Rabbit Mab, LI-COR Biosciences, Lincon, NE) for 1 hour at room
temperature. The blots were scanned with Li-Cor Scanner (LI-COR Biosciences, Lincon,
NE) and the densitometry data obtained from Image Studio Lite version 4.0 were used to
calculate the fold expression of the proteins. GAPDH was used as an internal loading
control to normalize the expression of sample proteins.
Measurement of Reactive Oxygen Species (ROS) and Cell Viability
ROS and cell viability were quantified by flow cytometry using the fluorescence
dye 5-(and-6)-chloromethyl 2’,7’- dichlorodihydrofluorescein diacetate (CM-H2DCFDA)
(Life Technologies, Oregon, USA) and Ghost Dye (Tonbo Biosciences, San Diego, CA),
respectively. The treated cells were thoroughly washed with PBS and resuspended in 1
mL of PBS containing 2% FBS supplemented with 2-5 μl of CM-H2DCFDA and 1 μl of
the Ghost dye. The cells were then incubated at room temperature in the dark for 30
minutes and subsequently washed and resuspended in 300 μl of PBS containing 2% FBS.
Dichlorodihydrofluorescein (DCF) emission at 525 ± 20 nm, which is proportional to the
ROS generated in the cells, and emission of Ghost dye at 780 nm, which is proportional
to the cell viability, were detected by flow cytometry (BD Biosciences, San Jose, CA).
The data were analyzed by using the BD FACS software version 8.
XTT Assay
Cell viability was also measured using the XTT assay kit (Cell Signaling
Technology Inc., Danvers, MA). The PAH-treated cells (0.12 million) were suspended in
200 μl of phenol red-free media. XTT detection solution was made by mixing electron
coupling solution and XTT reagent in the ratio of 1:50. Fifty microliters of the XTT
detection solution was added to each well of the 96-well plate containing 200 μl of the
cell suspension and the plate was incubated at 37°C for three hours. The absorbance
measured at 450 nm represented cell viability.
Caspase-3 Activity Assay
Caspase-3 activity was measured using Caspase-3 colorimetric assay kit
(BioVision, Inc., Milpitas, CA). Cells (1-5 millions) obtained after the treatments were
lysed and protein was extracted. About 100 μg of the protein was diluted to a final
volume of 50 μl in cell lysis buffer. Each protein sample was added to 50 μl of 2X
reaction buffer (containing 10 mM DTT) and 5 μl of 4 mM DEVD-pNA substrate and the
reaction mixture was incubated at 37°C for 1 hour. Absorbance of the samples was
measured at 405 nm.
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Statistical Analysis
For the statistical analysis of the data obtained from RTPCR, Western blot, cell
viability assay, ROS level, and caspase-3 activity assay, mean ± SEM was calculated and
One-way ANOVA was applied to calculate p values. A p value of ≤0.05 was considered
significant.
Results
Effect of Acute Treatment of BaP, NPh, and Phe on CYP and AOE Expression,
ROS and Cell Viability in U937 Cells
Initially, we monitored the effect of the acute exposure of BaP, NPh, and Phe in
U937 cells. The cells were treated with BaP (100 nM), NPh (1 μM), and Phe (1 μM) for
3, 6, and 9 hours. There was no significant change in ROS and cell viability in cells
treated with the PAHs for 3 and 6 hours (Figure 4-1A-B). However, a significant
decrease (p≤0.05) of ~10% in ROS was observed with all the three compounds after 9
hours of exposure (Figure 4-1A). The cell death at 9 hours was not particularly different
from the control. The small decrease in ROS would not have been sufficient enough to
cause a significant impact on cell viability. In general, there was minimal to no effect of
acute exposure of BaP, NPh, and Phe on oxidative stress and cytotoxicity in U937 cells.
Furthermore, there was no significant effect of the acute exposure of the PAHs
over the induction of CYPs (Figures 4-2 and 4-3) and AOEs (Figures 4-4 and 4-5). Only
BaP exposure showed a significant ascending trend in the mRNA expression of CYP1A1
over time (~10 fold increase at 6 hours to ~30 fold increase at 24 hours, p≤0.05), as well
as with increasing concentration (Figure 4-2A). However, there was no significant
increase in the expression of CYP1A1 protein with either 100 nM or 1 μM BaP
treatment. None of the PAHs showed significant change in either the mRNA and protein
expression levels of CYP3A4, except for the treatment with Phe (1 μM), which showed
~3 fold increase in CYP3A4 expression at mRNA level at 12 hours (p≤0.05)
(Figure 4-3C). At 24 hours, we observed a significant increase in the SOD1 mRNA
expression with (1 μM) BaP (~3 fold, p≤0.05) (Figure 4-4A). None of these compounds
showed significant alteration in the protein expression levels of SOD1. Similarly, no
significant change in the mRNA and protein expression levels of catalase was observed
with any of the acute PAH treatments (Figure 4-5).
Effect of Chronic Treatment of BaP, NPh, and Phe on ROS and Cell Viability
The cells were treated with three different concentrations of BaP (5 nM, 25 nM,
and 100 nM), 100 nM NPh, and 100 nM Phe for seven days to examine the chronic effect
of the PAHs on ROS generation and cell viability. A significant concentration-dependent
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Figure 4-1. Effect of acute treatment of BaP, NPh, and Phe on ROS level (A) and
cell viability (B) in U937 cells.
The U937 cells were treated with 100 nM BaP, 1 μM NPh, and 1 μM Phe for 3, 6, and 9
hours. ROS level and cell viability were measured using flow cytometry. Measured
values at every time point were normalized to control that was set at 100%. X-axis and
Y-axis correspond to time points and % of mean fluorescent intensity (%MFI),
respectively. The data are presented as a mean ± SEM of three independent experiments.
* represents p ≤ 0.05 compared with the control group.
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Figure 4-2. Effect of acute treatment of BaP (A), NPh (B), and Phe (C) on mRNA and protein expression of CYP1A1
in U937 cells.
The U937 cells were treated with 100 nM and 1 μM of BaP, NPh, and Phe for 6, 12 and 24 hours. The mRNA fold expressions
were calculated using qRT-PCR and the protein fold expressions were measured by Western blots, and normalized with
control (DMSO treated cells) whose expression was set at 1-fold. GAPDH was used as an endogenous control. Blots are
representative of at least three independent experiments. The data are presented as a mean ± SEM of three independent
experiments. * represents p ≤ 0.05, compared with the control group.
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Figure 4-3. Effect of acute treatment of BaP (A), NPh (B), and Phe (C) on mRNA and protein expression of CYP3A4
in U937 cells.
The U937 cells were treated with 100 nM and 1 μM of BaP, NPh, and Phe for 6, 12 and 24 hours. The mRNA fold expressions
were calculated using qRT-PCR and the protein fold expressions were quantified by Western blots, and normalized with
control (DMSO treated cells) whose expression was set at 1-fold. GAPDH was used as an endogenous control. Blots are
representative of at least three independent experiments. The data are presented as a mean ± SEM of three independent
experiments. * represents p ≤ 0.05, compared with the control group.
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Figure 4-4. Effect of acute treatment of BaP (A), NPh (B), and Phe (C) on mRNA and protein expression of SOD1 in
U937 cells.
The U937 cells were treated with 100 nM and 1 μM of BaP, NPh, and Phe for 6, 12 and 24 hours. The mRNA fold expressions
were calculated using qRT-PCR and the protein fold expressions were quantified by Western blots, and normalized with
control (DMSO treated cells) whose expression was set at 1-fold. GAPDH was used as an endogenous control. Blots are
representative of at least three independent experiments. The data are presented as a mean ± SEM of three independent
experiments. * represents p ≤ 0.05, compared with the control group.
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Figure 4-5. Effect of acute treatment of BaP (A), NPh (B), and Phe (C ) on mRNA and protein expression of catalase
in U937 cells.
The U937 cells were treated with 100 nM and 1 μM of BaP, NPh, and Phe for 6, 12 and 24 hours. The mRNA fold expressions
were calculated using qRT-PCR and the protein fold expressions were quantified by Western blots, and normalized with
control (DMSO treated cells) whose expression was set at 1-fold. GAPDH was used as an endogenous control. Blots are
representative of at least three independent experiments. The data are presented as a mean ± SEM of three independent
experiments. * represents p ≤ 0.05, compared with the control
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increase in ROS was observed with the chronic treatment of 25 nM BaP (~1.5 fold,
p≤0.05) and 100 nM BaP (~ 2.5 fold, p≤0.05) (Figure 4-6A-B). However, there was no
significant alteration in the ROS levels with 5 nM BaP. Similarly, no significant change
in ROS was observed with NPh and Phe treatments. A statistically significant (p≤0.05)
decrease in cell viability (~60%) was observed with 100 nM BaP treatment. Lower
concentrations (5 nM and 25 nM) of BaP, as well as, the 100 nM NPh and Phe
treatments, however, did not have any effect on cell toxicity (Figure 4-7B). Similar
decrease in cell viability with 100 nM BaP treatment was observed using XTT cell
viability assay (~40% decrease in cell viability, Figure 4-7C). Figure 4-7A show the
graphical representation of cell viability, measured via flow cytometry.
Effect of Chronic Treatment of BaP, NPh, and Phe on Caspase-3 Activity
In order to delineate the mechanism of cytotoxicity after chronic treatment of
PAHs (BaP, NPh, and Phe), we monitored the caspase-3 activity. We observed a
significant increase in caspase-3 activity with 100 nM BaP treatment (~2 fold, p≤0.05,
Figure 4-6C). However, there was no effect on caspase-3 activity with lesser
concentrations of BaP (5 nM and 25 nM) or 100 nM of NPh or Phe.
Effect of Chronic Treatment of BaP, NPh, and Phe on the Expression of CYPs at
mRNA and Protein Levels
PAHs are metabolized by various CYP enzymes, mainly CYPs 1A1, 1B1, and to
a lesser extent by CYPs 1A2, 2C9, 3A4, and 2C19 into reactive metabolites and produce
ROS that cause DNA damage [232]. Therefore, to examine the effect of these compounds
on expressions of CYPs 1A1 and 3A4 that are prominently present in U937 cells, we
treated the cells separately with 100 nM of each compound for seven days and measured
the mRNA and protein levels of CYP1A1 and CYP3A4 (Figure 4-8). With BaP
treatment, we observed ~15 folds increase (p≤0.05) in the CYP1A1 mRNA expression
(Figure 4-8A) and ~3 folds increase in CYP3A4 mRNA expression (Figure 4-8B).
However, the CYP1A1 and 3A4 protein expression levels quantified from the Western
blots did not correspond to the respective changes in mRNA expression levels. NPh and
Phe did not show much change in the induction of either CYPs. Interestingly, there was
~2.5 fold (p≤0.05) increase in the protein expression of CYP1A1 in the cells treated with
NPh (Figure 4-8A, lower panel).
Effect of Chronic Treatment of BaP, NPh, and Phe on the Expression of AOEs at
the mRNA and Protein Levels
PAHs are likely to induce expression of AOEs to combat PAH-induced oxidative
stress in U937 cells. To determine whether these compounds alter the expression of
AOEs, we measured the mRNA and protein levels of the major AOEs SOD1 and catalase
(Figure 4-9). Chronic (seven days) exposure of 100 nM BaP upregulated the mRNA
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Figure 4-6. Effect of chronic (7 days) treatment of BaP, NPh, and Phe on reactive oxygen species (ROS) level (A-B)
and caspase-3 activity (C) in U937 cells.
The U937 cells were treated with (5, 25 and 100) nM BaP, 100 nM NPh, and 100 nM Phe for seven days. ROS level and
caspase-3 activity were calculated and normalized with control that was set as 100%. The data is presented as mean ± SEM of
the three independent experiments. * represents p ≤ 0.05, compared with the control group.
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Figure 4-7. Cell viability upon chronic treatment by BaP, NPh, and Phe measured by flow cytometry (A-B) and XTT
assay (C).
The U937 cells were treated with (5, 25 and 100) nM BaP, 100 nM NPh, and 100 nM Phe for seven days. Cell viability was
calculated using flow cytometry and XTT assay, and normalized with control that was set as 100%. The data is presented as
mean ± SEM of the three independent experiments. * Represents p ≤ 0.05, compared with the control group.
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Figure 4-8. Effect of chronic (7 days) treatment of BaP, NPh, and Phe on mRNA
and protein expression of CYP1A1 (A) and CYP3A4 (B) in U937 cells.
The U937 cells were treated with 100 nM BaP, 100 nM NPh, and 100 nM Phe for seven
days. The mRNA fold expressions were calculated using qRT-PCR and normalized with
control (DMSO treated cells) whose expression was set at 1-fold. GAPDH was used as an
endogenous control. The protein fold expressions were quantified by Western blot and
normalized with control that was set to 1-fold at every time point. Blots are representative
of at least three independent experiments. The data are presented as a mean ± SEM of
three independent experiments. *represents p ≤ 0.05, compared with the control group.
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Figure 4-9. Effect of chronic (7 days) treatment of BaP, NPh, and Phe on mRNA
and protein expression of AOEs SOD1 (A) and catalase (B) in U937 cells.
The U937 cells were treated with 100 nM BaP, 100 nM NPh, and 100 nM Phe for seven
days. The mRNA fold expressions were calculated using qRT-PCR and normalized with
control (DMSO treated cells) whose expression was set at 1-fold. GAPDH was used as an
endogenous control. The protein fold expressions were quantified by Western blot and
normalized with control (DMSO treated cells) whose expression was set at 1 fold. Blots
are representative of at least three independent experiments. The data are presented as a
mean ± SEM of three independent experiments. *represents p ≤ 0.05, compared with the
control group.
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expression of both SOD1 (~2.5 folds, p≤0.05, Figure 4-9A) and catalase (~2 folds,
p≤0.05, Figure 4-9B).The corresponding protein expression levels of both AOEs were
also upregulated by similar proportions: SOD1 (~2.5 fold) and catalase (~2.5 fold) but the
data were not statistically significant (Figure 4-9A-B, lower panel). Further, treatment
with NPh or Phe did not significantly alter the mRNA or protein expression of AOEs.
Effect of Chronic Treatment of BeA and BeF on ROS, Cell Viability, and Caspase-3
Activity
In addition to three PAHs (BaP, NPh, and Phe), BeA and BeF are other PAHs that
have carcinogenic potential. Therefore, we also studied these compounds with regard to
oxidative stress and cytotoxicity. The cells were treated with 100 nM of BeA or BeF for
seven days and were examined for ROS level and cell viability. Cell viability data from
XTT assay showed approximately 10-13% cell death when treated with 100 nM of BeA
or BeF for seven days (Figure 4-10A). A significant decrease in ROS level was observed
with the chronic treatment of BeA 100 nM (~35%, p≤0.05) as well as BeF 100 nM
(~23%, p≤0.05) (Figure 4-10B). There was no significant change in the caspase-3
activity with chronic treatment of both the compounds (Figure 4-10C). Overall,
treatment with BeA and BeF had relatively less effect on the oxidative stress and cell
viability of U937 compared to BaP.
Effect of Chronic Treatment of BaP on CYP Expression, ROS and Cell Viability in
Primary Macrophages
Of the five compounds, only exposure with BaP (100 nM) resulted in significant
increased expression of CYPs and AOEs, ROS and cell death in U937 cells. So, we
exposed the primary macrophages with 100 nM BaP to verify our observations in U937
cells. When we treated the primary macrophages with BaP 100 nM for seven days, we
observed ~25% cell death accompanied by ~30% increase in ROS and ~10 and ~ 3 fold
(p≤0.05) increase in CYP 1A1 and 3A4 respectively (Figure 4-11A-D). These results
confirm that BaP exposure leads to cytotoxicity in monocytes/macrophages via CYPmediated oxidative stress pathway.
Discussion
Carcinogenic effects of smoking have been widely studied in various organs,
especially lungs and liver [233, 234]. Several studies have also reported CYP-mediated
PAH toxicity in different organs [26, 27]. However, relatively less information is
available on the effects of smoking constituents on the blood cells such as monocytes and
lymphocytes. A recent study conducted in our lab has shown that nicotine causes
oxidative stress in monocytic cells U937 cells through a CYP-mediated pathway [230].
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Figure 4-10. Cell viability (A), ROS level (B) and caspase-3 activity (C) upon chronic treatment by BeA and BeF in
U937 cells.
The U937 cells were treated with 100 nM BeA and 100 nM BeF for seven days. ROS level, cell viability, and caspase-3
activity were measured and normalized with control that was set as 100%. The data is presented as mean ± SEM of the three
independent experiments. * represents p ≤ 0.05, compared with the control group.
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Figure 4-11. Cell viability (A), ROS level (B) and mRNA expression level of
CYP1A1 (C) and CYP3A4 (D) upon chronic treatment by BaP in primary
macrophages.
The differentiated macrophages obtained from healthy donors were treated with BaP (100
nM) for 7 days. Cell viability and ROS were calculated and normalized with control that
was set as 100%. The mRNA expression of treated cells were normalized with control
(DMSO treated cells) whose expression was set at 1-fold. The results for cell viability
were confirmed using 3 different donors. Due to inadequate number of primary cells,
ROS and CYPs expression level were examined in only one donor. The data is presented
as mean ± SEM of the three replicates for ROS and two replicates for CYP expression
levels. * represents p ≤ 0.05, compared with the control group.
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However, there is no report on the effect of PAHs and relative contribution of different
PAHs on oxidative stress and cytotoxicity, and underlying mechanism in the monocytic
cells. The present study is the first report of relative contribution of five PAHs (BaP,
NPh, Phe, BeA, and BeF) on the expression of CYPs and AOEs, induction of ROS, and
cytotoxicity in U937 monocytic cells. The results from this study support the existing
literatures that among the tested PAHs, BaP is the most harmful compound, which causes
oxidative stress and subsequent cytotoxicity, at least in part through CYP pathway.
Zhu et al. (2014) have shown that BaP (5 μM) significantly increases the
expressions of CYP1A1 and CYP1B1, ROS level, and cytotoxicity in lung epithelial cells
(BEAS-2B cells) after 24 hour treatment [235]. In this paper, we examined the effect of
both acute (6-24 hours) and chronic (7 days) exposure of PAHs in U937 cells. We
initially treated the cells with 100 nM and 1 μM of each of the PAHs for acute study.
These concentrations are very near to the physiological concentrations of PAHs that
caused toxicity in different cell lines [235, 236]. For the chronic treatment, the lower
concentration (100 nM) was preferred because higher concentration (1 μM) resulted in
immense cell death when exposed for a prolonged period. There are very few reports that
account for the toxicity of chronic BaP exposure in human cells.The reports of chronic
BaP exposure in animal model suggest its association with neurotoxicity [237], DNA
damage [238], carcinogenicity, and cytotoxicity [239]. Most of the studies of BaP
toxicity have been conducted at higher concentration for an acute period. In this context,
our experimental design to study the acute as well as chronic effects of near physiological
concentrations of PAHs on monocytic cells is pragmatic because it closely simulates the
effects of tobacco on these cells in vivo.
We have used U937 cells derived from histiocytic lymphoma tissues, which have
functionally deficient p53 tumor suppressor gene due to gene mutation [240]. The
phenomenon of apoptosis is apparently ceased in these cell lines, causing massive cell
proliferation. However, apoptosis may occur in U937 cells when triggered by various
stress factors such as ROS, via a p53-independent mechanism. There are also reports that
associate p53 with BaP-induced CYP1A1 expression, which occur via p53 binding to a
p53RE in the CYP1A1 regulatory region [241]. Some studies suggest that p53
upregulates the gene associated with antioxidant activity and thereby prevent the genome
from oxidative damage by ROS [242]. Due to the lack of functional p53 in U937 cells,
induction of CYP1A1 and antioxidants by BaP occur via a p53 independent pathway,
probably via Nf-κB-mediated pathway. Another possible pathway for induction of CYPs
could be via binding of BaP to arylhydrocarbon receptor (AhR) and the subsequent gene
activation by constitution of the Arnt protein-BaP complex with XRE responsive element
[243].
With acute treatment of three PAHs BaP, NPh, and Phe, we did not observe any
significant change in the expressions of CYPs and AOEs, ROS level, or cell viability. So,
we exposed the cells for seven days with 100 nM of each of the compounds to monitor
their chronic effect. Out of five PAHs (BaP, NPh, Phe, BeA, and BeF), only BaP (100
nM) significantly increased the expressions of CYPs and AOEs, generation of ROS, and
cytotoxicity in U937 cells. The prolonged exposure of BaP to the cells probably caused
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the accumulation of ROS, via CYP-pathway. Elevated ROS then contributed to the
oxidative stress and cytotoxicity. An increased level of AOE expression with chronic BaP
treatment is also consistent with the finding that there was an increase in the ROS level.
BaP is considered a prototype compound for PAH carcinogenicity. IARC has
listed BaP as a group I human carcinogen, while NPh, Phe, BeA, and BeF have been
classified as compounds possibly carcinogenic to humans (IARC 2004). BaP-induced
carcinogenesis has been studied extensively for more than five decades. Previous studies
reveal that CYP metabolites of BaP form DNA adducts that inactivate the tumor
suppressor p53 in human epithelial cells and bronchial epithelial cells [233]. Kucab et al.
(2015) has also suggested the role of BaP and its metabolites in p53 mutagenesis, which
is a common pathway observed in almost half of human cancers [244]. However, the role
of BaP and other PAHs with respect to oxidative stress and cytotoxicity in monocytic
cells is not known. In this context, evaluation of the role of PAHs and their relative
contributions to the expressions of CYPs, induction of oxidative stress, and cytotoxicity
further validates the literature that BaP is toxic to many cells including monocytic cells.
BaP induces the expression of several CYPs including 1A1 and 1B1 in different
cells [245-247]. Since the basal expression of CYP1B1 in U937 cells is very low [248],
we examined the effect of PAHs on the expression of CYP1A1 only. Cytotoxicity
induced by CYP1A1 metabolites of BaP has been reported in different cellular systems:
lung cells [249], porcine urinary bladder epithelial cells [250], and bone marrow cells
[251]. CYP1A1 metabolizes BaP into BPDE which forms DNA adducts leading to
genotoxicity and carcinogenesis. Some studies also suggest that ROS generated from BaP
via CYP pathway causes oxidative stress that lead to cytotoxicity. In the present study,
CYP1A1 mRNA expression was consistently upregulated (~15 fold) following the acute
and chronic treatment of BaP (100 nM) in U937 cells. However, the CYP1A1 protein
levels were not consistent with the mRNA expression levels. Similar contradiction was
reported in earlier studies [252], the reason for which is not clear. However, it is possible
that CYP1A1 is relatively less stable upon extraction or there may be post-translational
modification of the protein. The metabolites obtained from the CYP1A1-mediated
oxidation of BaP may be responsible for the elevated ROS level and subsequent oxidative
stress and cytotoxicity. Further investigation is required to confirm our hypothesis that
CYP1A1 metabolizes BaP into ROS-generating metabolites that cause cytotoxicity in
U937 cells. This can be done either by knocking down CYP1A1 gene or by using a
selective inhibitor of CYP1A1 and treating with BaP to determine if ROS generation and
cytotoxicity still occur. The chronic exposure to NPh (100 nM) showed ~ 2 fold increase
in CY1A1 protein expression but there was no significant effect on AOE expression,
ROS, cell viability and caspase-3 activity. Although, we observed increase in CYP1A1
protein expression to some extent, the induced protein may not have been sufficient
enough to metabolize the compound.
CYP3A4 is a major drug metabolizing enzyme that metabolizes about 50% of the
xenobiotics and is present in relatively high abundance compared to other CYPs, not only
in hepatic cells, but also in U937 monocytic cells [252]. BaP-induced CYP3A4
upregulation at mRNA level has been observed in HepG2 liver cells and HEK-293
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kidney cells [253]. Kumagai et. al also suggested that BaP enhances CYP3A4 gene
expression via PXR activation in liver cells [254]. Furthermore, they suggested the
possibility that the metabolites obtained through CYP1A1 metabolism could act as
CYP3A4 inducers. It is important to study the expression level of CYP3A4 in context of
BaP metabolism and toxicity. CYP3A4 does not metabolize the PAH parent compounds
but it does convert dihydrodiols into diol epoxides. However, the rate of conversion is
slower than that observed through CYP1A1 metabolism [232]. In the present study, we
did not observe any significant change in CYP3A4 expression at mRNA and protein
levels after acute or chronic treatment with BaP. Since the overall CYP3A4 expression
was low, CYP1A1 metabolites also did not seem to contribute to CYP3A4 induction.
Cells are equipped with an antioxidant defense mechanism to counteract the
oxidative stress resulting from elevated ROS [255]. Oxidative stress is alleviated either
by endogenous antioxidants such as reduced glutathione (GSH) or by adaptive defense
mechanism through induction of genes encoding AOEs [256]. The induction of genes
encoding AOEs are regulated by nuclear factor erythroid 2- related factor (Nrf-2)
signaling pathway [257]. Any perturbations in the AOE defense system that decrease the
AOE expression may aid elevation in ROS level. Higher incidence of oxidative stressinduced carcinogenesis is reported in Nrf-2 knockout mice that are treated with BaP.
Furthermore, if the level of ROS exceeds the threshold, the AOEs may not be able to
overcome the resulting oxidative insult [153, 258]. SODs and catalase are major AOEs in
majority of the cell lines. In case of acute treatment of BaP, we observed a slight decrease
in ROS which may be attributed to the protective activity of the endogenous AOEs. We
anticipated higher levels of ROS and AOEs with chronic treatment of the PAHs, but we
observed the expected result only with BaP-treated cells. The elevation in gene
transcription of SOD1 and catalase over the course of seven-day treatment with BaP may
not be sufficient enough to alleviate the high ROS level. Rather, an increase in the
expression level of these AOEs are the indication that there is oxidative stress in the
system.
In addition to BaP-mediated mutagenesis and carcinogenesis through DNA
adduct formation, there are also reports of apoptosis induced by BaP metabolites in
different human cell lines: Daudi B cells [259], H460 lung cancer cells [260], hepatoma
HepG2 cells [261] and endometrial cancer RL95-2 cells [262], the latter two being
directly associated with CYP-mediated metabolism of BaP. ROS triggers apoptosis by
enhancing the permeability of the mitochondrial outer membrane and thereby leaking out
pro-apoptotic proteins [263]. Pro-apoptotic proteins aid in the activation of caspases,
cysteine proteases that cause cellular degradation. We observed apoptosis in U937 cells
via caspase-3 dependent pathway, with chronic treatment of BaP. Our data suggests the
involvement of CYP in the metabolism of BaP and generation of ROS with chronic
treatment of BaP.
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Conclusions
Therefore, we conclude that BaP causes apoptosis in U937 cells through a
caspase-3-dependent pathway. BaP-induced cytotoxicity, in turn, is mediated by ROS
that is likely to be generated through CYP-mediated metabolism of BaP. Our previous in
vitro and ex vivo studies have suggested the role of nicotine metabolism via CYP2A6 in
generating oxidative stress and HIV-1 replication in monocytic cells. The current study
has established the fact that, in addition to nicotine, BaP is the major PAHs that is
responsible for inducing oxidative stress, apoptosis, and cytotoxicity, perhaps through the
CYP pathway in monocytic cells. The confirmation of increase in CYP expression, ROS
generation and cytotoxicity mediated by chronic treatment of BaP in primary
macrophages has further strengthened our findings from U937 monocytic cells. We
speculate that BaP-induced oxidative stress via CYP metabolism would enhance HIV-1
replication. In fact, our study with cigarette smoke condensate (CSC), which contains
nicotine and PAHs, has demonstrated an increase in HIV-1 replication in primary human
monocyte-derived macrophages [153]. This is also based on the fact that BaP induced
greater levels of ROS (>150%) compared to nicotine (15-20%) [230]. Taken together
these findings indicate that BaP is likely the most active compound in cigarette smoke,
and may generate oxidative stress leading to cytotoxicity and increased HIV-1 replication
in monocytic cells. However, this has yet to be fully demonstrated using HIV-infected
U937 and human primary monocytic cells.
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CHAPTER 5.

BENZO(a)PYRENE ENHANCES HIV-1 REPLICATION IN
MONOCYTIC CELLS *
Introduction

The association of cigarette smoking and HIV-1 pathogenesis has been
demonstrated by multiple studies in the past two decades [153, 154, 157, 159, 264, 265].
Smoking increases HIV-1 infectivity and viral load, and it lowers the CD4+ T cell counts
in HIV-1 patients, with a subsequent increase in immunosuppression [135, 153].
Smoking also decreases the response to antiretroviral therapy (ART) by approximately
40% in HIV-1 patients [160], which further accentuates the hazards of smoking on HIV-1
pathogenesis. However, little is known about the mechanisms underlying smokinginduced HIV-1 replication. A recent study has shown that cigarette smoke condensate
(CSC) induces CYP expression and oxidative stress in HIV-1-infected monocyte-derived
macrophages, and the findings are consistent with increased oxidative stress, nicotine
metabolism and HIV-1 replication in HIV-infected individuals who smoke [154].
Another study has revealed that the toxic metabolites released through the CYP-mediated
metabolism of cigarette smoke constituents enhance HIV-1 gene expression through
DNA adduct formation [156]. Aqueous tobacco smoke extract is also known to enhance
the upregulation of genes that enhance HIV-1 infection, but downregulate the expression
of other genes that promote cell survival and antigen presentation [157].
Of the 5300 compounds that are present in CSC, polyaryl hydrocarbons (PAHs)
are a class of carcinogenic compounds that are implicated by several studies for their
potential to induce oxidative stress [266-268]. Benzo(a)pyrene (BaP) is a prototype PAH,
which has been widely studied for its carcinogenicity, genotoxicity, and mutagenicity
[269-272]. BaP is also known to induce CYP enzymes, especially CYP1A isoforms,
which can have a direct impact on the biological disposition of various drugs [253, 273].
BaP is metabolically activated by CYP 1A1/1B1 enzymes into epoxide intermediates,
which are further metabolized by CYPs or epoxide hydrolase into carcinogenic diol
products [220, 274]. As a result of CYP-mediated BaP metabolism, excessive reactive
oxygen species (ROS) are generated, leading to oxidative stress [275, 276]. Oxidative
stress further leads to oxidative DNA damage, lipid peroxidation, and the oxidation of
several proteins, ultimately causing cytotoxicity and cell death [277, 278]. Recently, we
have demonstrated that exposure of BaP causes the induction of CYPs and a subsequent
increase in oxidative stress and cytotoxicity in U937 monocytic cells [273].
Oxidative stress is implicated in enhanced replication of HIV-1 via the activation of
redox sensitive nuclear transcription factor Kappa- B (NF-κB) [192, 279-281]. Various
-------------------* Reprinted with permission. Ranjit, S., Sinha, N., Kodidela, S., Kumar, S.
Benzo(a)pyrene in Cigarette smoke enhances HIV-1 replication through NF-κB
activation via CYP-mediated oxidative stress pathway. Scientific Reports, 2018. 8:10394
| DOI:10.1038/s41598-018-28500-zpone.0163827

49

stress factors regulate the NF-κB pathway resulting in the transcription of over hundreds
of genes that regulate inflammation, immune response, cell proliferation, growth, and
survival [282-284]. NF-κB is activated by a number of triggers such as viral proteins and
drugs of abuse, leading to the expression of various cytokines, chemokines, and CYPs
[282, 285-287]. Interestingly, most of the stress factors use ROS as a secondary
messenger to modulate NF-κB activity [288]. In an inactive state, NF-κB proteins are
localized in the cytoplasm by forming a complex with inhibitors of NF-κB proteins (IKB)
proteins. ROS triggers the activation of the IKB kinase complex that facilitates the
ubiquitination of IKB proteins, thereby releasing the NF-κB proteins into the nucleus
[289]. Within the nucleus, the activated NF-κB proteins induce the transcription of HIV-1
structural genes by binding to the enhancer region of long terminal repeat (LTR) on HIV1 DNA, that contains NF-κB binding sites [290]. Several reports have emphasized the
role of ROS in the activation of NF-κB and its subsequent impact on HIV-1 gene
transcription [281, 291]. However, whether smoking/tobacco mediated oxidative stress
via CYP pathways causes the nuclear trafficking of NF-κB and resultant HIV-1
replication, is yet to be examined. In the current study, we examined the potential role of
CYP-mediated oxidative stress and subsequent HIV-1 replication via the NF-κB pathway
by an important tobacco constituent, BaP, in HIV-1-infected macrophages. We used
macrophages in this study because they are a secondary target of HIV-1 infection and a
major viral reservoir where it is difficult to effectively suppress the virus with
antiretroviral agents [292, 293]. Moreover, HIV-1-infected macrophages cross the bloodbrain-barrier (BBB) and infect CNS cells such as perivascular macrophages, microglia,
and to some extent astrocytes, which eventually cause HIV-1-associated neurocognitive
disorders [294, 295].
Materials and Methods
Cell Culture and Treatment
U1 cells. U1 cells, which are U937 cells chronically infected with HIV-1, were
obtained from the NIH AIDS Reagent Program (Germantown, MD). The cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640 media containing 10% Fetal
bovine serum (FBS) and penicillin. To differentiate the cells into macrophages, 0.8
million cells were seeded in 1.5 ml of media containing 100 nM phorbol 12-myristate 13acetate (PMA) in each well of a 6-well plate. After 3 days, the media containing PMA
and non-adherent cells was removed and the differentiated cells were washed with
phosphate buffer saline (PBS). The cells were topped with fresh 1 ml media and treated
with BaP (1 μM) every 24 hours for 3 days for acute treatment. An additional 0.5 ml of
media was added and BaP concentration was maintained constant at every treatment. In
order to monitor the chronic (7 days) effect of BaP, we initially treated U1 cells with BaP
(10-100 nM) for 7 days and later differentiated them into macrophages.
Human primary macrophages infected with HIV-1. Human primary
macrophages were derived from the whole blood of healthy individuals using a method
described in Chapter 4. The macrophages were treated with polybrene (2 μg/ml) and IL-2
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(interleukin-2, 10 ng/μl) and infected with HIV-Ada strain (20 ng/1 million cells/ml
media). The infected cells were then treated with BaP (100 nM) every 24 hours for 7
days.
Viral Load
The viral load of HIV-1 was determined by assessing the level of p24 antigen in
the supernatant collected from the treated U1 cells and primary macrophages. We used
the HIV-1 p24 Antigen ELISA kit (Zeptometrix Corporation, Buffalo, NY) for this
purpose. The kit is comprised of monoclonal antibody- coated microwells, which
specifically bind the HIV-1 p24 antigen in the added samples. The captured antigen was
incubated with biotin conjugated human anti-HIV-1 antibody at 37οC for 1 hr, followed
by incubation with enzyme, streptavidin-peroxidase and tetramethylbenzidine substrate at
37οC and room temperature/dark, respectively, for 30 minutes each. The reaction of the
enzyme with the substrate developed a blue color, the absorbance of which was measured
at 450 nm to determine the p24 level. The optical density of the samples was compared
against the standard curve.
Isolation of RNA and Protein
RNA was isolated using RNeasy Mini kit (250) (QIAGEN, Germantown, MD),
following the manufacturer’s protocol. The extracted RNA was quantified using
Nanodrop 2000c Spectrophotometer (Thermo Fisher Scientific) at 260 nm. To isolate the
protein from the treated cells, 100 μl of RIPA buffer was added to the cell pellet. The cell
suspension was sonicated for 30 seconds with pulse set at 4 and centrifuged at 13000 rpm
for 5 minutes. The supernatant containing the protein was collected and protein
quantification was done by using the BCA protein assay kit (Thermo Fischer Scientific).
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR)
The relative mRNA fold expression level of CYPs (CYP1A1 and CYP3A4) and
AOEs (Catalase, SOD1) after chronic BaP treatment was monitored using quantitative
RTPCR as described in Chapter 4.
Western Blotting
We determined the protein expression level of CYPs (CYP1A1 and CYP3A4) and
AOEs (Catalase, SOD1) after chronic BaP treatment in U1 cells using Western blotting
as described in Chapter 4. In addition to CYPs and AOEs, we also monitored the
expression of NFκB subunits, p50 and p65 in the cytoplasmic and nuclear fractions of
protein. We used β-lamin as a loading control for the nuclear protein fractions. We used
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NFκB p50 Rabbit Mab (1:200 dilution), NFκB p65 Mouse Mab (1:200), β-lamin Rabbit
Mab (1:400 dilution) from Santa Cruz Biotechnology. Inc. Dallas, TX.
Measurement of ROS Level
We quantified ROS generated after acute (3 days) treatment of BaP on U1 cells
using the NovoCyte flow cytometer (ACEA, Biosciences Inc., San Diego, CA). We
followed the method as described in Chapter 4 for the measurement of ROS level in the
cells. The data were analyzed by using the NovoExpress software.
7-Ethoxy-Resorufin-O-Deethylase (EROD) Assay
We used the EROD assay to determine the activity of CYP1A1 after the chronic
treatment of BaP. Briefly, the treated cells were washed with PBS and suspended in 900
μl 0.1 M Hepes buffer, pH 7.4. The cell suspension was then sonicated for 10 seconds, 3
times, with pulse on and off. The cell extract (90 μl) thus obtained was added with 1 μl of
substrate, 7-ethoxyresorufin (100 μM) and incubated at 37º C for 10 minutes. Later, 10 μl
NADPH (10 mM) was added to the reaction mixture and incubated for another 15
minutes. The reaction was stopped by using 75 μl fluorescamine solution in acetonitrile
(150 μg/ml). When the cell extracts were incubated with the substrate and NADPH, the
CYP1A1 enzyme present in the cells reacted with the substrate resulting in the formation
of a fluorescence product, resorufin. The fluorescence thus generated was measured at
excitation/emission wavelengths of 535/590 nm. The CYP1A1 activity was calculated by
measuring the amount of fluorescence generated per unit time. The quantity of resorufin
in the samples was calculated by comparing it with the standard calibration curve
prepared by using 0-100 pmol of resorufin standard.
Apoptotic DNA Damage
We used the Apoptag® Iso Dual Florescence Apoptosis Detection kit (Millipore
Sigma, Burlington, Massachusetts) to determine apoptotic DNA damage after BaP
treatment in U1 cells. The assay was carried out using the manufacturer’s protocol.
Statistical Analysis
All the data are presented as Mean ± SEM of at least three independent
experiments. The mean value obtained for the control group was normalized to 100% or
1-fold, to which the treated cells were compared as a % or fold of control, respectively.
Student’s t-test or one- or two-way ANOVA were used to calculate the statistical
differences (p≤0.05) between the control and the treated groups, where applicable. All the
statistical analyses were performed using GraphPad Prism 7 (San Diego, CA).
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Results
BaP Induces HIV-1 Replication in U1 Cells and HIV-1-infected Human Primary
Macrophages
Chronic exposure of BaP (100 nM for 7 days) showed an approximately 4-fold
increase in HIV-1 replication in U1 cells (Figure 5-1A). However, a 10-fold lower
concentration of BaP (10 nM) did not have any significant effect on the viral replication.
We also confirmed this result in HIV-1-infected human primary macrophages, in which,
BaP (100 nM) showed an approximately 2-fold increase in HIV-1 replication
(Figure 5-1B). Furthermore, we examined apoptotic DNA fragmentation in HIV-1infected human primary macrophages after 3 days exposure of BaP (100 nM). The
fluorescent images revealed an increased apoptotic DNA fragmentation with DNase Type
I ends in cells treated with BaP (100 nM) compared to that of the control (Figure 5-1C).
DNA fragmentation with DNase Type II ends were not visible in both the control and the
treated cells. The results suggest that BaP induces DNA fragmentation during the early
phase of apoptosis, within the nucleus of the treated cells. Upon validating the results of
the U1 cells in human primary macrophages, we performed the subsequent experiments
that examined the underlying mechanism in U1 cells.
BaP Induces the Expression of CYP1A1
The expression of CYP1A1 and CYP3A4, which are the major BaP-metabolizing
CYPs, were examined in U1 cells exposed to BaP (100 nM) for 7 days. The chronic
exposure of BaP showed an approximately 30-fold increase in the mRNA expression of
CYP1A1 in U1 cells (Figure 5-2A), but failed to show any significant expression of
CYP1A1 at the protein level (Figure 5-2B). The chronic exposure of BaP (100 nM)
increased the enzymatic activity of CYP1A1 by approximately 2-fold (Figure 5-2C). On
the other hand, we did not observe any significant change in the expression of CYP3A4
at both the mRNA and protein levels (Figure 5-2D-E).
BaP Does Not Alter the Expression of AOEs
The induction of CYPs could metabolize BaP and increase ROS. However, the
ROS could subsequently be neutralized by the induction of antioxidant enzymes (AOEs).
Therefore, we examined the induction of two of the most important and general AOEs;
superoxide dismutase 1 (SOD1) and catalase by 100 nM BaP. Our results demonstrated
no significant change in the mRNA and protein expression levels of both SOD1 and
catalase (Figure 5-3A-D).
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Figure 5-1. Chronic treatment of BaP induces HIV-1 replication and apoptotic
DNA damage in HIV-1-infected macrophages.
(A). The U1 cells were treated with 10 nM and 100 nM BaP for seven days. After the
BaP treatment, the U1 cells were stimulated with 100 nM of Phorbol 12-myristate 13acetate (PMA) to produce HIV-1. Supernatants were collected after two days of
differentiation, which were used for the p24 ELISA assay to assess the viral load. The
chronic (7 days) treatment of BaP (100 nM) significantly increased the viral replication in
U1 cells, while the 10-fold lower concentration did not have any significant effect. The
data is displayed as mean ± SEM (n= 6), calculated as a percentage of the control. (B).
HIV-1-infected human primary macrophages were treated with BaP (100 nM) for 3 days.
The supernatant was collected thereafter and used for the p24 ELISA assay to assess the
viral load. The acute (3 days) treatment of BaP (100 nM) significantly increased the viral
replication in HIV-1-infected macrophages. The data is displayed as mean ± SEM (n= 4),
calculated as percentage of the control. The statistical significance was calculated at p ≤
0.05 (*), where *** represents p ≤ 0.0005, compared with the control group. (C). The
apoptotic DNA damage assay was performed on the treated cells. DAPI, FAM and
CR590 stained nucleus (blue), apoptotic DNA damage with DNase Type II ends (green)
and Type I ends (red) respectively. A higher signal for CR590 is visible in the fluorescent
images, indicating apoptotic DNA fragmentation with DNase Type I ends in the infected
human primary macrophages after BaP (100 nM) exposure for 3 days. DNA
fragmentation with DNase Type II ends (green) was not visible in either the control or the
treated cells. Therefore, the images indicate that BaP (100 nM) induces DNA
fragmentation during the early phase of apoptosis in the HIV-1-infected human primary
macrophage
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Figure 5-2. Chronic treatment of BaP induces expression of CYPs in U1 cells.
The U1 cells were treated with 100 nM BaP for seven days. We measured the mRNA
expression (A, D) and protein expression (B, E) of CYPs (1A1, 3A4) using RTPCR and
western blotting, respectively. Chronic exposure of BaP (100 nM) significantly induced
the expression of CYP1A1 at the mRNA level, but not at the protein level. Therefore, we
measured activity of CYP1A1 using the EROD assay (C). Chronic BaP treatment
increased CYP1A1 activity by approximately 2-fold. However, there was no significant
change in the expression of CYP3A4 at both the mRNA and protein levels. The data are
displayed as mean ± SEM of at least three independent experiments (n ≥3). The
mRNA/protein expression of the treated cells are normalized to control cells, whose
expression was set at 1-fold. GAPDH was used as an endogenous control and loading
control for RTPCR and western blotting, respectively. The statistical significance was
calculated at p ≤ 0.05 (*) compared with the control group. The blots are representative
of at least three independent experiments.
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Figure 5-3. Chronic treatments of BaP have no significant effect on the expression
of AOEs in U1 cells.
The U1 cells were treated with 100 nM BaP for seven days. We measured the mRNA
expression (A, D) and protein expression (B, E) of AOEs (SOD1 and Catalase) using
RTPCR and western blotting, respectively. There was no significant change in the
expression of SOD1 and catalase at both the mRNA and protein levels after chronic
treatment of BaP (100 nM). The data are displayed as mean ± SEM of at least three
independent experiments (n ≥3). The mRNA/protein expression of treated cells are
normalized to control cells, whose expression was set at 1-fold. GAPDH was used as an
endogenous control and loading control for RTPCR and western blotting, respectively.
The statistical significance was calculated at p ≤ 0.05 (*) compared with the control
group. The blots are representative of at least three independent experiments.
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Role of CYP1A1 on BaP-induced ROS Generation
Treatment of BaP (1 μM) in U1 cells for 3 days increased the generation of ROS
by 30% (Figure 5-4A-B). In this and the subsequent experiments we used 1 μM BaP for
3 days to induce oxidative stress and/or HIV-1 replication, because chemical inhibitors
and antioxidants are toxic to the cells when treated for 7 days. Further, we pre-treated the
U1 cells with different antioxidants or CYP inhibitors prior to BaP exposure to determine
whether these compounds reduce the BaP-induced ROS generation. We used vitamin C
(100 μM), vitamin E (100 μM), resveratrol (50 μM), a resveratrol analog, pinostilbene (2
μM) as antioxidants, and a selective CYP1A1 inhibitor, ellipticine (1 μM) for the study at
the concentrations previously shown to be effective [296, 297]. Vitamin C and ellipticine
significantly reduced the BaP-induced production of ROS (Figure 5-4A-B). However,
there was no significant change in BaP-induced ROS after treatment with vitamin E,
resveratrol, and pinostilbene. Figure 5-4C shows the graphical representation of the
results obtained in Figure 5-4A-B.
Role of CYP1A1 and Oxidative Stress Pathways on BaP-induced HIV-1 Replication
The U1 cells treated with BaP (1 μM) for 3 days showed approximately 70%
increase in HIV-1 replication (Figure 5-5A). Treatment with antioxidants, vitamin C and
E (100 μM each) and, resveratrol (50 μM) rescued the viral replication caused by BaP (1
μM) (Figure 5-5A). In addition, treatment with the CYP1A1 inhibitor, ellipticine (1 μM)
also exhibited a reduction in viral load in BaP-treated U1 cells (Figure 5-5B). To further
validate our results, we knocked down the CYP1A1 gene in the U1 cells, using a siRNA
silencing technique prior to BaP treatment. The viral load significantly decreased after
silencing the CYP1A1 gene (Figure 5-5C), which further confirms a role of CYP1A1 on
BaP-induced HIV-1 replication.
Nuclear Translocation of NF-κB Subunits upon BaP Exposure
There was no prominent change in the expression level of NF-κB p50 and p65 in
the cytoplasmic fraction after chronic (Figure 5-6A, left panel) and acute (Figure 5-6B,
left panel) treatment of BaP (100 nM) and BaP (1μM), respectively. Interestingly, there
was an increase in the expression of both the NF-κB proteins, especially p65, in the
nuclear fraction after acute and chronic BaP exposures compared to the control
(Figure 5-6A-B, right panel).
Role of NF-κB Pathway in BaP-induced HIV-1 Replication
Treatment of BaP (1 μM)-exposed U1 cells with NF-κB inhibitors such as IKK16 (Figure 5-7A) or SC-514 (Figure 5-7B) for 3 days, significantly reduced HIV-1
replication in BaP-exposed U1 cells, suggesting that the viral replication occurred via the
NF-κB signaling pathway. We also monitored the translocation of NF-κB p65, the major
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Figure 5-4. Treatment of antioxidants and CYP1A1 inhibitors reduce ROS in U1 cells due to BaP exposure.
U1 cells were concomitantly treated with BaP (1μM) and antioxidants [vitamin C (100 μM), vitamin E (100 μM), pinostilbene
(2 μM), and resveratrol (50 μM)] (A) or a CYP1A1 inhibitor [ellipticine (1 μM)] (B). Treated cells were stained with CMDCFDA dye and the fluorescence emitted was measured using flow cytometry at excitation/ emission of 495/519 nm.
Treatment of BaP (1 μM) significantly increased ROS in U1 cells, which was rescued by the treatment of vitamin C, and
ellipticine. The data were obtained from the mean of at least three independent experiments. * and ** Represents p ≤ 0.05 and
p ≤ 0.005 respectively, compared with the control group while # and ## represent p ≤ 0.05 and p ≤ 0.005, respectively,
compared to the BaP-treated groups. Figure C. shows the graphical representation of mean fluorescence intensity due to the
treatmen
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Figure 5-5. Treatment of antioxidants and CYP1A1 inhibitors reduce HIV-1 replication in U1 cells due to BaP
exposure.
U1 cells were concomitantly treated with BaP (1μM) and antioxidants [vitamin C (100 μM) and vitamin E (100 μM),
pinostilbene (2 μM), and resveratrol (50 μM)] (A) or CYP1A1 inhibitor epiliptine (1 μM)] (B) for 3 days. Prior to BaP
treatment, the CYP1A1 gene was knocked down in the U1 cells using siRNA specific to CYP1A1 (C). The cells were then
treated with BaP (100 nM) for 3 days. After the treatment, supernatants were collected to determine the viral load using the
p24 ELISA assay. HIV-1 replication significantly increased with 3-days exposure of BaP (1 μM), which was rescued by all the
antioxidants (vitamin C and E, and resveratrol) as well as the CYP1A1 inhibitor, epilliptine. The knock-down of the CYP1A1
gene also rescued HIV-1 replication in BaP-exposed U1 cells. The data were obtained from the mean of at least three
independent experiments. * and ** Represents p ≤ 0.05 and p ≤ 0.005 compared with the control group while #, ## and ###
represents p ≤ 0.05, p ≤ 0.005 and p ≤ 0.0005, respectively, compared to the BaP-treated groups.
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Figure 5-6. Translocation of NF-κB subunits from cytoplasm to nucleus upon BaP exposure.
U1 cells were treated with BaP 100 nm (A) and 1 μM (B) for 7 days and 3 days, respectively. After the treatment, proteins
from the cytoplasm and nucleus were extracted from the cells. Western blot was run to determine the expression of the NF-κB
p50 and p65 subunits in the proteins in cytosolic fraction (CF) and nuclear fraction (NF). GAPDH and β-lamin were used as
loading controls for the cytoplasmic and nuclear proteins, respectively. The blots are representative of at least three
independent experiments. There is not much difference in the expression of NF-κB p50 and p65 between the control and the
BaP-treated cells. However, there is a clear increase in the expression of both the subunits in the nuclear fraction of acutely or
chronically BaP-treated cells compared to the control group.
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Figure 5-7. Treatment of NFκ-B inhibitors reduce HIV-1 replication in U1 cells due to BaP exposure.
U1 cells were concomitantly treated with BaP (1 μM) and NFκ-B inhibitors, IKK-16 (400 nM) (A), and SC-515 (10 μM) (B)
for 3 days. After the treatment, supernatants were collected to determine the viral load using the p24 ELISA assay. HIV-1
replication due to BaP (1 μM) exposure was significantly rescued by NFκ-B inhibitors, IKK-16 (400 nM) and SC-514 (10
μM). * Represents p ≤ 0.05 compared with the control group while ## represents p ≤ 0.005 compared to the BaP-treated
groups. Western blots were run using the nuclear fraction proteins obtained from the BaP-exposed cells treated with IKK-16
(C), SC-524 (D) or siRNA CYP1A1 (E) to determine the expression of NFκ-B p65 subunits. The blots indicate that treatment
with both the NFκ-B inhibitors and CYP1A1 siRNA reduced the expression of NFκ-B p65 in the nuclear fraction protein of the
BaP-treated cells compared to the control. The blots presented are representative of at least three different experiments.
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DNA-binding subunit of the NF-κB protein into the nucleus, after treatment with NF-κB
inhibitors, IKK-16 (Figure 5-7C) and SC-514 (Figure 5-7D) and after siRNA silencing
of CYP1A1 (Figure 5-7E). The results showed that the knock-down of CYP1A1 in BaPtreated cells reduces the translocation of the NF-κB p65 unit into the nucleus. As
expected, the expression of the NF-κB p65 protein was also observed to be lower in the
nucleus of BaP-treated cells, after treatment with IKK-16 and SC-514
Discussion
Several reports suggest that cigarette smoke exposure is associated with increased
HIV-1 replication and infectivity [140, 157, 211]. However, the mechanism of smoking
induced HIV-1 replication is poorly understood, except for the fact that oxidative stress is
a possible mechanism for enhanced viral load [153, 154]. The current report reveals a
novel mechanism for BaP-mediated HIV-1 replication in monocyte-derived macrophages
in vitro. In this study, we have demonstrated that oxidative stress generated by the
CYP1A1-mediated metabolism of BaP, triggers the redox-sensitive transcription factor,
NF-κB that leads to the amplification of HIV-1. This is the first evidence of the
involvement of a novel CYP-mediated oxidative stress pathway in tobacco-mediated
HIV-1 replication via NF-κB in macrophages (Figure 5-8)
Recently, we have shown that the exposure of CSC increases HIV-1 replication,
oxidative stress, and induction of CYP enzymes in U937 and/or U1 macrophages [154].
We have also shown the involvement of CYP2A6 in nicotine metabolism and oxidative
stress in U937 cells [230]. Further, our study using ex vivo samples from HIV-1-infected
individuals who smoke also demonstrated an increase in HIV-1 replication, oxidation
stress, and nicotine metabolism [153]. Taken together, these studies suggest an
association of CYP-mediated oxidative stress with HIV-1 replication in tobacco smokers.
Comparison of oxidative stress levels after nicotine and CSC exposure revealed that the
induction of ROS by CSC is much higher than ROS induction by nicotine [230].
Therefore, we recently studied the effect of BaP, an important PAH component of CSC,
in U937 cells and observed that BaP increases CYP1A1 expression, ROS levels, and
cytotoxicity [273]. The excessive ROS production by BaP likely disturbed the redox
homeostasis, causing oxidative stress, which resulted in cytotoxicity in U937 cells [298].
In the present study, we examined whether BaP induces HIV-1 replication in
HIV-1-infected macrophages via the CYP-induced oxidative stress pathway. To
demonstrate this, first we studied the effect of BaP in HIV-1 replication in U1 cells and
our findings suggested that chronic exposure of BaP (100 nM) increases HIV-1
replication in these cells. We have also confirmed this result in HIV-1-infected human
primary macrophages. Furthermore, BaP exposure induced DNA fragmentation during
the early phase of apoptosis. Secondly, the expression of CYP1A1 and CYP3A4, which
are the major BaP-metabolizing CYPs, were examined in U1 cells after BaP (100 nM)
exposure for 7 days. The results showed an increase in the mRNA expression of CYP1A1
by BaP which is consistent with the previous study findings [220, 273, 299, 300]. BaP
induces the expression of CYPs in cells by activating a nuclear receptor, aryl
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Figure 5-8. Schematic diagram showing the mechanism of BaP-induced -1-1
replication in macrophages.
Cigarette smoke constituents such as benzo(a)pyrene (BaP) induces expression of
CYP1A1 in HIV-1-infected cells. CYP1A1 in turn metabolizes BaP into various BaPmetabolites, during which large amounts of reactive oxygen species (ROS) are generated.
The resulting oxidative stress induces HIV-1 replication in the cells via a NF-κB
pathway. In an inactive state, NF-κB (p65 and p50 subunits) forms a complex with an
inhibitor of NF-κB proteins (IκB), which inhibits its translocation from the cytoplasm to
the nucleus. Oxidative stress due to BaP triggers the activation of IκB kinase (IKK) that
facilitates the ubiquitination of IκB proteins, thereby releasing the NF-κB subunits into
the nucleus. Within the nucleus, the NF-κB proteins bind to specific DNA regions and
trigger the expression of HIV-1 structural genes. Knock-down of CYP1A1 by siRNA
specific to CYP1A1 and inhibition of the NF-κB pathway using specific NF-κB
inhibitors such as IKK-16 and SC-514 significantly reduced HIV-1 replication in HIV-1infected macrophages.
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hydrocarbon receptor (AHR) [251]. The binding of BaP dissociates AHR from the AHRheat shock protein 90 complex, which facilitates AHR translocation into the nucleus.
Inside the nucleus, AHR binds to DNA with the help of AHR nuclear translocator
(ARNT) and activates the transcription of CYP1A1, CYP1A2 and CYP1B1 [301, 302].
This is a well-known pathway and therefore a similar mechanism likely occurs in
inducing CYP1A1 by BaP in macrophages presented in this study. However, as seen
before, we did not observe any significant expression of CYP1A1 at the protein level,
perhaps due to post translational modifications of the protein or instability of the protein
after extraction. Therefore, we determined its enzymatic activity using the Erod assay
[303]. The chronic exposure of BaP (100 nM) increased the enzymatic activity of
CYP1A1 by approximately 2-fold. On the other hand, we did not observe any significant
change in the expression of CYP3A4 at both the mRNA and protein levels. However,
BaP induced the expression of CYP3A4 in human primary monocytes [273]. This
discrepancy could be due to the use of two different, uninfected human primary
monocytes and HIV-1-infected (U1), monocytic cell lines.
Thirdly, it is well known that CYPs generate ROS while metabolizing a wide
range of substrates via coupling and auto oxidation reactions [304], and our results are in
agreement with previous reports [276, 305], showing that acute treatment of BaP (1 μM)
in U1 cells for 3 days increase the ROS levels. Further, we treated the U1 cells with
different antioxidants or CYP inhibitors prior to BaP exposure to determine whether these
compounds reduced the BaP-induced ROS generation. We chose a shorter duration of
time and a higher BaP concentration to induce ROS in this experiment, because chronic
treatment of antioxidants or CYP inhibitors along with BaP causes cytotoxicity. We used
vitamin C, vitamin E, resveratrol, a resveratrol analog, pinostilbene as antioxidants, and a
selective CYP1A1 inhibitor ellipticine to see if these antioxidants can block the BaPinduced oxidative stress. In addition to their antioxidant effects, resveratrol and
pinostilbene are also known to inhibit CYP1A1 [297]. Vitamin C and ellipticine
significantly reduced the BaP-induced production of ROS. The results suggest that BaPinduced ROS occurs via CYP1A1-mediated metabolic activation of BaP.
Cells express AOEs to neutralize the excessive accumulation of ROS generated
by various stress factors [278, 306]. BaP is known to induce the expression of AOEs by
the activation of the nuclear Nrf2 (nuclear factor erythroid 2-related factor) pathway
[307]. BaP downregulates the activity of the Nrf2 inhibitory protein, kelch-like ECHassociated protein 1(Keap1), which prevents the proteasomal degradation of Nrf2 and
promotes its translocation to the nucleus, where it binds to the enhancer ARE in DNA,
leading to the transcription of the AOEs [307, 308]. Therefore, we examined the
induction of two of the most important and general AOEs; superoxide dismutase 1
(SOD1) and catalase in U1 cells after BaP exposure. There was no significant change in
the mRNA and protein expression levels of both SOD1 and catalase. Although the basal
AOEs may have played their part in scavenging ROS, the persistent increase in oxidative
stress after BaP exposure suggests that their antioxidant capacity was not sufficient.
Furthermore, these results suggest that the inability of BaP to enhance AOE expression
could cause an increased generation of CYP-induced ROS by BaP.
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Next, we checked whether oxidative stress induced through the CYP1A1mediated metabolism of BaP increased HIV-1 replication in HIV-1-infected
macrophages. The treatment of U1 cells with BaP showed an approximately 70%
increase in HIV-1 replication, which was significantly reduced by the treatment of
antioxidants such as vitamin C and E, and resveratrol. In addition, treatment with the
CYP1A1 inhibitor, ellipticine, also exhibited a reduction in the viral load of BaP-treated
U1 cells. Taken together, these results suggest that BaP induces HIV-1 replication in U1
cells via the CYP-mediated oxidative stress pathway. We knocked down the CYP1A1
gene in the U1 cells, using the siRNA silencing technique prior to BaP treatment to
further confirm our results. The reduction in HIV-1 replication after siRNA silencing of
the CYP1A1 gene, further strengthens the role of CYP1A1 in BaP-induced HIV-1
replication.
Upon demonstrating that BaP enhances HIV-1 replication in U1 cells via the
CYP-mediated oxidative stress pathway, our next goal was to identify the molecular
mechanism of oxidative stress-induced viral replication upon BaP exposure. Several
studies have suggested that the NF-κB pathway triggered by ROS has a role in HIV-1
replication [192, 280]. Therefore, we monitored the translocation of NF-κB subunits from
the cytoplasm into the nucleus after chronic treatment of BaP in U1 cells. Since the
differentiated macrophages specifically express the transcriptionally active NF-κB p65p50 heterodimer [309], and this heterodimer is specifically expressed during NF- κBmediated HIV-1 transcription [310], we monitored the protein expression of these NF-κB
subunits in both the cytoplasm and the nucleus. We observed that BaP increases the
expression of both of the NF-κB proteins, especially p65, in the nuclear fraction after
acute and chronic BaP exposure. Based on these findings, we suggest that ROS generated
through CYP1A1-mediated metabolism of BaP could trigger the NF-κB pathway, which
eventually perpetuates viral transcription. Furthermore, we confirmed the involvement of
the NF-κB pathway in BaP-induced HIV-1 replication by treating BaP-exposed U1 cells
with NF-κB inhibitors such as IKK-16 and SC-514. Both of the compounds inhibit NFκB activity by selectively acting on IKK-β, an isoform of IKK protein [311, 312]. In
addition, SC-514 decreases the import of p65 into the nucleus and expedites the export of
p65 from the nucleus, as well as inhibiting the phosphorylation and transactivation of p65
[313]. Treatment of IKK-16 or SC-514 significantly reduced HIV-1 replication in BaPexposed U1 cells, which provides strong evidence that the viral replication occurred via
the NF-κB signaling pathway. To further verify our results, we monitored the
translocation of NF-κB p65, the major DNA-binding subunit of the NF-κB protein into
the nucleus, after treating the cells with the NF-κB inhibitors, IKK-16 and SC-514 and
after siRNA silencing of CYP1A1. The knock-down of CYP1A1 in BaP-treated cells
reduced the translocation of the NF-κB p65 unit into the nucleus, which shows an
association of CYP1A1 with NF-κB-mediated viral replication. As expected, the
expression of the NF-κB p65 protein was also observed to be lower in the nucleus of
BaP-treated cells, after treatment with IKK-16 and SC-514, which further confirms that
BaP-mediated HIV-1 replication occurs via the NF-κB signaling pathway. Our findings
reconfirm the role of ROS in the activation of NF-κB and its subsequent impact on HIV-1
gene transcription [147, 314].
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In addition to the ROS generated via the CYP-mediated metabolism of BaP, there
are other factors such as HIV-1 proteins whose contribution to ROS production cannot be
ruled out. HIV-1 proteins such as tat, gp120, Nef, and Vpr are known to cause oxidative
stress in the infected cells [150, 151, 286, 315, 316]. These HIV-1 proteins generate ROS
via different mechanisms: tat via upregulation of spermine oxidases [317] or by
activating the NADPH oxidase pathways [318]; gp120 via upregulation of CYP2E1,
NADPH oxidases [286], and proline oxidase [319]; Vpr via interaction with adenine
nucleotide translocator or NADPH oxidases 70; and Nef via direct interaction with
NADPH oxidases [320]. Moreover, some of these viral proteins, such as tat and nef, are
also known to enhance HIV-1 replication by interacting directly or indirectly on the LTR
of the viral DNA [321].
Conclusion
In conclusion, the present study suggests NF-κB activation through ROS
generated via CYP1A1-mediated activation/metabolism of BaP as a novel pathway to
explain smoking-mediated HIV-1 replication in monocytes-derived macrophages. This
study has clinical relevance because the outcomes obtained from this study provide
potential targets such as CYPs, oxidative stress, and NF-κB signaling pathways, for
developing novel interventions to improve treatment strategies for HIV-1-infected
smokers. We have demonstrated that antioxidants such as vitamin C and E, resveratrol,
and pinostilbene, and CYP1A1 inhibitors namely ellipticine are capable of neutralizing
the oxidative stress induced by BaP and subsequent viral load. These antioxidants and
CYP1A1 inhibitors, which are chemodietary agents, have the potential to effectively
control the viral replication in HIV-1-infected individuals who smoke tobacco.
Furthermore, reduction of the viral load in these cells by targeting CYPs and the
oxidative stress pathway may be beneficial in treating HIV-1-infected CNS cells.
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CHAPTER 6. EXOSOMES FROM HUMAN PAPILLOMA VIRUS-INFECTED
CERVICAL CANCER CELLS ENHANCE HIV-1 REPLICATION IN
MACROPHAGES
Introduction
HIV-1-infected women have a high prevalence of human papilloma virus (HPV),
particularly type 16 and 18 infection that causes cervical cancer [322, 323].
Epidemiological data suggests that the incidence of cervical cancer in HIV-1-infected
women is approximately 5- to 10-times higher compared to the uninfected women [324].
Cervical cancer has also been categorized into AIDS-defining cancer because of its
specific higher prevalence in HIV-1-infected patients [325]. HIV-1 increases HPV
infectivity by disrupting the tight junctions surrounding the epithelial cells. HIV-1 further
enhances the ability of HPV to develop precancerous lesions and ultimately cervical
cancer by promoting immunosuppression and upregulation of HPV oncogene [324].
However, whether HPV infection can have a reciprocal effect on HIV-1 pathogenesis is
largely unknown. Therefore, there is a need to examine the biological interactions among
HPV and HIV-1 to find a better preventive and treatment strategies to reduce HIV-1
pathogenesis in HIV-1/HPV coinfected patients
Evidences from previous reports show that cervical cancer cells constantly
undergo oxidative stress [210, 326, 327]. The clinical samples from the cervical cancer
patients have revealed higher ROS level, higher oxidative damage, and lower level of
antioxidants, compared to the samples from healthy individuals [328-330]. In vitro
experiments have also suggested a high level of ROS, profound downregulation in the
genes associated with antioxidant proteins such as superoxide dismutase 1 (SOD1),
SOD2, SOD3, peroxiredoxin 1 (PRDX1), PRDX2, glutathione S-synthetase (GSS), and
glutathione peroxidase 6 (GPX6), and high presence of Poly [ADP-ribose] polymerase 1
(PARP1), a marker of oxidative stress-induced DNA damage in cervical carcinomaderived Caski cells [210]. HPV oncoproteins E6 and E7 stimulate the degradation of
tumor-suppressor p53 protein [331], causing uncontrolled cell growth. p53 protein, which
primarily has a function in apoptosis and genomic stability, is also reported to have an
antioxidant role [332]. Downregulation of p53 suppresses its antioxidant potential and
renders the cells vulnerable to oxidative damage. Furthermore, the expression of HPV E6
and E7 oncoproteins alone is sufficient to cause oxidative stress. Marullo et al. (2015)
have demonstrated that HPV E6 and E7 proteins generate chronic oxidative response in
the host cells via NADPH oxidase 2 (NOX2) activation [134]. E6 expression also
downregulates SOD2 and glutathione peroxidase [134]. The suppression of antioxidant
activity of these antioxidants could be another mechanism by which HPV generates ROS
in the host cells.
Similar to other cells, HPV-infected cervical cells also secrete small nanosized
extracellular vesicles (30-150 nm in size) called exosomes [333, 334]. Exosomes
originate from the invagination of the lumen of the early endosomes. As the endosomes
reach the later phase of their development, these invaginations bud off forming hundreds
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of intraluminal vesicles. These vesicles are released into the extracellular matrix of the
cells through fusion into the cell membrane [335]. Exosomes carry wide variety of
cellular proteins, lipids, mRNA, miRNA, and DNA from their originating cells to other
cells via blood circulation. The role of exosomes in intracellular communication and
transport has been well supported by many studies [336]. In HPV-infected cells, the virus
hijacks the host exosomal system, thereby modulating both the contents and amount of
exosomes released from HPV-infected cervical cells [334, 337]. The exosomes from the
HPV-infected cervical cells are known to transport various cellular factors to the recipient
cells [337, 338]. It is possible that HPV-infected cells may be releasing oxidative stress
factors into exosomes and transferring them to other cells via blood stream.
Oxidative stress is known to enhance the frequency of integration and replication
of HPV genome [327, 339, 340]. ROS enhance HPV DNA integration by making a space
for the viral genome to integrate into the host DNA through DNA damage in the host
cells [339]. Oxidative DNA damage and the HPV oncoproteins E6 and E7 enhance the
viral amplification by activating the viral transcriptional and replication proteins, E1 and
E2 [327]. Oxidative stress-induced viral replication has also been observed in HIV-1
infection [149, 154]. We recently demonstrated that oxidative stress generated via CYPmediated metabolism of benzo(a)pyrene (BaP) triggered HIV-1 replication in monocytes
and macrophages [341]. We showed that ROS thus generated, activated the nuclear
transcription factor NF-κB, thereby inducing transcription of the HIV-1. In the current
study, we have introduced exosomes as a mediator for intracellular communication
between HPV-infected cervical cancer cells and macrophages latently infected with HIV1. Our findings demonstrate that cervical cancer cells release exosomes containing
oxidative stress factors into HIV-1-infected macrophages, where they induce HIV-1
replication.
Materials and Methods
Cell Culture and Treatment
Caski cells. Caski cells are human cervical cancer cell lines containing about 600
copies of HPV-16 genome per cell as well as sequences related to HPV-18 (ATCC). We
cultured the Caski cells in Roswell Park Memorial Institute (RPMI) 1640 media
containing 10% Fetal bovine serum (FBS) and penicillin. We seeded about 2.5 million
cells in a T-75 flask, cultured them for 3 days and collected the culture supernatant on the
4th day. For exosome isolation, we cultured the Caski cells in an RPMI media containing
10% exosome-free FBS and penicillin.
U1 cells. We cultured U1 cells as described in Chapter 5 and treated them with
CCS and CCS-Exo for 3-4 days.
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Exosome Isolation and Characterization
We isolated exosomes from Caski cell culture media using ultracentrifugation
method and Invitrogen-Total Exosome Isolation (from cell culture media) kit (Life
Technologies, NY). For ultracentrifugation method, we first centrifuged at a lower speed
300g followed by 2,000g for 10 minutes each, which removed live cells and dead cells
respectively. Further we centrifuged at 10,000g for 30 minutes to remove cellular debris
and microvesicles. Finally, we obtained exosomal pellet after centrifugation at 100,000200,000g for 70 minutes [342]. We followed the manufacturer’s protocol to isolate
exosomes using Invitrogen-Total Exosome Isolation kit. The cell culture supernatant was
centrifuged at 2000g for 30 minutes to remove any cellular debris present. Total exosome
isolation reagent was added to the cell culture supernatant in a 1:2 ratio and the mixture
was incubated overnight at 2°–8 °C. Next day, the mixture was centrifuged at 10,000g,
2°–8 °C for 1 hour, to obtain the exosomal pellets. Although ultracentrifugation method
yields exosomes of high purity, it is tedious and consumes >10-times media. The
exosomes we obtained from Invitrogen-Total Exosome Isolation kit had purity almost
equivalent to that obtained from the ultracentrifugation and the method takes less effort
and reagent. Therefore, we used Invitrogen-Total Exosome Isolation kit for isolating
exosomes for all our experiments. Western blotting was performed using antibodies
against specific exosomal markers such as CD63 and CD81 to confirm the identity of
exosomes. The exosomes were further characterized by measuring their size using zeta
sizer as described previously.
Viral Load
We collected the supernatant from U1 cells treated with Caski cell supernatant or
Caski cell-derived exosomes. HIV-1 viral p24 antigen level was measured in the U1 cell
culture supernatant to access the viral load, using HIV-1 p24 Antigen ELISA kit
(Zeptometrix Corporation, Buffalo, NY). We followed the manufacturer’s protocol to
perform the ELISA. The principle behind the p24 ELISA assay has been explained in
Chapter 5.
Measurement of ROS
ROS was measured in U1 cells after CCS or CCS-Exo treatment. ROS was
measured in the treated cells using the method described in Chapter 4. We used
NovoCyte flow cytometer (ACEA, Biosciences Inc., San Diego, CA) to measure ROS
and NovoExpress software to analyze the data. The background fluorescence signal due
to unlabeled cells was reduced and only the live healthy patch of cells was gated to
calculate the mean fluorescence intensity of the dye.
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Total Antioxidant Capacity
We measured antioxidant capacity of the CCS or CCS-exo treated U1 cells using
Total Antioxidant Capacity Assay Kit (Bio Vision, Milpitas, CA). The assay was
performed according to the manufacturer’s protocol and as described previously [211].
Cytotoxicity
We used Pierce TM LDH cytotoxicity assay kit (Thermo Scientific, Rockford, IL)
to measure the cytotoxicity in U1 cells after the exposure of Caski cell exosomes. We
followed the manufacturer’s protocol to conduct the assay. We performed the assay on
culture supernatant obtained after the treatment. Dead cells release LDH enzymes from
the cytosol into the culture supernatant through their damaged plasma membrane. The
measure of LDH in the culture supernatant is proportional to the cytotoxicity suffered by
the cells. The LDH kit is comprised of LDH reaction mixture containing lactate, NAD+,
diaphrose, and terazolium salt. A catalytic reaction between the LDH in the medium and
the reaction mixture generates a red color product, formazan, whose absorbance at 490
nm is directly proportional to the amount of LDH.
Apoptotic DNA Damage
We observed the DNA damage of the CCS or CCS-Exo treated U1 cells under
fluorescent microscope using the Apoptag® Iso Dual Fluorescence Apoptosis Detection
kit (Millipore Sigma, Burlington, Massachusetts). We followed the manufacturer’s
protocol to perform the assay.
RNA and Protein Isolation
We used the method described in Chapter 5 to isolate RNA and protein from the
cells.
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR)
We used RTPCR to calculate the relative mRNA fold expression level of CYPs
and AOEs in U1 cells after treatment of Caski supernatant/Caski-derived exosomes. The
mRNA expression was measured following the method described as earlier in Chapter 4.
We used the following specific TaqMan TM probes (CYP1A1 (Hs01054794_m1),
CYP2A6 (Hs00430021_m1), SOD1 (Hs00533490_m1), SOD2 (Hs00167309_m1),
catalase (Hs00156308_m1), and PRDX6 (Hs00705355_s1)) and GAPDH as an
endogenous control.
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Western Blotting
We used Western blotting to identify the presence of CYPs, antioxidants, and
HPV proteins in Caski-derived exosomes and to calculate the relative protein fold
expression level of CYPs and AOEs in U1 cells upon treatment with Caski
supernatant/Caski-derived exosomes. We performed western blotting as described in
Chapter 4. We used the following primary antibodies: GAPDH Rabbit Mab, 1:2000
dilution, Cell Signaling Technology, Danvers, MA; CYP1A1 rabbit Mab, 1:200 dilution;
CYP2A6 Mouse Mab, 1:200 dilution, Abcam, Cambridge, MA; SOD1 Mouse Mab,
1:1500 dilution; SOD2 Mouse Mab, 1:500 dilution; Catalase Mouse Mab, 1:1200
dilution, Santa Cruz Biotechnology. Inc., Dallas, TX; PRDX6 Rabbit Mab, 1:500
dilution, LifeSpan Biosciences, Inc., Seattle, WA; CD63, Rabbit Pab, 1:200 dilution,
Proteintech Group, Inc Rosemont, IL). GAPDH and CD63 were used as loading controls
for cellular and exosomal proteins, respectively.
Exosome Uptake
The CCS-Exo were labelled with GFP protein using Exo-GlowTM Exosome
Labeling Kits (System Biosciences, CA) and as described previously [211]. Exosomal
pellet containing ~ 42 μg of protein in 500 μl of 1X PBS was incubated with 50 μl of
10X Exo-Green dye at 37oC for 30 minutes. The labelling reaction was stopped by
adding 100 μl of ExoQuick-TC, provided along with the kit. The labelled CCS-Exo were
exposed to U1 cells for 6 hours and their uptake was monitored under fluorescent
microscope and flow cytometry.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism 7.0 (La Jolla, CA). All
data are presented as Mean ± SEM of 3-5 independent experiments. Student’s t-test or
one-way ANOVA were used to calculate the statistical differences between the control
and the treated groups, where appropriate. Significant difference was considered at
p<0.05.
Results
Cell Culture Supernatant from Caski Cells Enhances Oxidative Stress and Viral
Load in U1 Cells
The exposure of CCS for 4 days significantly (p-value = 0.0084, n=5) increased
the viral load in U1 cells by approximately 1.7-fold compared to the control (untreated
cells) (Figure 6-1A). ROS acts as a secondary messenger for inducing HIV-1 replication
in cells latently infected with HIV-1 [281]. To determine whether the viral replication is
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Figure 6-1. Caski cell culture supernatant (CCS) increases HIV-1 replication and
oxidative stress in U1 macrophages.
(A). U1 macrophages were treated with 250 μl of CCS every 24 hours for 4 days. p24
ELISA was performed on the supernatant obtained from the treatment to measure the
viral load. To minimize high standard deviation of the mean due to variability in
absorbance values in different experiments, we converted the control absorbance values
to 100% and normalized the values of treated groups to % of the control. (B). ROS was
measured in U1 macrophages after the 4 days exposure of CCS. The treated cells were
incubated with H2DCFDA, the fluorescence of which was monitored at maximum
excitation and emission spectra of 495 nm and 529 nm respectively, using flow
cytometer. (C). Figure C shows the graphical representation of ROS increase in CCStreated U1 cells (red graph) versus control cells (grey graph). X-axis represents mean
fluorescence intensity (MFI), showing ROS level. (D). Total antioxidant capacity of the
cells were measured in CCS-treated cells using Total antioxidant capacity assay kit. The
values on Y-axis represents the total amount of reduced Cu+ in nmol/μl, which
quantitatively gives the measure of antioxidant capacity of the cells. (E). Cytotoxicity
after CCS exposure was measured using Pierce TM LDH cytotoxicity assay kit. The
values on Y-axis represent the absorbance values of formazan dye at 490 nm, which
gives the measure of cytotoxicity. The mean absorbance is obtained by subtracting the
background absorbance at 680 nm. All the data were obtained from the mean of at least
three independent experiments with the error bars representing standard error of mean.
Significant difference was considered at p<0.05. *, **, *** represents p<0.05, p<0.005
and p<0.0005 respectively. (F). Apoptotic DNA damage was examined using Apoptag®
Iso Dual Fluorescence Apoptosis Detection kit. DAPI, FAM and CR590 dyes were used
to stain the nucleus, DNase II and I-type of DNA breaks respectively.
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associated with oxidative stress, we measured the levels of ROS in the CCS-treated U1
cells. Our results showed that 4 days exposure of CCS induces ROS by ~1.25-fold (pvalue = 0.0169, n=3) in U1 cells (Figure 6-1B). Figure 6-1C shows the graphical
representation of the ROS measurements shown in Figure 6-1B. The graph on
Figure 6-1C is also consistent with the result in Figure 6-1B. During the oxidative stress,
cells employ antioxidant enzymes and proteins to neutralize the excess ROS, which may
eventually wear away the total antioxidant capacity of the cells. Therefore, we monitored
antioxidant capacity of U1 cells after 4 days of CCS treatment using total antioxidant
capacity (TAC) assay kit. The TAC assay kit comprises of Cu2+, which is reduced by
antioxidant molecules/proteins in the cell supernatant into Cu+. Although not significant,
the data presented in Figure 6-1D shows a trend in decrease in the total antioxidant
capacity of the CCS-treated cells compared to the control.
Next, we were interested to examine whether the excessive ROS induces cellular
toxicity and DNA damage after CCS treatment. The cytotoxicity depicted in Figure 6-1E
was performed using LDH assay. Interestingly, the 4 days treatment of CCS significantly
(p-value <0.0001, n=6) decreased the cytotoxicity in U1 cells by ~ 60% (Figure 6-1E).
To further confirm this result, we monitored apoptotic DNA fragmentation in the CSCtreated U1 cells. Figure 6-1F shows the fluorescent images of control and CCS-treated
U1 cells labelled with DAPI, FAM, and CR590 dyes, which were used to stain the
nucleus, DNA fragmentation with DNase Type II, and Type I ends, respectively. DNA
fragmentation with Type I ends, commonly observed in most cells, occurs within the
nucleus, which is an indicative of apoptosis by self-driven cell disassembly. In contrast,
DNA fragmentation with Type II ends occurs in lysosomes of the phagocytes, where they
eliminate the remains of apoptotic bodies [343]. The merged panel of Figure 6-1F shows
reduced fluorescence intensity for CR590 in CCS-treated U1 cells compared to the
control, which suggests that treatment of CCS protects U1 cells from DNase I type of
DNA break. We did not observe any signal with FAM dye in both the control and treated
cells, which suggests the absence of DNase II type of DNA break.
Cell Culture Supernatant from Caski Cells Induces CYP Expression in U1 Cells
CYP enzymes are known to generate ROS as byproducts, while metabolizing
various endogenous and exogenous substances within the cells. Therefore, we monitored
the mRNA and protein expression of CYPs (CYP 1A1 and 2A6) in U1 cells after 4 days
of exposure of CCS. We particularly examined the expression of CYP 1A1 and 2A6,
because these CYPs are significantly expressed in U1 cells. The 4 days exposure of CCS
significantly increased the expression of CYP1A1 at the mRNA level (p-value = 0.0367,
n =3) (Figure 6-2A) and but not at the protein level (Figure 6-2B). The treatment also
increased the protein expression of CYP2A6 in U1 cells significantly (p- value = 0.0647,
n = 3) (Figure 6-2D). However, there was no significant change in the expression of
CYP2A6 at the mRNA level.
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Figure 6-2. Caski cell culture supernatant (CCS) enhances CYP expression in U1
macrophages.
U1 macrophages were treated with 250 μl of CCS every 24 hours for 4 days. Expression
of CYP1A1 and CYP2A6 at mRNA (A and B) and protein (C and D) level were
monitored in the treated cells. Data were obtained from the mean of at least three
independent experiments with the error bars representing standard error of mean.
Significant difference was considered at p<0.05, which is represented by *.
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Cell Culture Supernatant from Caski Cells Have No Significant Effect on AOEs
Expression in U1 Cells
AOE expression is expected to rise at the time of oxidative stress as a cellular
response to combat the resulting oxidative damage. Therefore, we monitored the mRNA
and protein expressions of major AOEs (SOD1, SOD2, catalase, and PRDX6) in U1 cells
after 4 days exposure of CCS. The 4 days exposure of CCS did not have any significant
effect on the expression of the AOEs at both the mRNA as well as protein level (Figure
6-3).
U1 Cells Uptake CCS-derived Exosomes Containing Oxidative Stress Factors
Since exosomes are one of the major factors that are secreted in the media from a
variety of cells and are gaining attention in intercellular communication, we isolated and
characterized exosomes secreted from the Caski cells. Recently, we reported isolation
and characterizations of exosomes from the media of monocytic cells [211], and in this
study we essentially used similar techniques. We characterized these exosomes with
CD63 and CD81 (commonly used exosomal marker) in the CCS-derived exosomes
(CCS-Exo) (Figure 6-4A) and size (~100 nm) (data not shown). Our western blot images
also showed the expression of CYP enzymes (CYP 1A1, 1B1 and 2A6), SOD1 and HPV
16 oncoprotein E6 in CCS-derived exosomes (Figure 6-4A). To show that U1 cells
uptake these exosomes, we first labelled the exosomes with GFP and monitored its
uptake by U1 cells under fluorescent microscope and flow cytometer after 6 hours. The
merged panel of Figure 6-4B shows higher GFP fluorescence in CCS-Exo treated U1
cells, compared to the untreated cells, indicating the exosome uptake by U1 cells. We
further verified this result by measuring the GFP fluorescence using flow cytometer. In
Figure 6-4C, we can see that the red graph (CCS-Exo treated U1 cells) shifts towards the
far right compared to the grey graph (untreated U1 cells), indicating higher mean
fluorescence intensity for the former and hence the uptake of CCS-Exo by U1 cells. Our
observation is consistent with our previous study, where we observed uptake of U937
monocytes-derived exosomes by U1 cells in 6 hours [211].
CCS-derived Exosomes Enhance Oxidative Stress and Viral Load in U1 Cells
To examine if the exosomes in the CCS were responsible for the increase in viral
load in U1 cells, we treated the CCS-Exo to the U1 cells. U1 cells were treated with
exosomes isolated from 1ml of CCS (equivalent to ~ 42 μg protein) and cultured for 4
days. Exposure of the CCS-Exo for 4 days significantly (p-value = 0.0007, n = 6)
increased the viral load by approximately 1.3-fold (Figure 6-5A). CCS-Exo treatment
significantly (p-value = 0.0236, n = 3) increased the ROS level in U1 cells (Figure 6-5BC). Although the data was not statistically significant, we observed a decreasing trend in
the total antioxidant capacity of the U1 cells after CCS-Exo treatment (Figure 6-5D). The
increase in ROS and decrease in total antioxidant capacity both are indicative of
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Figure 6-3. Caski cell culture supernatant (CCS) alters antioxidant enzyme
(AOE) expression in U1 macrophages.
U1 macrophages were treated with 250 μl of CCS every 24 hours for 4 days. Expression
of SOD1, SOD2, catalase and PRDX6 were monitored at mRNA (A-D) and protein (EH) levels in the treated cells. Data were obtained from the mean of at least three
independent experiments with the error bars representing standard error of mean.
Significant difference was considered at p<0.05, which is represented by *
.
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Figure 6-4. U1 macrophages uptake CCS-derived exosomes (CCS-Exo) that contain oxidative stress factors.
(A). The exosomal protein obtained from CCS-derived exosomes (CCS-Exo) were examined for the expression of exosomal
marker, CD63, CYPs (1A1, 1B1, 2A6, 3A4) and AOEs (SOD1, SOD2, catalase, PRDX6) and HPV 16 oncoproteins (E6). Data
not shown for the proteins which were absent. (B). To monitor the exosomes uptake by U1 cells, we labeled the CCS-Exo with
GFP and treated the labelled exosomes to U1 cells. After 6 hours of incubation, we monitored the fluorescent intensity of GFP
under fluorescent microscope. (C). The GFP fluorescence was further quantified using flow cytometry.
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Figure 6-5. CCS-derived exosomes (CCS-Exo) increases HIV-1 replication and
oxidative stress in U1 macrophages.
(A). U1 macrophages were exposed with exosomes derived from 1 ml of CCS (~ 42 μg
of exosomal protein) for 4 days. p24 ELISA was performed on the supernatant obtained
from the treatment to measure the viral load. To minimize high standard deviation of the
mean due to variability in absorbance values from different experiments, we converted
the control absorbance values to 100 % and normalized the values of treated groups to %
of the control. (B). ROS was measured in U1 macrophages after the 4 days exposure of
CCS-Exo. The treated cells were incubated with H2DCFDA, the fluorescence of which
was monitored at maximum excitation and emission spectra of 495 nm and 529 nm
respectively, using flow cytometer. (C). Figure C shows the graphical representation of
ROS increase in CCS-Exo-treated U1 cells (red graph) versus control cells (grey graph).
X-axis represents mean fluorescence intensity (MFI), showing ROS level. (D). Total
antioxidant capacity of the cells was measured in CCS-treated cells using Total
antioxidant capacity assay kit. The values on Y-axis represents the total amount of
reduced Cu+ in nmol/μl, which quantitatively gives the measure of antioxidant capacity
of the cells. (E). Cytotoxicity after CCS exposure was measured using Pierce TM LDH
cytotoxicity assay kit. The values on Y-axis represent the absorbance values of formazan
dye at 490 nm, which gives the measure of cytotoxicity. The mean absorbance is obtained
by subtracting the background absorbance at 680 nm. All the data were obtained from the
mean of at least three independent experiments with the error bars representing standard
error of mean. Significant difference was considered at p<0.05. *, **, *** represents
p<0.05, p<0.005 and p<0.0005 respectively. (F). Apoptotic DNA damage was examined
using Apoptag® Iso Dual Fluorescence Apoptosis Detection kit. DAPI, FAM and CR590
dyes were used to stain the nucleus, DNase II and I-type of DNA breaks respectively.

80

81

oxidative stress. Next, we monitored the cytotoxicity and DNA damage in CCS- Exo
treated U1 cells. Interestingly, we observed ~ 40% decrease (p-value < 0.0001, n = 6) in
cytotoxicity (Figure 6-5E) in the treated U1 cells. Similarly, the merged panel of
Figure 6-5F shows lower CR590 fluorescence for the treated cells than for the control,
indicating lower extent of DNA damage in the treated cells. These results are in
agreement with the results from CCS-treated U1 cells.
Treatment of Antioxidants, CYP-inhibitors, and Chemodietary Agents Reduce Viral
Load in Caski Exosomes-treated U1 Cells
To confirm that HIV-1 replication is occurring via a CYP-mediated oxidative
stress pathway, we treated the CCS-Exo exposed U1 cells with an antioxidant,
resveratrol, CYP1A1 inhibitor, ellipticine, and CYP2A6 inhibitor, tryptamine. These
inhibitors are relatively selective for the individual CYPs. U1 cells were exposed to
exosomes isolated from 1 ml of CCS (comprising of ~ 42 μg of exosomal protein) for 4
days. To the CCS-Exo-treated U1 cells resveratrol (25 μM), ellipticine (Epi, 1 μM), and
Tryptamine (Tryp, 20 μM) were added every 24 hours for 4 days. 500 μl of exosome-free
media was added after each treatment to ensure the healthy growth of the cells. Treatment
of resveratrol (p-value < 0.0001, n =3), ellipticine (p-value < 0.0001, n =3), or tryptamine
(p-value < 0.0001, n =3) significantly reduced the viral load in CCS-Exo exposed U1
cells, suggesting the role of CYP 1A1 and 2A6, and oxidative stress on viral load
increase in U1 cells (Figure 6-6A-B).
Chemodietary agents such as curcumin and cucurbitacin-D are known to reduce
cancer progression [344-346], as well as HIV-1 replication [347, 348] through their
antioxidant potential. We treated Curcumin (20 μM) and Cucurbitacin-D (0.1μM) to the
CCS or CCS-Exo-treated U1 cells for 4 days, every 24 hours, with an assumption that
they will combat the oxidative stress caused by CCS or CCS-Exo and hence reduce the
viral replication in U1 cells. As expected, treatment of curcumin (p-value <0.0001, n=7)
and cucurbitacin-D (p-value <0.001, n= 5) significantly reduced the viral load in CCStreated cells (Figure 6-6C). We also observed significant decrease in viral load in CCSExo-treated U1 cells with curcumin (p-value <0.01, n=3) or Cucurbitacin-D (p-value
<0.001, n=3) treatment (Figure 6-6D).
Discussion
There is a high risk and prevalence of HPV co-infection in HIV-1-infected
individuals, which causes severe forms of cervical cancer. HIV-1 modulates the host cell
microenvironment for HPV invasion, through destruction of tight junctions between the
cells and immunosuppression [324]. However, it is unknown if there exists a cross-talk
between HPV and HIV-1-infected cells. The current study highlights exosomes as a
means of intracellular communication between the two cells. Here, we demonstrate for
the first time that HPV-infected cervical cancer cells transfer oxidative stress factors
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Figure 6-6. Treatment of antioxidant, CYP inhibitors, and chemodietary agents
reduce CCS or CCS-derived exosomes (CCS-Exo)-induced HIV-1 replication in U1
macrophages.
To confirm the role of CYP-induced oxidative stress in CCS-Exo-treated U1 cells, we
treated U1 macrophages with antioxidant, resveratrol (A. Res, 25 μM), CYP1A1
inhibitor, ellipticine (B. Epi 1 μM) and CYP2A6 inhibitor, Tryptamine (B. Tryp, 20 μM).
We also treated the U1 cells exposed to CCS (C) or CCS-Exo (D) with curcumin (cur, 20
μM) and cucurbitacin-D (Cur-D, 0.1μM). All the data were obtained from the mean of at
least three independent experiments with the error bars representing standard error of
mean. Significant difference was considered at p<0.05. *, **, *** represents p<0.05,
p<0.005 and p<0.0005 respectively, when compared to the control. #, ##, ### represents
p<0.05, p<0.005 and p<0.0005 respectively, when compared CCS or CCS-Exo groups.
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(such as CYPs and HPV proteins) via exosomes to the recipient HIV-1-infeceted
monocytic cells to induce HIV-1 replication. The exosomal CYPs (CYP 1A1 and 2A6)
exert an additive effect on the basal CYPs of the recipient cells. The cumulative CYPs
promote the metabolism of endogenous substances, thereby generating massive ROS,
which eventually exacerbate the HIV-1 replication in the recipient cells (Figure 6-7). Our
study also suggests a treatment strategy for HIV-1-infected patients who are also infected
with HPV by using chemodietary agents.
In the current study, we have shown the interaction between HPV and HIV-1
infected cells using Caski cells and U1 cells, which are widely used cell models for HPV
and latent HIV-1 infection. To determine the interaction between the Caski cells and U1
cells, we initially exposed the U1 cells with Caski cell culture supernatant (CCS).
Exposure of CCS to U1 cells significantly increased oxidative stress and HIV-1
replication in U1 cells. Initially, we made an assumption that Caski cells released
oxidative stress factors into the cell culture media, which when transferred to the U1
cells, induced oxidative stress and viral replication in U1 cells. Later, we were interested
to investigate if Caski cells were communicating with the U1 cells via exosomes in the
CCS. Therefore, we isolated exosomes from CCS and exposed them to U1 cells.
Interestingly, exposure of CCS-derived exosomes (CCS-Exo) also revealed higher viral
load and ROS level.
We mostly used the exosome isolation kit method for isolating exosomes from the
CCS. Initially, we tried both ultracentrifugation and exosome isolation kit method to
isolate exosomes. As we did not observe a significant difference in the yield and purity of
the exosomes isolated from these methods, we opted to use the kit method because it is
easy to use, consumes less time and is cost-effective. The presence of specific exosome
markers such as CD63 and CD81 in the exosomal pellet obtained from CCS justifies its
identity as exosomes. Moreover, in our previous work we have used extensive
characterization methods to confirm the identity of exosomes from cell culture media
[211]. Our results from transmission electron microscope and zetasizer have shown that
the extracellular vesicles we isolated have size around 100 nm, which is about the size of
the exosomes; we also observed acetylcholinesterase activity in the isolated exosomes
and the presence of several exosomal marker proteins such as alix, CD63, CD81 and
Tsg101 in the exosomes.
ROS can activate cells latently infected with HIV-1 to produce new viruses via
activation of nuclear transcription factor, NF-κB [281, 341, 349]. ROS induces
translocation of cytosolic NF-κB subunits into the nucleus, where it binds to the core
enhancer region of HIV-1 long terminal repeat (LTR) to induce HIV-1 transcription.
ROS generated through CCS/CCS-derived exosomes could induce HIV-1 replication in
the U1 cells via similar mechanism. Furthermore, redox state of the
monocytes/macrophages are also reported to regulate the expression of C-C chemokine
receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4), which are
major coreceptors for HIV-1 entry into monocytes/macrophages [350, 351]. ROS
elevation through CCS/CCS-derived exosomes could facilitate the viral entry and hence
increased the viral load within the U1 cells via overexpression of these chemokine
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Figure 6-7. Proposed model for HPV-HIV-1 interaction via exosomes.
Exosomes from cervical cancer cells carry oxidative stress factors that exacerbates HIV-1
replication in HIV-1-infected macrophages. As a result of constant oxidative stress,
cervical cancer cells package oxidative stress factors like CYP enzymes (CYP 1A1, 2A6,
1B1), miRNAs, cytokines, HPV oncoproteins etc. into exosomes and transfer them to
cells, e.g. macrophages at distant sites. The exosomes then release the oxidative stress
factors in recipient cells, which further enhances ROS production in the cells. The ROS
thus generated contributes as a secondary messenger to trigger HIV-1 in macrophages.
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receptors. Treatment of antioxidants such as glutathione, glutathione ester, and N-acetylL-cysteine has been reported to suppress HIV-1 expression in U1 cells, which strongly
supports the involvement of oxidative stress in HIV-1 expression in macrophages [352].
Our findings are consistent with the previous reports and they further elaborate
CCS/CCS-derived exosomes as a novel source of ROS for HIV-1 replication in
macrophages.
We observed that exposure of CCS/CCS-derived exosome decreased the cell
death and DNA damage in U1 cells, despite the oxidative stress. Under the stressed
condition, the cells initially attempt to protect themselves from the insult by activating
signaling pathways that promote cell survival. In case they are unable to overcome the
insult, they activate death signaling pathways [353]. In the current context, treatment of
CCS/CCS-derived exosome is likely to activate cell survival pathways such as
antioxidant defense system, heat shock and unfolded protein response, and DNA damage
repair to rescue the U1 cells from the oxidative insult [353]. Furthermore, most of the
cancer cells, including cervical cancer are known to overexpress and release antiapoptotic factors like survivin, which arrest apoptosis by inhibiting caspase activation
[354, 355]. It could be possible that protective mechanism is mediated by anti-apoptotic
factors like survivin in the CCS-derived exosomes. In addition, HIV-1 protein Nef, is
known to protect HIV-1-infected host cells by inhibiting apoptosis signal-regulating
kinase 1 (ASK1) thus preventing Fas and TNF-α-mediated apoptotic cell death [356].
HIV-1 could be promoting the cell survival in the treated U1 cells, so as to frame a
favorable environment for its multiplication.
Next, we were interested in finding what oxidative stress factors are present in
CCS/CCS-derived exosomes, and what mechanistic pathway they trigger to induce
oxidative stress and consequently HIV-1 replication in U1 cells. Overexpression of CYPs
are observed in several cancers, including cervical cancer [357] and CYPs are known to
generate excessive ROS as a byproduct during the phase-I metabolism of various
endogenous and exogenous substrates [304]. Taking this fact into consideration, we
examined the effect of CCS in the expression of CYPs in U1 cells. We particularly
examined the expression of CYP1A1 and CYP2A6 because these enzymes are expressed
in monocytic cells. In addition to metabolize many endogenous compounds, CYP1A1
and CYP2A6 are the major enzymes for metabolizing polyaryl hydrocarbons and nicotine
present in the cigarette smoke respectively [155, 273]. As expected, we observed
significant increase in the protein expression of both the CYPs, 1A1 and 2A6 in U1 cells
after CCS exposure. The concurrent upregulation of CYPs and elevation in ROS levels
signified that the oxidative stress in the U1 cells could be occurring via a CYP-mediated
pathway. We did not observe any change in the expression of antioxidant enzymes after
CCS exposure. However, there was a decrease in the total antioxidant capacity of the
cells after CCS or CCS-mediated exosome treatment.
In this study, we observed increase in the expression of CYPs at the mRNA level
but not at the protein level. We have observed this kind of discrepancy in our previous
studies as well [154]. As mRNA is translated into protein, it is theoretically believed that,
there is a correlation between the expression of gene at the mRNA and the protein level
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but in practical, it is not necessary that mRNA expression changes would reflect similar
changes in the protein expression [358-360]. The reason for decrease in expression of the
proteins, despite their increased mRNA expression could be due to various transcriptional
and post-translational modifications, differential stability of mRNAs vs. proteins, or due
to interference by different miRNAs.
Next, we verified the presence of CYPs 1A1, 2A6 and 1B1 in the CCS-derived
exosomes, which further strengthens our assumption about involvement of CYP-pathway
in CCS-induced oxidative stress. To further confirm the role of CYPs in oxidative stressinduced HIV-1 replication, we treated the U1 cells exposed to CCS-derived exosomes
with resveratrol (an antioxidant), ellipticine (CYP1A1 inhibitor) and Tryptamine
(CYP2A6 inhibitor). Treatment of these antioxidant and CYP inhibitors significantly
reduced the viral load in the treated U1 cells. (role of CYP from CCS-derived exosomes
using siRNA) Overall, our findings suggested that Caski cells transfer CYPs to the U1
cells via exosomes. Upon reaching the U1 cells, these exosomes release the CYPs into
the cytosol where they induce oxidative stress and subsequently HIV-1 replication. Our
observations are in agreement with our previous reports, where we have observed higher
expression of CYPs, oxidative stress, and HIV-1 viral load in the plasma samples of HIV1 smokers, which shows the association of CYP-mediated oxidative stress pathway in
HIV-1 replication [153]. Recently, we have confirmed this association in vitro in U1 cells
where we demonstrated, CYP1A1 metabolizes benzo(a)pyrene (a harmful carcinogen in
cigarette smoke), causing massive production of ROS and subsequently trigger HIV-1
replication in the U1 cells [341].
Apart from CYPs, we also observed the presence of other oxidative stressinducing factors such as HPV type16 oncoprotein E6 in the CCS-derived exosomes.
HPV16 E6 and E7 oncoproteins are known to cause chronic oxidative stress in HPVinfected and uninfected cells via NOX2 activation [134]. Besides, CCS-derived exosomes
may also contain various cytokines and miRNAs that may trigger HIV-1 replication in
U1 macrophages. Cytokines such as, TNF-α triggers HIV-1 gene transcription through
activation of NF-κB; IL-6 increases the expression of viral proteins and RT; IL-6 together
with TNF-α have a synergistic effect on HIV-1 replication [189]. Micro RNA (miRNA)
34a and miRNA 181 are reported to enhance HIV-1 viral load by inhibiting the cellular
restriction factors (e.g., p21, TASK, and SAMHD1), which inhibits different stages of
HIV-1 life cycle [361, 362]. Since, these miRNAs are also expressed in cervical cancer
cells, it is possible that they are being transported to the host cells via exosomes, where
they contribute to HIV-1 replication.
Curcumin and cucurbitacin-D are shown to inhibit cancer growth in cervix by
inducing apoptosis and arresting cell cycle [344-346]. In addition to the anti-cancer
property, curcumin and cucurbitacin have also shown to suppress HIV-1 pathogenesis
through its antioxidant potential [347, 348]. Curcumin is shown to reduce HIV-1
transcription by inhibiting the HIV-1 protein, Tat-mediated LTR promotor transactivation
[347]. Considering their potential antioxidant and antiviral properties, we examined the
preventive effect of these agents to HIV-1 replication induced by CCS/CCS-derived
exosomes. As expected, treatment of both the compounds significantly reduced HIV-1
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viral load induced by CCS or CCS-derived exosomes in U1 cells. Curcumin and
cucurbitacin-D are known to scavenge hydroxyl and superoxide ions at higher
concentration [363]. It is therefore possible that these compounds are inhibiting the viral
replication by lowering the ROS level. Furthermore, the use of curcumin and
Cucurbitacin-D as antioxidants to block the viral replication is clinically safer as these
natural antioxidants are less carcinogenic compared to synthetic antioxidants, such as
butylatedhydroxy toluene (BHT) and butylatedhydroxy anisole (BHA). Furthermore, the
use of these chemodietary agents in HIV-1 patients with cervical cancer is more
beneficial because of their dual effect on reducing cancer progression and HIV-1
replication.
Conclusion
In conclusion, we have demonstrated that cervical cancer cells exacerbate HIV-1
replication in monocytic cells via transferring oxidative stress factors such as CYPs and
HPV oncoproteins through exosomes. We have also shown that the viral replication
undergoes via a CYP-mediated oxidative stress pathway and it can be reduced by
treatment of chemodietary agents like curcumin and Cucurbitacin-D. The present study
therefore, provides scientific rationale for the development of novel therapeutic treatment
for HIV-1 infected women with cervical cancer.
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CHAPTER 7.

CONCLUSIONS AND FUTURE DIRECTIONS

With the introduction of ART since 1995, the number of AIDS-related deaths
have significantly decreased and consequently, the number of PLWHA has increased
[364]. With the increase in life-span, numerous pathological complications including
cancers of various organs and tissues, neurological disorders and various opportunistic
infections have been observed in PLWHA. ART has been able to control plasma HIV-1
levels and improve CD4+ cell counts to large extent, however, complete eradication of
HIV-1 has not been achieved. One of the major hindrances to cure HIV-1 is the rapid
formation of latent HIV-1 reservoirs in memory T cells, monocytes, and macrophages.
The presence of these viral reservoirs is observed even in PLWHA on ART for lifelong.
The latent HIV-1 in these reservoirs are activated to produce new viruses in presence of
stress factors like cytokines and [133]infections [365] and exposure to various drugs of
abuse [366]. Most of these stress factors use ROS as a secondary messenger to stimulate
the nuclear transcription factors, NF-κB and NFAT, which enhance the transcription of
latent HIV-1 genome [149].
There is a high prevalence of drug abuse, especially tobacco smoking among
PLWHA. Several components in cigarette smoke such as nicotine and polyaryl
hydrocarbons are known to be metabolized by CYP enzymes through phase I
metabolism. During the metabolism, CYPs generate ROS as intermediate products
through various coupling and auto oxidation reactions. Therefore in project I, we initially
proposed that ROS generated through CYP-mediated metabolism of cigarette smoke
constituents, especially BaP, triggers HIV-1 replication in viral reservoirs such as
monocytes and macrophages. Furthermore, PLWHA also suffer from coinfection by
various pathogens due to immunosuppression by HIV-1. Among the various coinfections,
high-risk HPV coinfection by genotype 16 and 18 that causes cervical cancer is highly
prevalent in PLWHA. Infections by pathogens such as syphilis [367], mycobacterium
tuberculosis [365], and hepatitis [368] have been shown to induce HIV-1 replication.
Therefore in project II, we proposed that HPV may also trigger latent HIV-1 reactivation
in infected monocytes/macrophages via a mechanism similar to that proposed in project I.
Here, we hypothesized that, HPV-infected cells transport exosomes containing oxidative
stress factors, especially CYPs to monocytes/macrophages latently infected with HIV-1.
The CYPs from the exosomes are released into the infected macrophages and monocytes
where they add to the effect of the cellular CYPs to mediate oxidative stress and
ultimately HIV-1 replication.
As expected, our results indicated that, out of the five compounds tested, chronic
exposure (7 days) of BaP significantly increased oxidative stress and cytotoxicity in
U937 monocytic cells and human primary monocytic cells. Acute exposure of BaP did
not cause any significant increase in oxidative stress and cytotoxicity in U937 cells,
probably because of the protective effect from the basal antioxidant enzymes. Chronic
exposure of BaP also induced the mRNA expression of CYPs (CYP1A1 and CYP3A4)
and AOEs (SOD1 and catalase) in the monocytic cells, which indicated the possible
involvement of CYPs and oxidative stress pathway in BaP-induced cytotoxicity. Further,
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the increased caspase-3 activity after chronic BaP exposure suggested that BaP may be
causing cytotoxicity possibly via a caspase-3-dependent apoptotic pathway. Therefore,
we demonstrated that chronic treatment of BaP induces cytotoxicity in monocytes,
possibly through generation of ROS via a CYP pathway.
We also demonstrated that BaP induced oxidative stress and HIV-1 replication in
U1 cells as well as HIV-1-infected human primary macrophages. Treatment of
antioxidants and CYP1A1 inhibitor significantly decreased the oxidative stress and viral
replication induced by BaP, indicating that BaP-induced HIV-1 replication occurs via a
CYP-mediated oxidative stress pathway. Further, we also showed that ROS generated via
CYP metabolism of BaP facilitates the nuclear translocation of NF-κB subunits, leading
to enhanced HIV-1 transcription. We also confirmed the role of NF-κB pathway using
specific NF-κB inhibitors. Our results give an insight of a novel mechanism for smokinginduced HIV-1 replication, that CYP-mediated metabolism of BaP generates ROS, which
triggers NF-κB pathway to enhance the transcription of HIV-1 genome.
Next, we observed that, exosomes derived from HPV-infected caski cells package
oxidative stress factors (like CYPs, HPV oncoprotein and antioxidant enzymes) and
diffuse into the U1 cells. We also observed that the treatment with these exosomes
enhance oxidative stress and HIV-1 replication in U1 cells. Antioxidants and specific
CYP inhibitors significantly decreased exosomes-induced HIV-1 replication in U1 cells.
This confirms, at least in part, the role of oxidative stress and CYPs in the exosomemediated HIV-1 replication. Our results demonstrate that HPV-infected cells induce
HIV-1 replication in monocytic cells latently infected with HIV-1 via exosomes
containing CYPs. These CYPs along with the cellular CYPs may be generating ROS
during the metabolism of various endogenous and exogenous substrates within the cells,
thereby resulting oxidative stress and ultimately HIV-1 replication.
Overall, our study illustrates that comorbidities like smoking or HPV coinfection
contribute to HIV-1 replication and pathogenesis in monocytic cells, at least in part, via a
CYP-mediated oxidative stress pathway. This study is clinically relevant as it provides
the basis for potentially novel therapeutic targets like CYPs and oxidative stress. Since
there are no guidelines to titrate ART regimens in smokers, the outcomes from the
present study will also help in optimizing ART regimens for HIV-1-positive smokers.
Identification of the role of CYP enzymes in tobacco/HPV-mediated HIV-1 pathogenesis
would not only help to adjust the ART regimen, but would also help to design a better
treatment strategy for HIV-1-positive patients with tobacco addiction or HPVcoinfection. CYP enzymes are an important target for drug development to combat many
disease conditions, such as cancer (CYP1A1, 1A2, 1B1, 2A13) [369, 370],
cardiovascular disease (CYP1A, 1A2, 1B1) [371], inflammation and pain (CYP4A)
[372], hypertension [373], pulmonary disease (CYP1B1) [374], and HIV-1 (CYP3A4)
[153]. In the present study, we demonstrated that antioxidants (resveratrol, vitamin E and
C) and CYP inhibitors (ellipticine and tryptamine) reduce HIV-1 viral load in vitro in
BaP or HPV-exposed U1 cells. These compounds can further be optimized and
formulated into potent and clinically safe drug molecules to alleviate disease progression
in PLWHA who are either smokers or have HPV coinfection. Furthermore, we have
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shown that chemo-dietary agents such as curcumin and cucurbitacin-D reduce HPVinduced HIV-1 replication in monocytic cells. Curcumin and cucurbitacin-D have been
shown to have a significant impact on alleviating cervical cancer [344]. The identification
of these compounds provides a novel insight for the design and development of new
drugs, or their use as adjuvant therapy to alleviate both HIV-1 and HPV infection in
PLWHA.
Moreover, these antioxidants, CYP inhibitors, and chemo-dietary agents can be
synthetically loaded into exosomes and delivered to the target tissues. Exosomes are nonimmunogenic and biocompatible; they also have target specificity, a long circulating halflife, and no associated toxicological problems. These features make exosomes a
promising drug delivery system, compared to synthetically constructed nano-carriers
[375]. Recently, exosomes derived from brain cells have been shown to be an effective
drug carrier to deliver anticancer drugs across the BBB for the treatment of brain cancer
in a zebrafish model [376]. In another study, dendritic cells were engineered to produce
exosomes that expressed exosomal membrane proteins fused to the neuron-specific RVG
peptide. The RVG-targeted exosomes were capable of delivering siRNA targeted to
BACE1, a therapeutic target of Alzheimer’s disease, to brain tissues of mice, resulting in
successful BACE1 knockdown [377]. Furthermore, exosomes loaded with antioxidant
agents such as curcumin have also been reported to have a relatively improved
distribution in brain tissues and reduce loss of neurons, glia, and brain endothelia after
ischemia-reperfusion injury [378]. The exosomes loaded with antioxidants or CYP
inhibitors or chemo-dietary agents can also be therapeutically beneficial to reduce the
oxidative stress-induced HIV-1 replication in monocytic cells of HIV-1-infected smokers
as well as HIV-1 patients with HPV co-infection.
HIV-1-infected monocytes and macrophages circulating in the bloodstream can
spread HIV-1 infection in the CNS once they cross the BBB [379]. These cells further
activate astrocytes and microglia to produce various inflammatory chemokines and
cytokines. The release of cytokines, chemokines, viral particles, and ROS causes
oxidative stress and inflammation within the brain, ultimately leading to HIV-1associated neurological disorders (HAND) [380]. Currently available ART drugs have
very low bioavailability at the brain tissues as their diffusion to the CNS is limited by
BBB [381]. The viral reservoirs and the infected cells within the brain are therefore
protected from ART, which further makes it difficult to attain the complete eradication of
HIV-1. As exosomes can easily cross the BBB, the delivery of antioxidant/ART-loaded
exosomes can be an efficient therapeutic strategy to reduce the viral load in brain cells by
lowering ROS level. The use of exosomes as a therapeutic carrier to deliver ART in the
brain can also help to reduce HAND, which has been a rising problem among PLWHA in
the ART era.
In addition to smoking, individuals infected with HIV-1 often use various other
drugs of abuse such as cocaine, methamphetamine, marijuana, and alcohol, which result
in similar oxidative damage. The concomitant use of these drugs is likely to further
exacerbate oxidative stress and viral load in PLWHA. Thus our strategy discussed above
that contain CYP inhibitors/antioxidants/chemo-dietary agents loaded-exosomes may
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serve to alleviate oxidative damage due to abuse of these poly-drugs in different cells and
tissues. Furthermore, these exosomes may also have therapeutic benefits in other
neuropathological conditions associated with oxidative stress such as Alzheimer’s
disease, Parkinson’s disease, and multiple sclerosis.
The International Agency for research on Cancer (IARC) has classified smoking
as one of the risk factors for cervical cancer [212]. Several studies indicated that cigarette
smoking enhances the progression of HPV infection into cervical lesions and cancer
[381]. A meta-analysis study conducted by the International Collaboration of
Epidemiological Studies of Cervical Cancer on 23 different studies concluded that the
relative risk is 1.6 times higher for a current smoker to develop HPV infection into
squamous cell carcinoma, compared to a non-smoker [382]. Cigarette smoke constituents
such as nicotine and benzo(a)pyrene are found to be present in the mucus of cervical
cancer patients [204]. Tobacco has also been shown to enhance the transcription of HPV
oncoproteins E6 and E7 that reduce p53 levels and activity, enhance DNA damage and
mutation, thereby leading to cervical cancer [383]. Nicotine, BaP, and their metabolites
are known to form DNA and protein adducts that induce carcinogenesis in cervix [384].
Moreover, BaP has also been shown to increase HPV synthesis in cervical cancer cells
[385]. In the present study, we have shown how smoking and HPV independently impact
HIV-1 replication in monocytic cells. As smoking enhances HPV pathogenesis and
progression to cervical cancer, these factors together may further have an additive or
synergistic effect on the HIV-1 replication in monocytic cells. Therefore, in future, our
lab will be investigating the combined effect of smoking and HPV coinfection on HIV-1
replication in monocytic cells.
Numerous CYPs are upregulated in cervical cancer cells including the CYPs that
metabolize cigarette smoke constituents, especially polyaryl hydrocarbons
(CYP1A1/1A2/1B1) [386]. Exposure of polyaryl hydrocarbons, especially BaP, may
enhance oxidative stress in cervical cancer cells via CYP pathway. The packaging of
oxidative stress factors into the exosomes, as well as the release of the exosomes may be
altered after BaP exposure into the cervical cancer cells. In the current project, we have
only demonstrated the role of CYPs in the exosomes. We will be investigating other
oxidative stress factors in the exosomes that are responsible for reactivating latent HIV-1
in monocytic cells, using proteomic and microarray analysis. Based on their known
contribution in reactivating latent HIV-1, we speculate that cytokines (IL-6, TNF-α) and
miRNAs (34a, 181) may have a role in activating HIV-1 replication in monocytic cells.
We also observed the presence of HPV oncoprotein E6 in the exosomes derived from
HPV-infected cervical cancer cells, which adds the possibility that these oncoproteins
may also have a role in generating oxidative stress in the recipient cells. We propose that
the exosomes derived from cervical cancer cells, exposed to BaP may have a greater
potential to reactivate latent HIV-1 in monocytic cells than the exosomes from cervical
cancer cells alone. Overall, this new project will demonstrate how smoking and HPV
coinfection together impact reactivation of latent HIV-1 in viral reservoirs such as
monocytes.
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